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ABSTRACT OF DISSERTATION 
 
 
 
 
SURFACE FUNCTIONALIZED MAGNETIC NANOPARTICLES FOR  
CANCER THERAPY APPLICATIONS 
 
 Despite recent advances, cancer remains the second leading cause of deaths in the 
United States.  Magnetic nanoparticles have found various applications in cancer research 
as drug delivery platforms, enhanced contrast agents for improved diagnostic imaging, and 
the delivery of thermal energy as standalone therapy.  Iron oxide nanoparticles absorb the 
energy from an alternating magnetic field and convert it into heat through Brownian and 
Neel relaxations.  To better utilize magnetic nanoparticles for cancer therapy, surface 
functionalization is essential for such factors as decreasing cytotoxicity of healthy tissue, 
extending circulation time, specific targeting of cancer cells, and manage the controlled 
delivery of therapeutics. 
 
 In the first study, iron oxide nanoparticles were coated with a poly(ethylene glycol) 
(PEG) based polymer shell.  The PEG coating was selected to prevent protein adsorption 
and thus improve circulation time and minimize host response to the nanoparticles.  
Thermal therapy application feasibility was demonstrated in vitro with a thermoablation 
study on lung carcinoma cells. 
 
 Building on the thermal therapy demonstration with iron oxide nanoparticles, the 
second area of work focused on intracellular delivery.  Nanoparticles can be appropriately 
tailored to enter the cell and deliver energy on the nanoscale eliminating individual cancer 
cells.  The underlying mechanism of action is still under study, and we were interested in 
determining the role of reactive oxygen species (ROS) catalytically generated from the 
surface of iron oxide nanoparticles in this measured cytotoxicity.  When exposed to an 
AMF, the nanoscale heating effects are capable of enhancing the Fenton-like generation of 
ROS determined through a methylene blue degradation assay.  To deliver this enhanced 
ROS effect to cells, monosaccharide coated nanoparticles were developed and successfully 
internalized by colon cancer cell lines.  Upon AMF exposure, there was a measured 
increase in cellular ROS and apoptosis that was attributed to lysosomal disruption since 
the surface functionalization selected inhibited the Fenton-like surface chemistry.  To 
overcome this surface inhibition, a biodegradable poly(β-amino ester) (PBAE) polymer 
coating was synthesized to deliver bare iron oxide to intracellular components.  Delivering 
enhanced ROS to cancer cells is a promising new route of therapy that deserves future 
studies. 
 
KEYWORDS: Magnetic nanoparticles, thermal therapy, free radical generation, 
Fenton catalyst, magnetically mediated energy delivery, 
biodegradable polymer 
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Chapter 1: Introduction 
 This dissertation investigates the development of tailored novel nanomaterials for 
cancer therapy.  The core nanoparticle utilized was iron oxide which has been previously 
studied for a wide range of biomedical applications.  Iron oxide nanoparticles have the 
unique physical property of being able to remotely heat when exposed to an alternating 
magnetic field (AMF).  This heat can be used as a standalone therapy, a component of a 
combination therapy, or be used to activate the release of drug molecules from thermo-
responsive matrices.  To better utilize this property, appropriate surface functionalization 
must be performed.  This research builds off of two basic platforms previously developed 
in our lab: co-precipitation synthesis of uncoated iron oxide nanoparticles and one-pot 
addition of stabilizing molecules to the surface of these nanoparticles.  These core 
nanoparticles were further modified with polymers through atom transfer radical 
polymerization and surface attachment and biomolecules – monosaccharide and glycerol 
lipids.  Chapter 2 presents a background on the range of polymeric coating used in core-
shell architectures to increase stability, decrease toxicity, extend circulation time, and 
manage the controlled release of therapeutics. 
 Despite recent advances, development of cancer therapeutics remains one of the 
most important challenges facing biomedical researchers today.  To combat this disease, a 
multi-modal treatment strategy is often utilized and thermal therapy usually represents one 
potential aspect of the strategy.  Thermal therapy is the process of elevating tumor tissue 
temperature for therapeutic gains and has been studied for decades, but it has yet to gain 
widespread clinical recognition either as an independent treatment or in conjunction with 
traditional therapies.  Two temperature ranges have been identified: hyperthermia, 40-45 
2 
 
°C, and thermoablation, ≥46 °C.  Hyperthermia can induce cellular death on its own, but it 
is better suited for enhancing the effects of chemotherapy and/or radiation therapy.  Due to 
the elevated temperature, thermoablation leads to direct cell necrosis and can be used as an 
independent treatment.  Magnetic fluid hyperthermia involves using the remote heating 
property of magnetic nanoparticles to deliver heat in a controlled localized area.  An in 
depth discussion on the mechanics of hyperthermia and recent advances in magnetic 
mediated energy delivery can be found in chapter 3.  In order to successfully deliver 
magnetic nanoparticles to the tumor surface, surface modification is necessary.  
Poly(ethylene glycol) (PEG)-based functionalization is common for biological applications 
as a means to prevent protein adsorption and thus improve circulation time and minimize 
host response to the particles.  In chapter 4, core-shell nanoparticles were prepared using 
atomic transfer radical polymerization to coat iron oxide with PEG-based polymer shell.  
They were developed to achieve thermal therapy that can ablate cancer cells in a remotely 
controlled manner.   
 Despite clinical interest in magnetic fluid hyperthermia, researchers have faced a 
major barrier in that a large ratio of nanoparticles to surrounding cells is necessary to 
achieve the required elevated temperature.  Thus, it is generally considered only applicable 
for direct injection into solid tumors.  Recently, Creixell et al. have created new excitement 
in the field by demonstrating that targeted nanoparticles that have been internalized by 
cancer cells can induce cellular death when exposed to an AMF without a measurable 
temperature rise.  Instead of relying on bulk heating, nanoparticles can be specifically 
tailored to enter cells minimizing potential damage to surrounding tissue. Additionally, this 
technology raises the possibility of targeting micrometastatic sites previously considered 
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untreatable.  Understanding the underlying mechanisms of this intracellular energy 
delivery is one of the provocative questions facing researchers in the field.  In addition to 
heating effects from the local temperature rise, other chemical effects or mechanical 
damage from the physically rotation and vibration of nanoparticles in the field may induce 
toxicity.  One potential chemical effect would be the result of surface mediated production 
of reactive oxygen species (ROS).  ROS is considered one of the culprits of concentration 
dependent iron oxide cytotoxicity.  In chapter 5, the effects of an AMF on surface ROS 
generation was explored.  Using a methylene blue assay, an increase in degradation was 
observed when a suspension of magnetic nanoparticles was exposed to an AMF indicating 
there was an increase in the ROS generation in response to the field.  To demonstrate this 
result in vitro nanoparticles functionalized with monosaccharides was explored in chapter 
6.    Monosaccharides can provide a level of passivation similar to PEG or polysaccharide 
coatings while targeting cancer cells which typically over express glucose transporters.  
While intracellular ROS increased with internalized nanoparticles, the coatings inhibited 
surface ROS generation meaning the measured cellular effect was due in part to lysosomal 
disruption.  Lastly, nanoparticles coated with biodegradable polymer coatings were 
prepared in chapter 7.  The nanoparticles consist of an iron oxide core and biodegradable 
polymer shell developed to maximize the potential surface reactivity for ROS generation.  
When tuned properly, such a platform can be combined with targeting ligands to increase 
treatment efficacy. 
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1.1. Specific Objectives  
The overall objective of this research was to develop novel nanomaterials (i.e., 
functionalized iron oxide nanoparticles) for cancer therapy.  This involved four projects, 
and the specific objectives of these are outlined below: 
1. Synthesis and characterization of PEG-iron oxide core-shell composite 
nanoparticles for thermal therapy applications 
a. Synthesize core-shell nanoparticles utilizing atom transfer radical 
polymerization techniques 
b. Perform physiochemical characterizations to verify successful coating 
c. Investigate cytotoxicity by exposing two cell lines to nanoparticles systems 
d. Demonstrate the ability of the core-shell nanoparticles to ablate cancer cells 
to demonstrate therapeutic potential 
2. Accelerated generation of free radicals by iron oxide nanoparticles in the presence 
of an alternating magnetic field 
a. Synthesize and characterize uncoated iron oxide nanoparticles 
b. Determine the kinetic behavior of the Fenton-like surface chemistry to 
generate free radicals using a methylene blue degradation assay 
c. Analyze the kinetic data to determine an Arrhenius relationship 
d. Demonstrate an enhancement in ROS generation through AMF exposure 
3. The role of ROS generation from magnetic nanoparticles in an alternating magnetic 
field on cytotoxicity 
a. Synthesize glucose functionalized iron oxide nanoparticles 
b. Perform physiochemical characterizations to verify successful coating 
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c. Determine the uptake rate and localization pattern in cancer cells 
d. Demonstrate cellular ROS enhancement with AMF exposure 
e. Investigate surface reactivity of coated nanoparticles  
4. Synthesis and characterization of magnetic nanoparticles with biodegradable 
polymer coatings for the treatment of cancer 
a. Synthesize poly(β-amino ester) for coating 
b. Attach biodegradable coating to nanoparticle surface 
c. Perform physiochemical characterizations to verify successful coating 
d. Determine effects of coating on surface ROS generation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Robert John Wydra 2015   
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Chapter 2: Polymeric Coatings and Additives on Nanoparticles for Biomedical 
Applications 
2.1. Introduction 
Surface modification plays an essential role in determining the successful 
application of nanoparticles by improving stability, preventing agglomeration, improving 
biocompatibility, and providing additional functionalities such as targeting and drug 
release.  In recent years, nanoparticles have been studied for a wide range of biomedical 
applications including enhanced imaging, drug delivery, thermal therapy of cancer, and as 
bioprobes and sensors.  Core-shell architectures allow researchers to combine multiple 
functionalities on a single nanoparticle.  A common example is an inorganic core that is 
selected for its unique physical properties that is coated with an organic shell that improves 
the colloidal stability while reducing the core nanoparticle toxicity.  However, researchers 
have been striving for the ultimate goal of a nanosized “smart bomb”, where a carefully 
designed nanoparticle is capable of being safely delivered to the body, carrying its drug 
payload to a specific location, and only releasing the drug at the target location to minimize 
any systemic effects [1].  This chapter will focus on the different uses of polymeric coatings 
in core-shell nanoparticles.  Briefly, common core particles and synthesis techniques will 
be introduced.  The different functionalities of the polymeric shell will be discussed, 
specifically their role in improving colloidal stability, reducing nanoparticle toxicity, 
increasing circulation time, active targeting, and controlling different mechanisms of drug 
loading and release. 
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2.2. Core Nanoparticle Systems 
When designing a nanoparticle system for drug delivery, it is of particular interest 
to select the appropriate core.  As highlighted in the introduction, spherical core-shell 
nanoparticles are of major interest as a way of combining different physicochemical 
properties from the core and shell materials.  In the following section, commonly utilized 
core nanoparticles will be briefly described. 
2.2.1 Magnetic Nanoparticles 
Magnetic nanoparticles are the focus of much research due to their many 
biomedical applications, such as targeted delivery, magnetic resonance imaging (MRI), 
and the thermal therapy of cancer [2-5].  Magnetic nanoparticles have the unique physical 
property of being able to remotely heat when exposed to an alternating magnetic field due 
due to the absorption of energy from the magnetic field and conversion into heat primarily 
through Brownian relaxation and Neel relaxation [6].  In addition to coating magnetic 
nanoparticles with a material to improve colloidal stability and biocompatibility, an 
additional concern is preventing the further oxidation of magnetic core altering its physical 
properties.  In terms of drug delivery, magnetic nanoparticles are potential candidates for 
drug tracking with magnetic resonance imaging and the thermal delivery of a therapeutic 
agent.   
2.2.2 Gold Nanoparticles 
Similar to magnetic nanoparticles, gold is being studied by biomedical researchers 
for its potential use as a diagnostic or therapeutic agent as a result of its unique chemical 
and physical properties [7-10].  Gold is considered inert and non-toxic, and it is usually 
functionalized to carry out an intended biological application; in most cases a facile gold-
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thiol surface chemistry is utilized.  When irradiated with light, gold nanoparticles interact 
with the electromagnetic wave through a phenomenon called surface plasmon resonance 
(SPR).  Through SPR, heat can be generated through electron-phonon and phonon-phonon 
interactions and this heat can act alone as a therapeutic or work to thermally trigger the 
release of a drug.  The plasmonic peak, or excitation wavelength, can be controlled by 
engineering the shape and structure of the gold nanoparticle; the general structures are 
classified as spherical gold nanoparticles, gold nanorods, gold nanoshells and gold 
nanocages.  For a detailed review on the role of structure on plasmonic properties, the 
reader is referred to the review article by M. Hu et al. [11]. 
2.2.3 Mesoporous Silica Nanoparticles 
Mesoporous silica nanoparticles are currently being studied to serve as drug 
delivery systems based on their unique design.  These silica nanoparticles have been 
templated with porous channels that can serve as potential drug carriers [12, 13].  Unlike 
magnetic and gold nanoparticles, which rely on a multifunctional platform, these particles 
are functionalized to better control drug adsorption and release from the pores.  It should 
be noted that silica is considered relatively biocompatible and is sometimes used as a 
coating to reduce the toxicity of other inorganic nanoparticles [1]. 
2.3. Nanoparticle Architectures 
Core-shell structures provide the opportunity to design nanoparticles with multiple 
functionalities.  In general, core-shell nanoparticles can be prepared in one of two ways 
based on the way the polymer coating is applied to the surface.  ‘Grafting to’ involves the 
addition of end functionalized polymers that interact with the nanoparticle surface.  
‘Grafting from’ involves a controlled surface initiated polymerization, whereby an initiator 
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is bound to the nanoparticle surface and the polymer is grown from the surface.  Schematic 
representations of ‘grafting to’ and ‘grafting from’ are illustrated in Figure 2.1.   
2.3.1 ‘Grafting to’ 
In the ‘grafting to’ approach, the polymer chains are immobilized on the surface 
either through a chemical adsorption or physical adsorption.  In the case of physical 
adsorption, the bond is non-covalent and therefore easily reversible and susceptible to 
removal by shear stress or other interactions [14].  Physical adsorption is usually carried 
out with block co-polymers where one chain segment has an affinity (e.g., electrostatic or 
hydrophobic interactions) for the nanoparticle surface.  Because of the required chain 
segment, the ability to introduce functional groups is hampered, and a polymer may coat 
more than one particle introducing clusters [14, 15].  Chemical adsorption results when a 
covalent bond is formed between the reactive end group of the polymer chain and the 
nanoparticle surface.  Since it is a covalent bond, the resulting functionalization is typically 
more stable than physical adsorption.  Polymer orientation becomes a limiting factor as the 
end group has to come in contact with the surface.  Both ‘grafting to’ approaches suffer 
from the limitation of low grafting density.  As the polymer chains begin to adhere to the 
surface, steric crowding limits the possible reaction sites.  Despite limitations, it should be 
noted that ‘grafting to’ is a very common technique selected for its simplicity of generating 
a multifunctional core-shell structure. 
2.3.2 ‘Grafting from’ 
The ‘grafting from’ technique is a two-step process.  First, the nanoparticle surface 
must be functionalized with initiator group.  Depending on the substrate, a variety of known 
surface chemistries can be used (e.g., thiols on gold and silanes on glass) [14, 16].  A 
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solution containing catalyst and monomer will be added to the nanoparticles, and the 
initiator group will be transformed to a radical that is confined to the nanoparticle surface.  
The radical serves as the site of the polymerization, and the shell is propagated from the 
surface in a uniform and precise manner.  The key advantage of a ‘grafting from’ approach 
lies in that the coating is constructed one monomer at a time allowing for a higher polymer 
density, up to 1 chain/nm2 and a variety of polymer combinations [17].  There are multiple 
surface initiated polymerization mechanisms utilized to create core-shell nanoparticles.  
Some of them will be highlighted below, but for an in depth description, the author 
recommends the following review articles [14, 16, 18-20]. 
One of the most extensively used surface initiated polymerization is metal catalyzed 
atom transfer radical polymerization (ATRP), which is selected for its compatibility with 
a wide range of monomers yielding polymers with low polydispersity indexes (PDI), less 
stringent experimental conditions, and remains end functionalized with the initiator for the 
synthesis of copolymers [14, 19].  During the reaction (see Figure 2.2.a), the reduction of 
the alkyl halide by a transition metal complex initiator generates a radical utilized in the 
propagation of the polymer.  The radicals are deactivated by the oxidized form of the 
transition metal complex, and this reversible activation-deactivation allows control over 
the polymerization.   Typically, the transition metal complexes are copper or iron based, 
and the initiators are either α-haloesters or benzyl halides.    
Similar to ATRP, reversible addition-fragmentation chain transfer (RAFT) 
polymerization allows for the synthesis of a range of polymers with a narrow PDI and 
controlled end groups.  The polymerization (see Figure 2.2.b) is controlled by the 
degenerative transfer by a dithioester agent.  Conventional free radical initiators are used  
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Figure 2.1.  Schematic displaying the different surface functionalization methods: 
‘grafting to’ (a) and ‘grafting from’ (b). 
 
 
Figure 2.2.  General reaction mechanism of (a) ATRP, where X = halogen, Y = transition 
metal complex, and Y0 = oxidized form of the transition metal complex and (b) RAFT 
polymerization where X = transfer agent. 
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to generate the initial radicals that drive the reversible exchange mediated by the transfer 
agent. 
2.4. Coating Functionality 
2.4.1 Colloidal Stability 
Nanoparticles, with their high surface area to volume ratio, are prone to aggregation 
and agglomeration issues unless addressed with a coating to provide colloidal stability.  
Colloidal stability additives either work by providing electrostatic repulsion (i.e., placing 
charged groups on the surface to repel nearby particles) or by steric repulsion (i.e., adding 
non-ionic materials to the surface to prevent surface contact with nearby particles).  When 
selecting a polymeric material for steric stabilization, three factors must be addressed: 
surface density, layer thickness, and outer surface profile [21].  An illustration of the 
different surface coatings can be seen below in Figure 2.3.  In the diagram, the local 
polymer concentration, denoted as ρ2, is shown to change with distance away from the 
particle surface.  Brush systems anchored to the surface (Figure 2.3.a) have the highest 
segment density, ρ2, at the radius of gyration and trail off from there.  Brush systems 
absorbed to the surface (Figure 2.3.b) have a higher density closer to the particle surface.  
Due to lower polydispersity of surfactant layers (Figure 2.3.c), the outer concentration 
profile sharply declines compared to polymeric systems. 
Colloidal stability is modeled as the linear combination of the total energy of 
interaction.  These interactions are generally separated into three contributions: attractive 
(VA), electrostatic repulsion (VR), and steric repulsion (VS) [22]: 
 VT = VA + VR + VS     Equation 2.1 
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Figure 2.3.  Illustration of polymer chains in solution near a surface: a) terminally anchored 
polymer; b) adsorbed chain; c) adsorbed surfactant layer; and the effects of surface 
coverage where the Flory radius is in the order of radius of gyration resulting in low 
coverage (d) and high coverage leading to a brush system (e). 
 
 
Figure 2.4.  Illustration of overlap areas of polymeric stabilizers for a) plate-plate; b) 
sphere-sphere; and c) plate-sphere. 
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The classical DLVO theory for spherical nanoparticles neglects steric repulsion and 
assumes the sum of the electrostatic double layer repulsion and van der Waals attraction 
[21, 23, 24].  For spheres of identical radius, the van der Waals attraction term can be 
reduced to the following expression: 
 𝑉𝐴 = −
𝐴
12𝐻
[1 +
𝐻
2𝑎+𝐻
+
𝐻
𝑎
ln (
𝐻
2𝑎+𝐻
)]  Equation 2.2 
Where A is the Hamaker constant, H is the closest distance between particle surfaces, and 
a is the particle radius.  Two forms of the electrostatic repulsion are commonly used based 
on the value of κa, where κ is the inverse Debye length [24]: 
 VR = 2πεrε0aψδ2 ln[1 + exp(-κH)]   Equation 2.3 
 VR = 2πεrε0aψδ2 exp(-κH)    Equation 2.4 
where εrε0 is the dielectric permittivity and ψδ is the surface potential.  Equation 2.3 is for 
the case where κa > 10, and Equation 2.4 is for the case where κa < 5.  When polymer 
coatings are used for steric stability, the development of the interaction energy equation is 
of greater interest.  Figure 2.4 displays the overlap areas of different polymer coated 
surfaces with a thickness of δ and a separation distance of h.  The chain concentration is 
denoted as c2 and is twice as concentrated in the overlap area resulting in an osmotic 
pressure, ΠE, that acts to separate the particles.  The interaction energy is defined as the 
integral of force within the overlap area [21]: 
 VS= ∫ -ΠEAdx
h
2δ
     Equation 2.5  
The osmotic pressure can be expressed as a virial expansion in terms of the polymer 
concentration: 
 ΠE=RT (
c2
M2
+ (
v2̅
M2
)
2
1
v1̅
(0.5-χ)c2
2
+…)    Equation 2.6 
Where: 
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 B2= (
v2̅
M2
)
2
1
v1̅
(0.5-χ)     Equation 2.7 
In the above equations, v͞1 and ͞v2 are the molar volumes of the solvent and polymer 
respectively, M2 is the number average molar mass, and χ is the Flory-Huggins interaction 
parameter.  The integral of Adx is the overlap volume, which is defined as vo.  Thus, 
Equation 2.5 can be reduced to the following: 
 Vs = -(2voΠx=2δ – voΠx=h)    Equation 2.8 
Substituting the two term virial expansion for the osmotic pressure gives the final form: 
 Vs = 2RTB2C22vo     Equation 2.9 
In the case of sphere-sphere interaction, the overlap volume can be defined as the 
following: 
 vo=
2π
3
(δ-H/2)2(3a+2δ+H/2)    Equation 2.10 
While the above model is relatively simplistic, it does provide insight on the factors that 
affect colloidal stability which include solvent properties (pH, ionic strength, and χ 
parameter), solution temperature, surface composition, particle size, and particle 
concentration. 
Colloidal stability in blood is a major concern when designing a nanoparticle 
system for drug delivery.  Preventing aggregation is keen since any particle over 200 nm 
will be readily cleared by the spleen [25].  Once the nanoparticles enter the vasculature, 
they will encounter cells, plasma proteins, and various electrolytes.  Considering this 
environment, electrostatic repulsion stabilizers would be rendered relatively useless.  The 
ionic concentration from the electrolytes would screen the electrostatic double layer 
reducing its potential as a barrier [23, 26].  An additional concern of electrostatic repulsion 
stabilizers is the increased detection by macrophages leading to reticuloendothelial system 
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(RES) clearance as nanoparticles of high surface charge, either positive or negative, are 
readily engulfed by macrophages [27]. 
A common stabilizing technique is the addition of poly(ethylene glycol) (PEG) 
based polymer brushes to provide both steric repulsion and stealth properties (discussed in 
the following sections) [28, 29].  Zhang et al. studied the effects of both conjugation 
chemistry and molecular weight of PEG on the colloidal stability of gold nanoparticles 
[29].  Typically, gold nanoparticles are conjugated with PEG through covalently attaching 
a thiol-terminated chain to the particle surface.  An alternative route is to use PEG chains 
capped with thioctic acid which contains a cyclic disulfide.  To evaluate the stability under 
physiological conditions, the nanoparticles were suspended in a solution of phosphate-
buffered saline containing 10% fetal bovine serum at 37 °C while particle size was 
monitored with dynamic light scattering.  The PEG coated systems experienced minimal 
change in particle size over the 48 hour period, and there was no change in trend from the 
low to high molecular weight PEG.  However, the citrate coated particles which rely on 
electrostatic repulsion experienced a fivefold increase in particle size over a period of 10 
minutes.  Similar trends were observed for the 40 nm core nanoparticles; however the 80 
nm core nanoparticles were less stable and experienced aggregation over 24 hours. 
2.4.2 Biocompatibility 
Biocompatibility is a broad term which has come to define an engineered system 
able to fulfill its intended application while minimizing unwanted interactions with the 
body.  In the case of nanoparticle systems, toxicity is typically the critical factor in defining 
their biocompatibility [30].  Polymer coatings are added to nanoparticles to reduce their 
toxicity and help shield them from unintended biological interactions. 
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2.4.2.1 Poly(ethylene glycol) 
One of the most widely studied polymers for biological applications is PEG.  PEG 
is a synthetic hydrophilic polymer that is selected as a means to prevent protein adsorption 
and thus improve circulation time, which minimizes host response to nanoparticles, and 
this will be discussed further in the following section [31, 32].  Surface coatings of PEG, 
which is often referred to as PEGylated, can be arranged as simple polymer brushes 
extending from the surface or as a hydrogel, a crosslinked hydrophilic network. 
For example, Gupta et al. have studied PEG-coated iron oxide and have evaluated 
their toxicity with both live-dead and MTT assays  and effects on cell adhesion and 
morphology on human fibroblasts (hTERT-BJ1) [33, 34].  At concentrations up to 1.0 
mg/ml, PEG-coated nanoparticles remained 99% viable and displayed favorable cell 
proliferation after a 24 hour period [34].  In comparison, uncoated particles observed a 25-
50% decrease in viability starting at a concentration of 250 µg/ml. When studying cell 
adhesion and morphology, the uncoated particles exhibited a significant decrease in 
adhered cells and a disruption in cell membrane and disorganized cytoskeleton from 
endocytosis [33].  PEG-coated particles were still internalized, but they did not display the 
negative effects to morphology [33].   
F. Hu et al. synthesized PEGylated iron oxide nanoparticles through a copper 
mediated atom transfer radical polymerization [35].   When mouse macrophage cells 
(RAW 264.7) were exposed to the PEGylated nanoparticles, the live cell count was 
determined to be >93% of the control indicating no toxic effect at 0.2 mg/ml concentration 
over a 5 day period.  In comparison, uncoated iron oxide nanoparticles observed a 30% 
loss in viability by the second day, but by the fifth day, the viability improved to 90%.  
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Studying the amount of particles internalized, the uncoated iron oxide decreased from 154 
pg/cell to 58 pg/cell over the 5 days, while the PEG-coated remained less than 2 pg/cell.  
Due to cell division, the number of cells would have increased resulting in a lower amount 
of particles internalized per cell. 
While the gold surface is considered inert, the surfactant used in synthesis of gold 
nanorods, hexadecyltrimethylammonium bromide (CTAB), is toxic and remains present 
on the surface [36].  Three approaches were identified as ways to minimize the toxic effect 
of CTAB: removal of excess CTAB through centrifugation or filtration, overcoat with a 
polyelectrolyte such as polystyrene sulfonate (PSS), or through PEGylation.  Rayavarapu 
et al. measured the toxicity using a MTS assay of four independent cell lines exposed to a 
range of concentrations of as-prepared gold nanorods, filtered nanorods to partially remove 
CTAB, PSS treated, and PEG-thiol coated.  The as-prepared and filtered nanorods 
displayed 100% death at all concentrations tested.  At low concentrations, the PSS treated 
nanorods had viabilities of 80+% for all cell lines.  As the concentration increased, the 
viability decreased which the authors attributed to desorption of the PSS-CTAB complex 
from aggregation.  Except for one cell line (human leukemia, HL60), the PEGylated 
particles displayed high viabilities and can be considered nontoxic.  The authors performed 
viability studies and determined dose dependent curves on four independent cell lines: 
human mammary adenocarcinoma (SKBR3), Chinese Hamster Ovary cells (CHO), mouse 
myoblast (C2C12), and HL60.  The LC50 of the HL60 cell line was 103 pM which is 
considerable higher than the other nanorod systems.  HL60 also displayed lower LC50 
values from exposure to the other nanorod systems suggesting it is a less robust cell line.  
Rayavarapu et al. also observed that the PEGylated nanoparticles were the most colloidally 
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stable, and the PSS treated and possibly other polyelectrolytes aggregated upon exposure 
to cell culture media. 
2.4.2.2 Poly(vinyl alcohol) 
In addition to PEG, poly(vinyl alcohol) (PVA) is another synthetic polymer 
commonly synthesized as a hydrogel.  PVA hydrogels are stable and elastic and can be 
formed by either physical or chemical crosslinking [31].  Physically crosslinked PVA 
hydrogels are considered biocompatible and thus have multiple biomedical applications, 
especially in the field of drug delivery. 
An interesting example of the use of PVA coated nanoparticles comes from Petri-
Fink et al. where cell interaction and cellular uptake was preferred since it is required in 
drug delivery [37].  PVA was selected for its ability to form a hydrogel through the 
hydrogen bonding between chains to provide steric repulsion.  Hydrogen bonding also 
forms between the hydroxylated surfaces of the iron oxide nanoparticles and the polymer 
chains resulting in an absorbed hydrogel shell.  In this study, four variations of PVA were 
tested to determine which has the most potential interaction with human melanoma cells: 
unmodified PVA, vinyl alcohol/vinyl amine copolymer, PVA with a random distribution 
of carboxylic acid groups, and PVA with a random distribution of thiol groups.  First, Petri-
Fink et al. determined that only the amine modified PVA coated nanoparticles displayed 
significant interaction by the melanoma cells over 24 hours.  Cytotoxicity analysis, 
measured with a MTT assay, showed that PVA, carboxyl modified PVA, and thiol 
modified PVA coated nanoparticles were non-toxic at 2 and 24 hours.  After 2 hours, the 
amine modified PVA coated nanoparticles displayed no toxicity at all the polymer/iron 
ratios tested.  However, at 24 hours, the high polymer concentration displayed toxicity.  By  
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Figure 2.5.  Structures of cellulose, dextran, pullulan, and chitosan; note the location of 
the glycosidic bonds of the glucose unit. 
  
21 
 
understanding the interaction mechanism, iron oxide shells can be further modified for a 
range of biomedical applications. 
2.4.2.3 Polysaccharides 
Natural occurring polysaccharides have been explored as potential coatings to 
reduce the toxicity of core nanoparticles in addition to PEG or other synthetic polymers.  
Common polysaccharides utilized for coatings include cellulose, dextran, pullulan, and 
chitosan; the structures can be found below in Figure 2.5   [38, 39].  Besides being selected 
for improving biocompatibility, polysaccharides have the potential for selectively targeting 
organs or tissues based on recognition of the molecular structure [40]. 
Iron oxide nanoparticles are a popular candidate for polysaccharide coatings, and 
currently, dextran coated iron oxide nanoparticles are approved by the FDA for MRI 
contrast agent use [41].  Dextran molecules can be attached to the surface of iron oxide 
through various methods, such as the common methods where it is physically adsorbed 
followed by crosslinking or adsorbed through carboxyl modification to facilitate 
interaction with iron atoms on the particle surface [42].  However, when placed in 
phosphate buffer saline solutions, these particles tend to aggregate due to the displacement 
of the dextran by the phosphate salts.  To combat this effect, recently Creixell et al. have 
devised a strategy to covalently bind carboxymethyl dextran to iron oxide nanoparticles by 
first attaching an aminosaline to the particle surface and then utilizing carbodiimide 
chemistry to covalently bind the dextran coating.  They have assessed the stability and 
cytotoxicity, through a resazurin assay, and have determined that the covalently bound 
carboxymethyl dextran nanoparticles were more stable in cellular media and buffer 
solutions and displayed minimal toxicity over a 48 hour and one week period compared to 
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the adsorbed carboxymethyl dextran nanoparticles which displayed significant toxicity at 
higher concentrations.  In addition to dextran-coated iron oxide, Gupta et al. have studied 
pullulan, a nonionic polysaccharide, coated iron oxide assessing viability and effects on 
cellular morphology on hTERT-BJ1 fibroblast using a MTT viability assay and 
visualization [43].  Minimal toxicity was observed by the pullulan coated particles at up to 
2.0 mg/ml concentration after 24 hours of exposure, minimal change in adhesion, and there 
was an enhanced internalization without major disruption of the cytoskeleton due to the 
surface coating. 
Wotschadlo et al. performed an interesting study where they examined the 
interaction of three different polysaccharide coatings with two different cell lines (i.e., 
breast carcinoma, MCF-7, and leukocytes) [39].  The polysaccharides were selected to 
study in the influence of the polymer backbone on cell interaction measured with magnetic 
separation after brief incubation times of 4, 8, and 12 minutes with nanoparticles.  Dextran 
with its α-1→6 linkage displayed a time dependent interaction with both the cancer cells 
and leukocytes with greater uptake by the cancer cells.  Cellulose with its β-1→4 linkage 
displayed limited labeling and no time dependent behavior.  Pullulan with its mixture of α-
1→4 and α-1→6 linkages displayed greater labeling than cellulose and a suggested time 
dependent behavior with the leukocytes.  This seems to imply that the uptake of 
nanoparticles by cells is partially receptor mediated and the architecture of the shell has 
influence over the kinetics of uptake, namely that β-linked polymers are barely 
incorporated in cells. 
Chitosan is a natural polymer derived from the exoskeleton of crustaceans and has 
been of interest to researchers because of its hydrophilic, biodegradable, non-antigenic, 
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non-toxic, and biofunctional properties [44].  Its structure consists of one amino group and 
hydroxyl groups in repeating sequence.  In acidic pH, the amino group will protonate and 
can effectively bind to DNA, making chitosan an interesting candidate for non-viral gene 
carriers that can utilize the oral route of delivery [45].  In addition to native chitosan, 
hydrophobically modified chitosan is being studied for gene delivery.  Bhattarai et al. have 
grafted N-acylated chitosan on gold nanoparticles resulting in a colloidally stable, 
relatively non-toxic carrier [45].  Cytotoxicity was evaluated with MTT assay on three 
different cell lines (i.e., mouse embryo cells, NIH 3T3, colon cancer cells, CT-26, and 
breast carcinoma, MCF-7) and after 24 hours of exposure, all cell lines demonstrated a 
concentration dependent behavior.  The slight toxicity at higher concentrations was 
attributed to cell membrane damage from the polycations interacting with the negatively 
changed membrane.  This toxic effect was minimized by the stability of the nanoparticles.  
At higher concentrations it was still expected that the nanoparticles would aggregate and 
accumulate around the cell membrane. 
2.4.3 Extended Circulation 
In addition to cell toxicity, it is important to gain an understanding of how 
nanoparticles for drug delivery behave in an organism, specifically possessing adequate 
circulation time to reach the intended target, release its active ingredient, and then be 
eliminated from the body without any negative side-effects.  In addition to the factors 
affecting colloidal stability, once a nanoparticle enters the blood stream it will encounter 
phagocytic cells of the RES.  Without specific design considerations, nanoparticles are 
quickly detected and removed from the blood circulation in approximately 10 minutes [46].  
This process is mediated by the adsorption of plasma proteins, opsonins, to the nanoparticle 
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surface rendering the particle more susceptible to phagocytosis either through increased 
activation of phagocytic cells or the formation of aggregates [47].  Opsonins bind to the 
surface primarily through hydrophobic interactions, but electrostatic interactions also play 
a role.  Generally, the goal of surface modification is to reduce the nanoparticle 
hydrophobicity and surface charge density to shield the nanoparticle surface from 
opsonins. 
Along with being selected for its non-toxic properties, PEG is the most widely 
studied polymer for increasing the circulation time of nanoparticles.  The physicochemical 
properties of PEG (i.e., it is nonionic, flexible, and hydrophilic) allow it to form a steric 
barrier on a nanoparticle surface preventing opsonization [25, 46, 47].  In addition to 
hydrophobicity and surface charge, chain flexibility is another factor to consider when 
designing a polymer coating [25].  If the exposed surface consists of flexible chains, it will 
be constantly changing surface structure preventing the immune system from adequately 
designing an antibody around it.  The key design parameters for a PEG coating are chain 
length, shape, and surface density.  The surface density has to be high enough to prevent 
opsonization while not decreasing mobility and flexibility which would decrease 
circulation time.  While significantly increasing circulation time from a few minutes, PEG 
coated nanoparticles are generally cleared within 24 hours which might be attributed to 
desorption or degradation of the PEG shell [46]. 
Polysaccharide coatings are employed to camouflage the nanoparticle surface by 
utilizing their biomimetic properties.  Polysaccharides such as dextran, heparin, hyaluronic 
acid, and chitosan have been shown to alter the opsonization process and increase 
circulation times [46].  In comparison to PEG coatings, polysaccharides might have a more 
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hydrophilic nature but a shorter circulation time [25].  This can be contributed to the 
decreased flexibility of polymer chain due to steric restrictions of the repeating sugar units.  
An additional concern is low levels of circulating antibodies for certain polysaccharides 
which would lead to immunogenic detection and subsequent clearance [46]. 
2.4.4 Active Targeting  
 To ensure the effectiveness of an engineered nanoparticle to the application site an 
active targeting moiety is often utilized.  To increase these specific interactions, 
nanoparticles can be functionalized with a wide range of targeting ligands such as peptides, 
antibodies, small molecules, and carbohydrates [48-53].  By utilizing an extended 
circulation strategy discussed above in conjunction with an active targeting agent, the 
nanoparticles are capable of circulating the body until finding the desired location. 
 One research area where active targeting schemes are of growing interest is cancer 
therapeutic applications.  Due to the systemic side effects associated with current treatment 
modalities, development of a tailored nanoparticle capable of localizing treatment is of 
great interest.  Cancer cells proliferate in an uncontrolled manor so targeting cell markers 
associated with proliferation is a promising area.  Folic acid is essential for cell division 
and cancer cells typically overexpress the folate receptors [50, 54].   For example, chitosan 
functionalized iron oxide nanoparticles were labeled with folate for imaging applications 
and displayed preferential uptake by folate receptor over-expressing cells [55].  In addition 
to folic acid, monosaccharides have been used to not only provide passivation but target 
glucose transport overexpressing cancer cells [56-58].  The family of human epidermal 
receptors, epidermal growth factor receptor (EGFR) and human epidermal receptor-2 
(HER-2), are responsible for cell signaling for growth and proliferation and thus heavily 
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researched [59].  EGFR targeted nanoparticles have demonstrated significant selectivity 
for cancer cells and once internalized, the nanoparticles can induce cellular death when 
exposed to an alternating magnetic field without a measurable temperature rise [60].  
Interestingly, HER-2 targeted nanoparticles are not only capable of reaching the primary 
tumor but micrometastatic sites as well suggesting nanoparticles are able to treat metastatic 
diseases [61].   
 Beyond specific cancer cell targeting, nanoparticles have been designed to target 
the tumor itself.  Recently, Kruse et al. developed CREKA-conjugated iron oxide 
nanoparticles, utilizing the peptide sequence for tumor homing [62].  They demonstrated 
the potential of the nanoparticle system to specifically bind to fibrin–fibronectin complexes 
associated with tumors while at the same time demonstrating a combinational effect of co-
delivering heat from the iron oxide core with cisplatin.   
2.4.5 Drug Loading 
Many drug compounds suffer from poor solubility and poor stability resulting in 
undesired pharmacokinetic and biodistribution properties.  Nanoparticle carriers present a 
solution to this issue.  By incorporating the drug compound into the nanoparticulate system, 
the drug can be successfully transported in the body while being shielded from early 
degradation or release.  In the growing field of nanoparticle drug delivery, there is interest 
in developing smart systems capable of the controlled delivery of the therapeutic. 
2.4.5.1 Temperature Responsive Coatings 
Temperature responsive polymers undergo a reversible phase transition at a certain 
environmental temperature, known as the lower critical solution temperature (LCST).  At 
the LCST, the polymer phase separates resulting in the shrinking or collapsing of a 
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crosslinked polymer system (e.g., hydrogel).  Poly(N-isopropylacrylamide) (PNIPAAm) 
undergoes this transition at around 33 °C and is one of the most widely studied temperature 
responsive polymers studied in the field of drug delivery [31].  By coating nanoparticles 
capable of absorbing a specific stimulus to generate heat, a remote actuated drug delivery 
system can be created.  A schematic overview of drug loading and release from PNIPAAm 
core-shell nanoparticles can be seen below in Figure 2.6.  For example, Wei et al. utilized 
ATRP to coat gold nanorods with PNIPAAm and loaded norvancomycin into the polymer 
shell utilizing hydrogen bonding interactions [63].  When irradiated with near infrared 
light, the gold nanorods generated localized heat which drove the PNIPAAm shell through 
a phase transition modulating the release of the drug molecules. 
Similar to gold nanoparticles, magnetic particles have been functionalized with PNIPAAm 
coatings for the controlled actuation and release of drugs following an exposure to an 
alternating magnetic field.  Purushotham et al. have developed PNIPAAm coated iron 
oxide nanoparticles for multimodal cancer therapy consisting of the simultaneous delivery 
of a chemotherapeutic (doxorubicin) and hyperthermia [64-66].  When performing the 
release, two different polymer states were utilized with significantly different release rates 
observed.  Initially, the doxorubicin loaded nanoparticles were dehydrated and transferred 
to PBS at 24, 37, and 42 °C resulting in the cumulative release of 28.8%, 36.3%, and 41%, 
respectively, after an initial burst release followed by similar steady state release [64].  In 
comparison, swollen nanoparticles dispersed in PBS at the same temperature observed at 
cumulative release of 42.6% (24 °C), 63.7% (37 °C), and 78.1% (42 °C) after a longer 
rapid release phase [66].  Purushotham et al. attribute the difference to changes the 
PNIPAAm matrix undergoes during the vacuum dehydration.  During the dehydration step,  
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Figure 2.6. Schematic overview of the (a) drug loading and (b) subsequent release 
experiments at temperatures above the LCST. 
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there is a heterogeneous distribution of doxorubicin from the migration of water due to 
evaporation and the re-swelling behavior of the shell is altered.  The collapse of the 
NIPAAm shell above the LCST was only observed in the swollen state nanoparticles 
making triggered response experiments feasible.  Purushotham et al. demonstrated that 
drug release can be controlled by cycling the temperature across the LCST [66].  In addition 
to developing the nanoparticle system, they set out to develop a mathematical model to 
predict the performance in multimodal cancer therapy [65].  Using the experimental data 
highlighted above to determine the diffusion coefficient of doxorubicin, Ddox, the different 
release profiles of nanoparticles of different sizes and drug loaded were modeled with the 
following equation derived from Fick’s second law of diffusion: 
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    Equation 2.11 
where Mt is the cumulative mass of drug released in time t, M∞ is the cumulative mass of 
drug released at infinite time (assumed to be the total drug loaded in the nanoparticles), 
and R is the radius of the composite nanoparticles.  The model demonstrates that drug 
release occurs faster at higher temperatures and decreased shell thickness.  By changing 
the shell thickness the release rates can be tuned to meet the designer’s needs.   
One of the key pitfalls to PNIPAAm loaded shells is that the drug compound of 
choice must be hydrophilic, while most novel drugs tend to be hydrophobic.  To deliver 
hydrophobic drugs, different nanoparticle carriers had to be developed. 
2.4.5.2 Cyclodextrin Functional Groups 
Cyclodextrin molecules are cyclical formations of glycosidic bonds that have been 
studied as potential drug carriers.  When arranged in this cyclical structure, the hydroxyl 
groups from the sugar molecules are oriented on the outside resulting in a relatively 
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hydrophobic core.  Since solubility is a major issue with most pharmaceutical agents, 
hydrophobic drugs can be successfully loaded into the cavity improving the solubility of 
the compound.  The drug is held in the cavity through hydrophobic interactions which can 
be depressed by the application of heat thereby accelerating the release of the compound 
[67].  Hayashi et al. have developed β-cyclodextrin (CD) functionalized magnetic 
nanoparticles with folic acid targeting ligands for the controlled delivery of tamoxifen 
(TMX) to breast cancer tumors.  They demonstrated a pulsatile release behavior of TMX 
from the CD functionalized nanoparticles when an alternating magnetic field is applied.  
Similarly, Yallapu et al. has synthesized CD functionalized iron oxide nanoparticles for the 
encapsulation and delivery of curcumin for cancer therapy [68].  In addition to CD, the 
nanoparticle was further functionalized with a pluronic F127 (co-polymer containing PEG 
and polypropylene chains) coating to add additional stability to the system. 
2.4.5.3 Gatekeeping Structures 
Mesoporous silica nanoparticles (MSNs) provide the opportunity to directly load 
the therapeutic agent into the core nanoparticle and then using a stimuli-responsive shell 
as the gatekeeper to regulate the encapsulation and release.  Potential candidates to act as 
gatekeepers are smaller nanoparticles, organic molecules, or supramolecular chemical 
entities [12].  For example, Slowing et al. have used cadium sulfide (CdS) nanoparticles to 
block drug loaded pores preventing any premature release [69].  CdS was held in place 
with a chemically cleavable disulfide linkage that was cleaved by the addition of a reducing 
agent allowing up to 85% of the loaded molecules to be released.  Hong et al. developed a 
core-shell architecture by coating MSNs in PNIPAAm coating using RAFT polymerization 
where the polymeric coating acts as the gatekeeper [70].  Unlike drug loading in the 
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polymeric network, the active compounds can be loaded in the pores of the core 
nanoparticle allowing compounds with various chemical properties.  When the temperature 
falls below the LCST, the polymeric shell expands allowing drug release. 
2.5. Conclusions and Perspectives 
 This chapter has explored a variety of coatings and additives incorporated onto 
nanoparticles in a core-shell architecture for biomedical applications.  An emphasis was 
placed on coatings selected for improving colloidal stability, reducing nanoparticle 
toxicity, increasing circulation time, active targeting, and controlling different mechanisms 
of drug loading and release, but those are only few of the functions imagined by 
researchers.  As nanotechnology progresses, researchers will become more and more 
creative in the quest to develop a perfect nanoparticle capable of being safely delivered to 
the body, actively finding the optimal location for delivery, and delivering the payload in 
a controlled fashion. 
2.6. References  
 References are located at the end of the dissertation subdivided by chapters. 
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Chapter 3: Magnetic Nanoparticle Mediated Energy Delivery for Cancer Therapy 
3.1. Introduction 
Magnetic nanoparticles are being studied for a wide range of biomedical 
applications usually relaying on the theranostic capabilities of the magnetic core to provide 
alternating magnetic field mediated thermal therapy and enhanced contrast in magnetic 
resonance imaging [1-4].  Thermal therapy is the process of elevating tumor tissue 
temperature for therapeutic gains and has been studied for decades, but has yet to gain 
widespread clinical recognition either as an independent treatment or in conjunction with 
traditional therapies.  To overcome the barriers of traditional hyperthermia methods – such 
as localizing the heat, tumor targeting, and even temperature distribution across the tumor 
– it is of particular interest to utilize the remote heating of magnetic nanoparticles known 
as magnetic fluid hyperthermia (MFH) [5].  This chapter will explore the use of magnetic 
nanoparticles as a means to deliver thermal therapy.  Briefly, the underlying physics of 
magnetic nanoparticles will be discussed followed by mechanisms of thermal therapy.  The 
chapter will end with the most recent advances in the area of magnetically mediated energy 
delivery (MagMED) therapy, which holds great promise in treatments. 
3.2. Magnetic Properties  
3.2.1 Magnetic States   
 Magnetic materials are classified based on the arrangement and behavior of their 
magnetic dipole moments.  In the presence of an external magnetic field, the material’s 
response is characterized by the magnetic susceptibility, χ, defined by the following 
equation: 
 χ = M/H      Equation 3.1 
33 
 
 
Figure 3.1. Arrangement of magnetic dipoles for different magnetic materials where H 
indicated the direction of an external magnetic field (a).  Representative magnetization 
curves highlighting the dominant processes and hysteresis loop (b). 
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where M is the magnetization of the material defined by the magnetic moment per unit 
volume and H is the macroscopic magnetic field intensity [6].  Materials with a negative 
magnetic susceptibility are called diamagnetic since the induced moment is opposite of the 
external field.  Materials with a positive susceptibility are called paramagnetic since the 
induced moment is aligned with the external field.  Once the external field is removed, the 
material does not retain a magnetic moment as thermal fluctuations randomize the dipoles.  
When a material has an ordered array of magnetic moments without an external field 
present, they can be classified as ferromagnetic, ferromagnetic, antiferromagnetic, helical 
or more complex forms.  Illustrated in Figure 3.1a are the various arrangements on 
magnetic dipoles in the presence and absence of an external magnetic field. 
Actual macroscopic materials are composed of magnetic domains, or small regions 
where the local magnetization is uniform.  In a multi-domain material the moments are not 
necessarily parallel.  When a magnetic field is applied, the magnetization of material 
undergoes a typical closed loop response curve.  In a weakly applied field, favorable 
orientated domains increase in size at the expense of unfavorable oriented domains.  As the 
field strength increases the domain magnetization rotates with respect to the field direction 
until saturation is reached.  When the field is shut off, the material will retain residual 
magnetization and a reverse field is required to reduce the induction back to zero.  In a 
multi-domain material, the energy required to move the domain walls and overcome 
anisotropic energy results in an irreversible path illustrated as the typical hysteresis loop in 
Figure 3.1b.   
Below a certain particle size, multi-domains become energy unfavorable and the 
particle becomes a single domain [7, 8].  In the case of magnetite, this single domain state 
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occurs around 30 nm in diameter [9].  At this small particle size, the magnetic reversal 
energy is small enough that the dipole moment becomes thermally unstable at ambient 
temperature [10].  This phenomenon is known as superparamagnetism.  The magnetic 
response curve of superparamagnetic materials have zero hysteresis since thermal energy 
is sufficient to destabilize the magnetic moments to the initial orientation. 
3.2.2 Heat Generation  
 In an alternating magnetic field, magnetic materials dissipate heat in response to 
the reversal in magnetization.  Heat generation occurs primarily though hysteresis losses 
and relaxation losses.  In the case of multi-domain materials, area between the hysteresis 
loops quantifies the magnetic energy delivered as heat.  Single domain materials can 
display similar hysteresis losses when the external field exceeds the coercivity field [7].  
However, in relevant clinical settings such parameters would rarely be achieved [11].  
Thus, the heating properties of superparamagnetic particles are dominated by Brownian 
and Neel relaxation losses [12].  Neel relaxation is defined by the rotation of the internal 
magnetic moment in response to the magnetic field.  As a suspension of particles is free to 
rotate, the Brownian relaxation is defined as the physical alignment with respect to the 
alternating magnetic field. 
 Since Brownian and Neel relaxations occur in parallel, the effective relaxation time 
is given by the following equation: 
 
1
𝜏
=  
1
𝜏𝐵
+ 
1
𝜏𝑁
      Equation 3.2  
where τB and τN are the Brownian and Neel components respectively.  These relaxation 
times are defined by the following relationships: 
 𝜏𝐵 =
3𝜂𝑉𝐻
𝑘𝐵𝑇
      Equation 3.3 
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 𝜏𝑁 = 𝜏0exp
𝐾𝑉
𝑘𝐵𝑇
     Equation 3.4  
where η is the viscosity of the fluid, VH is the hydrodynamic volume, kB is the Boltzmann 
constant, T the absolute temperature, τ0 is the characteristic flipping time (on the order of 
10-9 s), K is the magnetic anisotropy, and V is the magnetic volume.  From the above 
equations, the Brownian relaxation is governed by the hydrodynamic properties of the 
system.  For example, if the particles become constrained by viscosity the relaxation time 
increases and Neel relaxation component dominates.  The Neel relaxation is governed by 
the energy barrier against magnetization reversal and thus an inherent material property.  
 The specific loss power, SLP, is a means of quantifying the heat generated by the 
particle system in response to the alternating magnetic field.  Assuming the system is 
monodispersed, it can be expressed as the following: 
 𝑆𝐿𝑃 = 𝜒0𝐻0
2𝜇0𝜋
2𝜋𝑓2𝜏
1+(2𝜋𝑓𝜏)2
    Equation 3.5 
where χ0 is the initial susceptibility, H0 is the field amplitude, µ0 is the permeability of free 
space, f is the field frequency, and τ is the relaxation time.  The initial susceptibility, χ0, can 
further be determined through the Langevin equation such that it becomes a function of 
domain magnetization and volume fraction of particles [12].  From Equations 3.2-5, the 
heat generated by particles is dependent on field properties (strength and frequency), 
material properties (domain magnetization, anisotropy constant, particle size) and fluid 
properties (viscosity, hydrodynamic size, and concentration). 
 While the above SLP equation is effective for modeling the theoretical performance 
of a particle system, experimental quantification typically relies on the specific absorbance 
rate (SAR) value.  SAR reports the heat output normalized to mass and serves as a means 
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of comparing the heating performance of different magnetic particle systems.  SAR can be 
calculated as: 
SAR = (∑iCimi)/m * (ΔT/Δt)   Equation 3.6 
where Ci is the heat capacity, mi is the individual mass of the components heated (fluid and 
particles), m is the mass of the component generating heat, and ΔT/Δt is the initial slope of 
the heating profile.  SAR should be noted for its inherent simplicity to calculate based on 
experimental data and material properties.  However, it does not incorporate the field 
parameters which makes direct comparisons of particle systems difficult.  
3.3. Thermal Therapy 
Two temperature ranges of thermal therapy have traditionally been identified: 
hyperthermia, 40-45 °C, and thermoablation, ≥46 °C.  Hyperthermia can induce cellular 
death on its own, but it is better suited for enhancing the effects of chemotherapy and/or 
radiation therapies [13-16].  The exact cause of the increased sensitivity is still under 
investigation, but it is believed to be a combination of cellular effects – changes in the cell 
membrane, impaired transport, cytoskeleton damage, and impairment and damage to 
cellular proteins and DNA – and physiological effects – changes in the vasculature, 
increased perfusion, and oxygen levels [15, 17, 18].  Due to the elevated temperature, 
thermoablation leads to direct cell necrosis and can be used an independent treatment [19]. 
The main issue facing hyperthermia is a clinical means to deliver the elevated temperature 
to the tumor site.  Current methods are characterized by the amount of surrounding tissue 
heated and subdivided into whole body hyperthermia (water baths or heating chambers), 
localized hyperthermia (antennas emitting microwaves or ultrasound), and regional 
hyperthermia (array of antennas) [13, 15].  Localizing the heat, tumor targeting, and even 
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temperature distribution across the tumor are some of the shortcomings of the current 
methods of delivering hyperthermia.  Localization of the thermal therapy is necessary to 
prevent damage to the surrounding tissue and minimize patient discomfort and even 
heating is necessary to guarantee therapy effectiveness.   
As discussed in the previous section, nanoparticles can generate heat when exposed 
to an alternating magnetic field.  Magnetic fluid hyperthermia (MFH) involves the 
collection of nanoparticles at the tumor site through either active or passive targeting or 
direct injection, and the application of the alternating magnetic field to provide localized 
heating throughout the tumor.  This therapy overcomes the barriers of traditional 
hyperthermia methods by treating deep-seated and poorly accessible tumors, delivering 
heat specific to tumor ensuring less damage to healthy tissue, providing uniform 
temperature distribution, and a higher rate of heat transfer for improved efficacy [20, 21]. 
3.3.1 Physiological Effects  
 Despite being written over a decade ago, the hallmark paper examining the 
physiological effects of hyperthermia remains the review by Hildebrandt et al. [17].  While 
assessing in vitro studies, Hildebrandt et al. observed that toxicity at increasing 
temperatures often displays a two-step curve where initial damage results in cellular arrest 
and with additional heat the trend displays exponential cell death.  This trend indicates 
protein denaturing as the thermal dose required to reach the irreversible cell death 
corresponds to the energy required to denature proteins.  Hyperthermia was observed to be 
most lethal in the M and S phase where the mitotic apparatus and chromosomes are most 
susceptible to damage.  During heating both RNA and DNA synthesis is impaired along 
with the inhibition of repair mechanisms to compound the initial damage.  Beyond protein 
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denaturing, the fluidity and stability of the cell membrane is altered along with transport 
proteins being impeded.  However, it appears that this observation is more tied to early 
indications of apoptosis instead of a direct effect.  When multiple cycles of hyperthermia 
are applied, cells often display a thermal tolerance explained by the activation of heat shock 
proteins protecting unfolded proteins.   
When applying hyperthermia in vivo specific features become apparent.  The 
application of heat above 42 °C decreases blood flow exacerbating the already hypoxic and 
acidic environment of the tumor.  Initial studies with whole body hyperthermia have 
demonstrated that despite changes in blood flow, healthy tissue has better thermoregulation 
and remains relatively unaffected. However, moderate hyperthermia (< 42 °C) may have 
the opposite effect and increase blood supply to the tumor.  Such an effect would improve 
oxygen flow and thereby improve the efficacy of radiation therapy.  Initial clinical studies 
during the 1980’s and 1990’s were performed without any molecular basis and future 
research needs to account for the mechanisms of action to improve the efficacy of 
treatment. 
3.3.2 Combinational Effects with Chemotherapy  
 When used in conjunction with chemotherapy, hyperthermia has the potential of 
producing synergistic effects.   Elevated temperatures are able to influence the 
pharmacodynamics aspects by accelerating the primary mode of drug action and increasing 
intracellular drug concentration [22].  The pharmacokinetic aspects are also affected 
whereby drug uptake, distribution, and metabolism are altered.  When selecting a 
chemotherapy for dual therapy it is important to consider the mechanism of action so the 
therapies will not work against each other.  A recent review by Torres-Lugo and Rinaldi 
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provides a detailed summary of common chemotherapeutics used in conjunction with 
hyperthermia [23].  Perhaps most interesting from the summary is that the local delivery 
of heat via magnetic nanoparticles often improves chemotherapy efficacy more than bulk 
delivered heat suggesting a localized effect.  
Beyond a co-delivery of magnetic nanoparticles with chemotherapeutic, 
nanoparticles are being functionalized to be drug carriers for dual therapy applications.  
Such functionalization allows the possibility to track drug location with MRI and utilize 
magnetic targeting [24-26].  One of the most common techniques is to load the drug into a 
polymer coating or polymer particle composite [27, 28].  Release is based on diffusion and 
the increased temperature during hyperthermia accelerates the release rate.  A concern with 
this technique is sufficient drug loading and the nanoscale release path.  However, 
Purushotham et al. predicts that the amount of doxorubicin required and loaded into 
nanoparticles is similar to the amount of particles required for hyperthermia [11].  More 
complex structures can be employed such as attaching the drug to the particle surface or 
tethering a drug loading group to the surface.  For example, Hayashi et al. provide an 
interesting strategy of attaching cyclodextrin groups to the surface to transport hydrophobic 
drugs [29].  An in-depth discussion of drug loading in polymeric coatings was explored in 
the previous chapter. 
 To determine the effectiveness of dual therapy, Babincova et al. described a simple 
synergy test for combinational therapy based on a model previously established for two 
drug systems [30, 31].  Their nanoparticle system consisted of cisplatin functionalized to 
the particle surface.  In the synergy test the following variables were defined [A], [B], and 
[A+B] as the percent viability of hyperthermia, chemotherapy, and combinational therapy 
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respectively.  The combined effect is quantified as: [A+B] < [A] x [B] / 100, synergistic; 
[A+B] = [A] x [B] / 100, additive; [A] x [B] / 100 < [A+B] < [A], if [A] < [B], subadditive; 
[A] < [A+B] < [B], interference; and [B] < [A+B], if [A] < [B], antagonistic. 
 Dual magnetic particle delivered hyperthermia and chemotherapy has recently been 
studied by our research group.  Meenach et al. explored the potential of utilizing bulk 
nanocomposite hydrogels to deliver paclitaxel and heat [32].  Paclitaxel was released from 
the hydrogel in a non-Fickian profile.  Three independent cell lines were exposed to the 
combinations of therapy and it was determined that hyperthermia improved the efficacy of 
paclitaxel in A549 cells.  Kruse et al. studied the co-delivery of CREKA-conjugated iron 
oxide nanoparticles with cisplatin [33].  CREKA was selected for its tumor homing 
properties.  The effectiveness of the combination of cisplatin and magnetic nanoparticle 
delivered hyperthermia was found to be additive using the equation described above. 
3.4. Intracellular Hyperthermia and MagMED 
 A major translational hurdle of magnetic nanoparticle mediated hyperthermia is 
that a large concentration of nanoparticles is required to achieve the necessary increase in 
temperature in vitro and especially in vivo, thus limiting the application to direct injection 
into solid tumors for in vivo application [34, 35].  Medical imaging would be required to 
facilitate guided injection into a solid tumor in which the advantages of MFH over 
traditional surgical resection or other localized treatments would become minimal or 
nonexistent.  While utilizing the enhanced permeability and retention effect has been 
proposed for systemic delivery of nanoparticles, concerns over achieving sufficient tumor 
accumulation has been raised [36, 37].  When MFH was in its infancy, Gordon et al. 
hypothesized that intracellular hyperthermia would be more effective than extracellular by 
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overcoming a potential thermal barrier created by the cell membrane [38].  Intracellular 
hyperthermia would negate the clinical issue of high nanoparticle concentrations as only 
the cells themselves and not the surrounding tissue would have to be heated to the 
hyperthermia range.  To facilitate nanoparticle internalization, nanoparticles have been 
functionalized with a wide range of targeting ligands such as peptides, antibodies, small 
molecules, and carbohydrates [39-44].  Usually, these targeting ligands were developed for 
medical imaging and diagnostic purposes.  Combining the therapeutic potential and 
enhanced contrast properties of nanoparticles has created the new field of theranostics.  For 
a more detailed discussion on this field, the authors refer the reader to the following reviews 
[45-47].  
 Following successful results demonstrating the potential for MFH, researchers 
turned their attention to intracellular hyperthermia [48-50].  For example, Jordan et al. 
explored the internalization of dextran and amine functionalized nanoparticles by four cell 
lines in vitro [51].  Based on the internalization, they observed a three-fold decrease in 
clonogenic survival by nanoparticle mediated hyperthermia compared to water bath 
mediated hyperthermia, which demonstrated the potential to deliver heat to the targeted 
cells.  Fortin et al. studied anionic coated maghemite and cobalt ferrite and determined that 
cancer cells sufficiently internalize the particles at the rate of about 25 pg per cell over the 
course of 1 hour [52].  These cells were collected and dispersed at a concentration of 20 
million cells per 0.3 ml and generated sufficient heating in a magnetic field to achieve the 
hyperthermia range.  The authors explored the heating contributions from the two 
relaxations and concluded that Neel relaxation is dominant during intracellular 
hyperthermia as the Brownian contribution was minimized while entrapped in intracellular 
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vesicles. Thus, future designed particles should emphasize the Neel contribution.  Iron 
oxide based nanoparticles can be doped with various transitional metals to generate 
different physical and magnetic properties to improve the likelihood of successful 
intracellular hyperthermia [53, 54].  However, concerns over the toxicity of transition 
metals in the body have stalled future advances. 
 Despite promising initial results and room for conceptual development, the 
mechanism and feasibility of intracellular hyperthermia has been debated for over a decade.  
The debate stems from the heat transport calculations by Rabin that demonstrated 
theoretically that the relative heat transfer should be insufficient to induce damage to a cell 
[55].  In the paper, Rabin explored three length scales: nanoscale (5-100 nm), microscale 
(2-20 µm), and macroscale (20 mm).  For a typical particle, the steady state temperature 
difference for a single particle is no greater than 10-5 °C implying that a single particle is 
incapable of thermal damage.  Scaling up to the microscale, in order to achieve a local 
threshold of 43 °C would require a cluster of nanoparticles close to 200 µm in diameter – 
far larger than a single cell.  If the local scale is changed to just heating a single cell of 15 
µm is used, the heating power required would be two times what is typically achieved in 
literature.  At the macroscale, the analysis modeled a spherical tumor containing uniformly 
distributed nanoparticles.  He determined that the minimal diameter required would be 1.1 
mm limiting the therapy to large tumors.  All calculations were performed in the absence 
of blood perfusion which would add an additional cooling effect to the macroscale 
calculations.   
 However, ground breaking work by Creixell et al. demonstrated that internalized 
targeted nanoparticles can induce cellular death when exposed to an alternating magnetic 
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field without a measurable temperature rise [56].  The iron oxide nanoparticles were coated 
with carboxymethyl-dextan and conjugated with epidermal growth factor (EGF) targeting 
ligands.  The targeted nanoparticles were internalized by breast cancer cells at a greater 
rate than non-targeted, and when exposed to the alternating magnetic field, a 99.9% 
reduction in cell viability was demonstrated. By utilizing appropriate targeting ligands and 
this observed intracellular effect where internalized nanoparticles deliver therapeutic gains 
without perceived temperature rise, the possibility of using magnetic nanoparticles to treat 
metastatic lesions could be realized instead of being limited to solid tumors.  For example, 
HER-2 targeted nanoparticles are not only capable of reaching the primary tumor but 
micrometastatic sites as well and could be a good targeting ligand for this form of therapy 
[57].  This potential therapy has been coined as ‘magnetically mediated energy delivery’ 
(MagMED), and it represents a promising field of therapeutics [58].  The provocative 
question now facing researchers is the exact mechanism of cytotoxicity, and this still needs 
to be explored.  Possible mechanisms at play are local heating effects, physical-mechanical 
effects (rotational or vibrational movements), or chemical effects, and each of these will 
be explored below.   
 Experimental evidence demonstrating local or nanoscale heating usually involves 
changes in a fluorescent polymeric shell or involves nanoparticles in the direct vicinity of 
a liposomal carrier increasing the permeability of the bilayer [59-61].  For example, Polo-
Corrales and Rinaldi developed iron oxide nanoparticles coated with a poly(N-
isopropylacrylamide) shell with a fluorescent tagged acrylamide incorporated into the 
polymeric coating [60].  The polymeric shell is temperature responsive undergoing a lower 
critical solution temperature at 35 °C, at which the fluorescence intensity increases with 
45 
 
the changes in local solvent polarity.  It was observed with magnetic field exposure that 
the surface temperature of the nanoparticles was able to immediately drive this transition 
temperature while the solution temperature lagged behind.  The localized heating effect 
observed experimentally may attribute to the cytotoxicity of the therapy by directly heating 
and damaging local subcellular components. 
 In the presence of the alternating magnetic field, the nanoparticles would be 
physically rotating and realigning themselves in chains along the field.  The mechanical 
forces from magnetic nanoparticle actuation on the range of femto to piconewton have been 
reported in literature to cluster cellular receptors, distort ion channels, and stimulate the 
cytoskeleton [62-64].  These mechanical forces could be used to induce apoptosis through 
lysosomal membrane permeabilization.  Increasing the permeability of lysosomes will 
induce cellular death through the release of cathepsins from the lysosomal compartment 
into the cytosol where they participate in apoptotic pathways [65-67].  Such a strategy is 
attractive to researchers as it has been shown to induce cellular death in cancer cells which 
typically have resistance to apoptotic pathways [68].  In follow-up work with the EGF 
targeted iron oxide nanoparticles developed by Creixell et al., Domenech et al. observed 
that the nanoparticles were specifically being internalized into lysosomal compartments 
[69, 70].  Upon exposure to the alternating magnetic field, they observed an increase in 
lysosomal permeability and decreased viability as a result of their intracellular treatment.  
They attributed this observation to either heat dissipation or mechanical disruption of the 
lysosomes.  Zhang et al. developed iron oxide nanoparticles coated with lysosomal protein 
marker antibodies to specifically accumulate along the lysosome membrane [71].  In this 
case, the alternating magnetic field applied was at 20 Hz where only physical rotations by  
46 
 
 
Figure 3.2. Schematic of envisioned route of MagMED therapy through apoptosis 
triggered by lysosomal membrane permeabilization.  Targeted nanoparticles would 
circulate the body until coming into contact with cancer cells.  The targeting ligand binds 
to the respective cell marker (A) and the nanoparticles are internalized by the cell entering 
lysosomes (B).  When the alternating magnetic field is turned on the nanoparticles are 
actuated and the energy delivered disrupts the lysosomal membrane spewing the contents 
(C). 
  
 
B) A) C) 
47 
 
the nanoparticles would be actuated.  The resulting cellular apoptosis occurred due to the 
lysosomal disruption from the rotational forces.  A schematic of magnetic nanoparticle 
actuated lysosomal membrane permeabilization can be found below in Figure 3.2. 
 Further evidence of lysosomal membrane permeabilization was also observed by 
Sanchez et al. through iron oxide nanoparticles conjugated with a synthetic replica of 
gastrin to target CCK2R receptors frequently overexpressed by cancer cell lines [72].  
Despite a relatively low heating power from the core nanoparticles and low amount of 
internalization, with alternating magnetic field exposure the cells displayed lysosome 
membrane permeabilization followed by the leaking of cathepsin B resulting in cellular 
death.  In follow-up work, the authors fabricated a miniaturized electromagnet to produce 
an alternating magnetic field while cells are studied in real-time using confocal microscopy 
[73].  Within 30 minutes of alternating magnetic field exposure, the cells displayed elevated 
reactive oxygen species levels and lysosomal permeabilization.  Interesting, in some cells 
the lysosomes were influenced by the field and organized in needle-like formations.  
Considering the wide variety of assays available, this technology opens the possibility to 
gain fundamental knowledge of cellular and molecular mechanisms occurring during 
treatments. 
 One potential chemical effect would be the production of reactive oxygen species 
(ROS) from iron oxide nanoparticles.  In the presence of endogenous hydrogen peroxide, 
free radicals are generated through Fenton-like chemistry [74, 75].  Free radical generation 
results in cellular oxidative stress, which is believed to be one of the key underlying 
mechanisms of concentration dependent cytotoxicity [76, 77].  In previous work, we have 
demonstrated that targeted antioxidant nanoparticles of polytrolox are able to suppress 
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ROS generation and protect cells from concentration dependent iron oxide cytotoxicity 
[78].  One of the interesting questions in this field is whether the source of the Fenton-like 
chemistry is homogeneous or heterogeneous catalytically driven.  Voinov et al. have 
demonstrated through spin-trapping EPR that γ-Fe2O3 nanoparticles produce hydroxyl 
radicals on the surface at a 50-fold increase compared to dissolution of free ions [79].  
However, accounting for nanoparticles primarily being internalized into lysosomes, the 
shift in pH (~4.5) would result in some dissolution of iron oxide to iron ions.  These free 
ions have the potential to leave the lysosome to the cytosol, mitochondria, or endoplasmic 
reticulum where they would encounter conditions more favorable to Fenton-like chemistry 
in terms of available hydrogen peroxide [74, 80-83].  While studying the roles of silica 
coatings for surface passivation, the toxicity of iron oxide nanoparticles were tied to 
intracellular release of iron ions which would react with mitochondrial hydrogen peroxide 
[84].  Limited research has been performed studying the effects of magnetic nanoparticles 
in an alternating magnetic field on ROS production.  Recently, we have demonstrated that 
the generation of ROS is enhanced in presence of an alternating magnetic field [85].  At 
nanoparticle concentrations where there was no observable temperature rise, we observed 
a significant increase in ROS generation compared to the Arrhenius prediction.  We believe 
that as a result of the local nanoscale heating the heterogeneous catalytic generation of ROS 
is accelerated.  However, in follow up work we studied the role of nanoparticle coatings 
and observed the ROS generation was significantly impaired (submitted to Acta 
Biomaterialia).  One of the coated systems involved glucose functionalization, and it was 
efficiently internalized into lysosomes and induced significant apoptosis compared to the 
other nanoparticles, reinforcing the physical or thermal mechanisms discussed above.  
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Despite this one study, heterogeneous catalysis coupled with the enhanced reactivity 
though nanoscale heating is another route of MagMED worth exploring. 
While not a direct chemical effect, Ito et al. has provided an interesting example of 
intracellular hyperthermia inducing an immune response in cancer cells demonstrating the 
potential to deliver immunotherapy [86].  Antibody targeted liposomes containing iron 
oxide nanoparticles were synthesized capable of being internalized by cells and providing 
sufficient heating to achieve hyperthermia.  The authors determined this therapy to have 
two mechanisms of actions revolving the expression of heat shock proteins (HSP).  When 
sub lethal damage is applied, the cells over express HSP, which in-turn increase the amount 
of surface MHC peptide complexes, which recruit cytotoxic T cells.  Alternatively, the heat 
generated by the nanoparticles is capable of inducing necrosis.  This sudden cellular death 
releases the cell content including HSP complexes, which interact with neighboring tumor 
cells and recruit monocytes.  Thus, if any targeted therapy only effectively eliminates the 
outer cells of a tumor, the resulting immune response could assist in eliminating core cells. 
3.5. Conclusions and Perspectives  
Through MagMED, cancer cells are eliminated without a macroscopic temperature 
rise, and this mode of therapy opens the possibility of applying magnetic nanoparticles in 
ways previously not imagined.  Previously, the focus was improving the heating 
capabilities to overcome the thermal delivery limitations, and now, the attention is shifting 
to intracellular targets.  Further studies need to be performed to gain a better fundamental 
understanding of the mechanisms at play.  However, an exciting prospectus is to combine 
the knowledge gained through combined chemotherapy and MFH with this new therapy.  
Novel nanoparticle architectures can be synthesized to deliver the chemotherapeutic 
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intracellular, relying on the nanoscale effects to improve efficacy.  For example, the 
nanoscale heating could be used trigger drug release or the mechanical effects could 
increase the lysosomal permeability facilitating better drug leakage to the cytosol.  The 
future of cancer medicine is personalized care, and novel architectures should be designed 
with interchangeable targeting ligands and chemotherapy payloads to tailor treatment to 
each individual patient and disease. 
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Chapter 4: Synthesis and Characterization of PEG-Iron Oxide Core-shell Composite 
Nanoparticles for Thermal Therapy 
In this study, core-shell nanoparticles were developed to achieve thermal therapy that can 
ablate cancer cells in a remotely controlled manner.  The core-shell nanoparticles were 
prepared using atomic transfer radical polymerization (ATRP) to coat iron oxide (Fe3O4) 
nanoparticles with a poly(ethylene glycol) (PEG) based polymer shell.  The iron oxide core 
allows for the remote heating of the particles in an alternating magnetic field (AMF).  The 
coating of iron oxide with PEG was verified through Fourier transform infrared 
spectroscopy and thermal gravimetric analysis.  A thermoablation (55 °C) study was 
performed on A549 lung carcinoma cells exposed to nanoparticles and over a 10 minute 
AMF exposure.  The successful thermoablation of A549 demonstrates the potential use of 
polymer coated particles for thermal therapy.  The information included here is adapted or 
directly taken from work previously published: 
Robert J. Wydra, Anastasia M. Kruse, Younsoo Bae, Kimberly W. Anderson, J. 
Zach Hilt. Synthesis and Characterization of PEG-Iron Oxide Core-Shell 
Nanoparticles for Thermal Therapy. Materials Science and Engineering C: 
Materials for Biological Applications, 33(8): 4660-4666, 2013. 
 Reprinted with permission from Elsevier. 
4.1. Introduction 
 Due to their unique physical properties, iron oxide nanoparticles are being studied 
for a wide range of biomedical applications such as imaging, targeted delivery, and thermal 
therapy of cancer [1-4].   Superparamagnetic nanoparticles remotely heat in an alternating 
magnetic field primarily due to the Brownian relaxation (physical rotation of the particles) 
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and Neel relaxation (rotation of the magnetic moment) [5-7].  The particles absorb the 
energy from the magnetic field and convert it into heat through the aforementioned 
relaxations [8].  Surface modification plays an essential role in determining the success of 
nanoparticles in their application by improving stability, preventing agglomeration, 
improving biocompatibility, and providing additional functionalities (e.g. targeting 
antibodies) [9-13].  PEG-based functionalization is common for biological applications as 
a means to prevent protein adsorption and thus improve circulation time and minimize host 
response to the particles [14].  One method of functionalizing the particles is utilizing a 
surface initiated atom transfer radical polymerization (ATRP) [15-17].  This method first 
involves attaching an initiator group to the surface that serves as the seed for 
polymerization.  Various polymeric systems can be grafted from the surface making ATRP 
a very flexible platform.  For in vivo applications, PEG functionalization would be essential 
for the stability of the nanoparticles by preventing premature clearance [18].  To date, most 
surface initiated polymerizations have been utilized to coat iron oxide nanoparticles with a 
polymer brushes [19]. PEG brushes have been successfully used to prevent rapid clearance 
by macrophages, resist protein adsorption, and have reduced cytotoxic effects [20-22].  By 
utilizing a PEG-based hydrogel coating, similar biological properties are expected while 
having the additional benefit of future applications such as drug loading for controlled 
delivery.  Coating stability is an additional concern to guarantee the long term effectiveness 
of a nanoparticle system.  Miles et al. have demonstrated that carboxylic acid anchors can 
be displaced by phosphate ions effecting colloidal stability [23, 24].  In the case of a 
crosslinked hydrogel shell, the stability of the coating will not be affected by anchoring 
group displacement as a continuous shell entraps the core nanoparticle. 
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Thermal therapy is the process of elevating tumor tissue temperature for therapeutic 
gains and has been studied for decades, but has yet to gain widespread clinical recognition 
[25-27].  Two temperature ranges have been identified: hyperthermia, 40-45 °C, and 
thermoablation, ≥46 °C.  Hyperthermia can induce cellular death on its own, but it is better 
suited for enhancing the effects of chemotherapy and/or radiation therapy [25, 28-30].  The 
exact cause of the increased sensitivity is still under investigation, but it is believed to be a 
combination of cellular effects: changes in the cell membrane, impaired transport, 
cytoskeleton damage, and impairment and damage to cellular proteins and DNA; and 
physiological effects: changes in the vasculature, increased perfusion, and changes in 
oxygen levels [29-31].  Due to the elevated temperature, thermoablation leads to direct cell 
necrosis and can be used as an independent treatment [32]. The main issue facing thermal 
therapy is a clinical means to deliver elevated temperatures to the tumor site.  Current 
methods are characterized by the amount of surrounding tissue heated and subdivided into 
whole body hyperthermia (water baths or heating chambers), localized hyperthermia 
(antennas emitting microwaves or ultrasound), and regional hyperthermia (array of 
antennas) [28, 30]. Localizing the heat, tumor targeting, and even temperature distribution 
across the tumor are some of the shortcomings of the current methods of delivering 
hyperthermia.  Localization of the thermal therapy is necessary to prevent damage to the 
surrounding tissue and minimize patient discomfort and uniform heating is necessary to 
guarantee therapy effectiveness.  It is of particular interest to utilize the remote heating of 
the nanoparticles to overcome the barriers of traditional hyperthermia methods [33].  It has 
recently been demonstrated that hyperthermia induced by magnetic nanoparticles has an 
advantage over conventional hyperthermia methods in inducing cell death in vitro [34].  By 
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passive targeting, nanoparticles can collect at the tumor site and by the application of the 
alternating magnetic field provide localized heating throughout the tumor. 
In this study, core-shell nanoparticles were prepared using ATRP to coat iron oxide 
(Fe3O4) nanoparticles with a PEG-based polymer shell.  Cytotoxicity on two independent 
cell lines was examined to determine potential systemic effects.  Thermal therapy 
application feasibility was demonstrated in vitro with a thermoablation (55 °C) study on 
A549 lung carcinoma cells. 
4.2. Materials and Methods 
4.2.1 Materials 
 Iron (III) chloride hexahydrate (FeCl3•6H2O); iron (II) chloride tetrahydrate 
(FeCl2•4H2O); 2, 2 bipyridine (Bpy); copper (I) bromide (CuBr); and copper (powder <425 
micron) were obtained from Sigma Aldrich (St Louis, MO).  Citric acid monohydrate (CA) 
was obtained from Fisher Scientific and ammonium hydroxide (NH4OH) from EMD 
Chemicals (Gibbstown, NJ).  3-bromopropyl trimethoxysilane (BPTS) was obtained from 
Gelest Inc. (Morrisville, PA).  Poly(ethylene glycol) (N = 400) dimethacrylate 
(PEG400DMA) was obtained from Polysciences Inc. (Warrington, PA). All materials were 
used as received. 
4.2.2 Iron Oxide Nanoparticle Synthesis 
 A one-pot co-precipitation method was used to prepare the core citric acid coated 
iron oxide nanoparticles [35].  Aqueous solutions of FeCl3•6H2O and FeCl2•4H2O were 
combined in a 2:1 molar ratio in a sealed three-neck flask under vigorous stirring and an 
inert N2 environment.  Once 85 °C was reached, 5 mL of NH4OH was injected into the 
vessel followed by 4 ml of 2 M citric acid.  The reaction was carried out for 1 hour.  The  
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Scheme 4.1. Chemical structures of materials utilized in the iron oxide functionalization: 
(a) citric acid (CA), (b) 3-bromopropyl trimethoxysilane (BPTS), (c) Poly(ethylene glycol) 
(N = 400) dimethacrylate (PEG400DMA).  (d) Schematic of ligand exchange and ATRP 
reaction on the nanoparticles. 
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particles were washed with ethanol and retrieved with magnetic decanting.  Following the 
wash the particles were dried and stored under vacuum. 
4.2.3 Silane Initiator 
 Through a ligand exchange, the citric acid coating was replaced with a silane 
initiator, BPTS.  The particles and initiator were mixed in a 1:2.5 mass ratio in a water-
ethanol solution.  The mixture was stirred for 24 hours at room temperature.  The particles 
were washed with ethanol and retrieved by magnetic decanting.  
 4.2.4 Surface Initiated Polymerization 
 The initiator coated particles were re-suspended in ethanol for the ATRP reaction.  
The amount of Bpy and CuBr catalyst was determined as a ratio to macromer.  The ratios 
used were 1:0.01 for CuBr and 1:0.04 for Bpy.  4-5 crystals of Cu(0) were combined with 
the catalyst in 15 ml of ethanol.  The catalyst solution and particles were placed in a flask 
under N2 flow and heated to 50 °C.  5 g of PEG400DMA macromer was diluted in 10 ml 
of ethanol and injected into the vessel once the temperature reached 50 °C.  The reaction 
was carried out for 24 hours and after which the particles were magnetically decanted and 
washed and stored under vacuum. 
4.2.5 Characterization 
Fourier Transform infrared (FTIR) spectra.  Attenuated total reflectance FTIR (ATR-
FTIR) was used to determine surface functionalization with a Varian Inc. 7000e 
spectrometer.  Dried samples were placed on the diamond ATR crystal and the spectrum 
was obtained between 700 and 4000 cm−1 for 32 scans. 
Thermal gravimetric analysis (TGA).  TGA was used to quantify the mass percent of the 
iron oxide core particle.  Measurements were performed using a Netzsch Instruments STA 
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449A instrument.  Approximately 10 mg of dried sample was loaded and a heat rate of 5 
°C/min under constant air flow was used.  At 120 °C, the sample was held isothermal for 
10 minutes to vaporize residual solvent and potential water vapor.  The sample continued 
to heat at 5 °C/min until 600 °C.  The presented values are normalized to the mass at 120 
°C. 
Dynamic Light Scattering (DLS).  DLS measurements were obtained using a Malvern 
Zetasizer, Nano ZS90 instrument.  Dried nanoparticles were diluted in DI water to a 
concentration of 200 μg/mL and dispersed using ultrasonication.  
Alternating Magnetic Field heating.  The AMF heating profile was observed using a 
custom made Taylor Winfield magnetic induction source and temperature was measured 
with a Luxtron FOT Lab Kit.  Dried particles were diluted in DI water to a concentration 
of 5 mg/mL.  One ml of solution was placed in a 2 ml centrifuge tube and placed in the 
center of the coil.  The solution was heated in a field of approximately 55 kA/m in strength 
at 300 kHz frequency for 10 minutes.  
4.2.6 Cytotoxicity Studies 
 NIH 3T3 murine fibroblasts (ATCC, Manassas, VA) at passages 6-8 were cultured 
in Dulbecco’s Modified Eagle’s Medium supplemented with 10 % v/v calf bovine serum, 
10 μg/mL Fungizone (Invitrogen, Carlsbad, CA), and 2 μg/mL Penicillin-Streptomycin-
Glutamine (ATCC) in an incubator at 37°C and 5% CO2.  The fibroblasts were then seeded 
into 12-well plates at 5000cells/cm2 and incubated for 24 hours.  A549 lung carcinoma 
cells (ATCC) at passages 5-8 were cultured in F-12K medium supplemented with 10% 
fetal bovine serum, 10 μg/mL Fungizone, and 2 μg/mL Penicillin-Streptomycin-Glutamine 
and seeded into 12-well plates at 6000cells/cm2 and incubated for 24 hours.  After 24 hours, 
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the cells were exposed to the various concentrations of nanoparticles. Nanoparticles were 
added to cell media at concentrations of 100 μg/mL, 500 μg/mL, and 1000 μg/mL.  The 
nanoparticle solutions were made by dissolving dry nanoparticles into the respected cell 
media.   After removal of the spent media, one milliliter of the nanoparticles solutions was 
added to each well containing the cells.  The control wells also underwent a change with 
fresh media.  The well plates were returned to the incubator for 24 and 48 hours.  
Cytotoxicity was determined using a Live/Dead Viability Assay, calcein AM and ethidium 
homodimer-1 were obtained from Invitrogen.  The cells were imaged with fluorescent 
microscopy (Nikon Eclipse LV 100) and counted using the NIS-Elements BR 3.0 imaging 
software. 
4.2.7 In Vitro Thermal Therapy 
 A549 lung carcinoma cells at the same passages as the cytotoxicity studies were 
used for in vitro thermal therapy.  The cells were seeded into 6-well plates and 35 mm 
culture dishes at 6000 cells/cm2 and incubated overnight.  The cells were then exposed to 
10 mg/mL nanoparticle solutions and allowed to incubate for 3 hours to allow interaction 
between the cells and the particles.  After the 3 hour incubation period, the cells in the 35 
mm dishes were exposed to the AMF source (citric acid coated: 27.9 kA/m at 301 kHz; 
PEG400DMA coated: 30.1 kA/m at 301 kHz) for 10 minutes while the real time 
temperature was measured with the fiber optic thermometer inserted into the center of the 
dish.  Following the AMF exposure, the cells were returned to the incubator and allowed 
to incubate for 2 hours to allow time for the cellular response.  Results of the thermal 
therapy were determined using the Live/Dead Viability Assay. 
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Figure 4.1: FTIR spectra of citric acid coated nanoparticles, particles after the BPTS ligand 
exchange, and particles functionalized with PEG400DMA. 
 
 
Figure 4.2: Mass loss and derivative profile of citrate and PEG400DMA coated iron oxide. 
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Figure 4.3: ΔT heating profile for citrate and PEG400DMA coated particles.  Note: 
starting temperature was room temperature. 
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4.2.8 Statistical Analysis  
 Statistical analysis of the cytotoxicity and thermal therapy studies was performed 
using a two sample Student’s t-test comparing viability to the control.  To indicate 
significant toxicity defined by the following ranges: p < 0.05, p < 0.001 and p < 0.001, a 
single, double, or triple asterisk was included in the figures. 
4.3. Results and Discussion 
4.3.1 Nanoparticle Characterization 
 Confirmation of the successful ATRP reaction was observed in the FTIR spectra in 
Figure 4.1 by the presence of peaks indicated by vertical lines at 1715 cm-1 and 1102 cm-
1 corresponding to the carbonyl (C=O) stretch band and ether (C-O-C) stretch band from 
the PEGDMA coating.  
 From Figure 4.2, TGA indicated similar mass loss for both citrate and 
PEG400DMA coated particles, approximately 12 and 14% respectively, however a change 
in the profile was observed indicating different compounds.  The citrate coating displayed 
its greatest mass loss between 150 and 220 °C which is similar to the values reported by 
Frimpong et al. [35].  PEG400DMA coated particles underwent its greatest mass loss 
between 200 and 320 °C.  Hu et al. similarly reported the elimination of poly(ethylene 
glycol) chains from PEGylated magnetic nanoparticles by 350 °C which further confirms 
the presence of the polymer coating [20]. 
 The hydrodynamic size of the particles was determined with DLS and reported as 
Z-average.  Citrate coated nanoparticles were 62 nm with a PDI of 0.337% and 
PEG400DMA coated particles were 198 nm with a PDI of 0.227%.  The larger size of the 
PEG400DMA coated particles may be the result of a cluster of iron oxide nanoparticles 
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forming the core due to aggregation during the synthesis and washing steps.  Previous work 
with TEM has determined the citrate coated nanoparticles to be on the order of 10 nm. 
 The heating characteristic of the nanoparticle systems in an AMF was examined, 
and the heating profiles can be seen below in Figure 4.3.  The specific absorption ratio 
(SAR) was calculated: 
SAR = (∑iCimi)/m * (ΔT/Δt)   Equation 4.1 
where Ci is the heat capacity, mi is the individual mass of the components heated (in this 
case water and iron oxide nanoparticles), m is the mass of the component generating heat 
(iron oxide), and ΔT/Δt is the initial slope of the heating profile (the 25 and 30 second time 
points were used to calculate the slope).  Calculations were based on specific heat 
capacities of 0.65 and 4.18 J/g*K for iron oxide and water respectively.  The SAR values 
were determined to be 177.45 W/g and 62.26 W/g for citrate coated and PEG400DMA 
coated iron oxide respectively.  The difference in SAR values can be explained by the 
citrate coated nanoparticles are in a freely dispersed stage while in aqueous solution 
allowing the iron oxide to be available for better heat effects [36]. 
4.3.2 Cytotoxicity Evaluation 
 Initial cytotoxicity studies have been carried out on both NIH 3T3 fibroblasts and 
A549 lung carcinoma cells with the PEG400DMA and citric acid coated iron oxide 
nanoparticles.  The fibroblasts were selected to represent a general toxicity screen and the 
results are displayed below in Figure 4.4.  At the 100 µg/mL concentration, the particles 
were relatively non-toxic as viability remained in the 80-85% range.  As the concentration 
increased to 500 µg/mL and 1000 µg/mL there was a very significant decrease in viability 
for both particle systems.  Looking at the fluorescent overlaid on the bright field images at  
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Figure 4.4: Percent viability of NIH 3T3 fibroblasts exposed to Fe3O4+CA and 
PEG400DMA coated nanoparticles. The error is reported as standard error. 
 
 
Figure 4.5: Fluorescent overlaid on bright field images for citrate coated particles at 100 
μg/mL (a), 500 μg/mL (b), and 1000 μg/mL (c); and PEG400DMA coated particles at 100 
μg/mL (d), 500 μg/mL (e), and 1000 μg/mL (f). 
 
b) a) c) 
d) e) f) 
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Figure 4.6: Percent viability of A549 lung carcinoma cells exposed to Fe3O4+CA and 
PEG400DMA coated nanoparticles. The error is reported as standard error. 
 
 
Figure 4.7: Fluorescent overlaid on bright field images for citrate coated particles at 100 
μg/mL (a), 500 μg/mL (b), and 1000 μg/mL (c); and PEG400DMA coated particles at 100 
μg/mL (d), 500 μg/mL (e), and 1000 μg/mL (f). 
 
b) a) c) 
d) e) f) 
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48 hour (Figure 4.5), the stability of the particles was an issue and the increased settling 
may have caused physical damage or had a suffocation effect on the cells. 
A549 lung carcinoma was the cell line was selected for thermal therapy studies, so 
it too underwent the toxicity screening (Figure 4.6).  Unlike the NIH 3T3 fibroblasts, 
minimal toxicity was observed until the 48 hour 1000 µg/mL PEG400DMA trial.  At all 
three concentrations, the citric acid coated nanoparticles observed a bounce back behavior 
between 24 and 48 hours.  This suggests that there was an initial stress from the exposure 
of the nanoparticles, but the cells recovered and continued to grow.  PEG400DMA systems 
did not display this behavior and instead observed a decrease in viability between 24 and 
48 hours at the higher concentrations.  Representative images with the fluorescent overlaid 
on the bright field at 48 hours are shown in Figure 4.7 and nanoparticle instability is 
observed as was the case with Figure 4.5.  Since PEG is capable of preventing cell 
adhesion, perhaps the nanoparticles that have aggregated and coated the bottom of the well 
plate limited the space for cell growth and affected the cell viability between 24 and 48 
hours.   
From the NIH 3T3 results, we speculated that stability plays a major role in 
determining viability.  The agglomeration of nanoparticles could have a physical 
suffocating effect by landing on top of the cells or occupying the space needed for 
propagation.  However, a similar amount of particles can be seen out of solution in the 
PEG400DMA study where there was a minimal toxic effect at the higher concentrations, 
except for the 48 hour 1000 µg/mL PEG400DMA.  Particle stability may still play a role 
since the local concentration of particles would increase over time, but cancer cells, 
generally being more resilient cell lines, and are able to withstand the higher local 
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concentration and physical effects especially during the first 24 hours.  The results from 
the A549 screen indicate that high concentrations of nanoparticles can be used over a short 
time of exposure with limited toxicity.  
4.3.3 Thermal Therapy Demonstration 
The ability of the nanoparticle systems to kill cancer cells was explored by exposing 
cells doped with nanoparticle solutions to the AMF and heating to the thermoablation 
range.  Scheme 4.2 displays the set up utilized in this trial.  Since the 35 mm dish was 
larger than the 0.625”ID coil, there was a distinct region in the center of the well where the 
field was the strongest and the particles heated more resulting in greater cellular death [37].  
When determining the viability, images were taken from both the periphery and the center 
to demonstrate the two regions. 
During the 10 minute field exposure, the real time temperature at the center of the 
well was monitored with a fiber optic thermometer.  As seen in Figure 4.8, both 
nanoparticle systems heated to 55 °C, 9 °C above the thermoablation threshold which is 
indicated by the light blue line.  The temperature surpasses the hyperthermia range within 
the first 100 seconds and steady state temperature is achieved after the 250 second mark. 
When performing the live/dead assay, two regions were studied – the center of the 
well, where the field was the strongest, and the periphery, where the field strength is weaker 
and less nanoparticle heat is generated in this region.  Particle systems exposed to the AMF 
are indicated by ‘F’ and systems remaining in the incubator are indicated by ‘NF.’  The 
control underwent a fresh media change at the same time as the samples dosed with 
nanoparticles.  Figure 4.9 displays the viability for each of the systems – both the center 
and periphery viabilities are displayed.  During the relatively short exposure time, minimal  
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Scheme 4.2: (Left) Illustration of the alternating magnetic field set up and location of the 
35 mm dish.  (Right) Illustration of the distinct live/dead regions due to the greater heat 
generated in the center of the well. 
 
 
Figure 4.8: Real time temperature data measured at the center of the 35 mm dish.  The 
light blue line indicates 46 °C, the thermoablation threshold.  Citric acid coated particles 
have positive error bars (standard deviation) and PEG400DMA have negative error bars at 
every 15 s time point. 
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Figure 4.9: Cell viability of A549 lung carcinoma cells exposed to both citrate and 
PEG400DMA coated particles and AMF exposure (F – field exposure, NF – no field 
exposure). 
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toxicity was observed in the systems with nanoparticle solutions and no field exposure 
indicating that any cellular death with field exposure would be the result of the nanoparticle 
heating and not cytotoxicity.  When the field was applied, there was total death at the center 
of the well for both the citric acid coated and PEG400DMA coated nanoparticles.  This 
was expected since the thermoablation range was achieved and the cells underwent intense 
heating inducing necrosis.  In the case of the citric acid coated nanoparticles, there was 
minimal toxicity in the periphery, and the viability was similar to the nanoparticle only 
systems.  The PEG400DMA had a lower viability (60% range) but the two distinct regions 
of live/dead were observed. 
4.4. Conclusion 
 This study reports the use of ATRP to successfully coat iron oxide nanoparticles 
with a PEG-based polymer shell and studied the thermoablative properties.  During the 24 
and 48 hour cytotoxicity studies, the viability of the NIH 3T3 fibroblasts decreased with 
increasing concentration, and the lower viability for cells exposed to PEG400DMA coated 
particles was likely a result of stability issues with that system.  Using a relatively short 
exposure time, higher concentrations of magnetic nanoparticles were shown to be effective 
in thermal therapy studies demonstrating cellular death in the center of the well where the 
field was the strongest and the temperature achieved was in the thermoablative range.  This 
nanoparticle system can further be explored as a means of co-delivering thermal therapy at 
hyperthermia temperatures with chemotherapeutics to improve the treatment efficacy. 
4.5. References  
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Chapter 5: Accelerated Generation of Free Radicals by Iron Oxide Nanoparticles in 
the Presence of an Alternating Magnetic Field 
The surfaces of iron oxide nanoparticles are capable of catalytically generating reactive 
oxygen species (ROS) through the Fenton and Haber-Weiss reactions.  When exposed to 
an alternating magnetic field (AMF), iron oxide nanoparticles absorb the energy from the 
magnetic field and convert it into heat.  In this study, we observed an increase in the 
degradation of methylene blue when a suspension of magnetite (Fe3O4) nanoparticles was 
exposed to an AMF indicating there was an increase in the ROS generation in response to 
the AMF.  The increase in ROS generation compared to the Arrhenius prediction was both 
time and concentration dependent; in which we observed a decrease in ROS enhancement 
with increased time of exposure and concentration.  We postulate that the decrease is due 
to agglomeration in the presence of the field.  As the nanoparticles agglomerate, there is a 
decrease in surface area per mass limiting the reaction rate.  The information included here 
is adapted or directly taken from work previously published: 
Robert J. Wydra, Catherine E. Oliver, Kimberly W. Anderson, Thomas D. Dziubla, 
J. Zach Hilt. Accelerated Generation of Free Radicals by Iron Oxide Nanoparticles 
in the Presence of an Alternating Magnetic Field. RSC Advances. 5: 18888-18893, 
2015. 
Reprinted with permission from The Royal Society of Chemistry. 
5.1. Introduction 
 Magnetic nanoparticles are of great interest to a wide range of applications due to 
their unique physical properties [1, 2].  These applications include catalysis, biomedical 
imaging, anemia supplement, drug delivery, thermal therapy, and environmental 
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remediation [3-9].  One physical property that has presented itself as a double-edged sword 
is the generation of free radicals attributed to Fenton and Haber-Weiss chemistries.  In the 
case of biomedical applications, the generation of free radicals leads to oxidative stress 
which is believed to be one of the key underlying mechanisms of concentration dependent 
cytotoxicity [10-16].  At the same time, iron oxide nanoparticles are combined with 
hydrogen peroxide and successfully used as advanced oxidation processes for the removal 
organic contaminates from wastewater [17].  In both cases, iron oxide nanoparticles act as 
a homogeneous and heterogeneous catalyst for the degradation of hydrogen peroxide into 
free radicals.  The catalytic mechanism is based on the environment.  Under neutral 
conditions, Voinov et al. have demonstrated through spin-trapping EPR that γ-Fe2O3 
nanoparticles produce hydroxyl radicals primarily on the surface rather than dissolution of 
free ions [18].  At lower pH, such as the microenvironment of a lysosome, iron ions can be 
released from the nanoparticle surface resulting in a greater extent of homogeneous 
catalysis [19]. 
 When exposed to an alternating magnetic field (AMF), magnetic nanoparticles 
absorb the energy from the magnetic field and convert it into heat through primarily 
through Brownian relaxation (physical rotation of the particles) and Neel relaxation 
(rotation of the magnetic moment) [20].  This heat generation has been extensively studied 
as magnetic fluid thermal therapy for the treatment of cancer [21, 22].  Until recently, 
intracellular hyperthermia has been considered improbable due to heat transport 
calculations by Rabin that demonstrated theoretically the heat generated from a single 
nanoparticle or cluster of nanoparticles would be negligible to the cell [23].  However, 
work by Creixell et al. has demonstrated that internalized targeted nanoparticles can induce 
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cellular death when exposed to an alternating magnetic field without a measurable 
temperature rise [24].  In follow-up work, the surface temperature of the nanoparticles was 
shown to instantly increase and to drive a temperature responsive polymer beyond its lower 
critical solution temperature of 35 °C without an immediate increase in solution 
temperature [25].  Thereby, they demonstrated that the localized heating from the 
nanoparticle surface is capable of altering surrounding chemistry and possibly a 
mechanism of the previously reported toxicity.  The exact mechanism of toxicity is still 
under debate, however the evidence of a local heating effect provides interesting scenarios 
where the energy dissipated by the nanoparticles can be utilized to only alter the near 
surrounding volume. 
 The kinetic behavior of the advanced oxidation process involving magnetic 
nanoparticles to mineralize pollutants has been extensively studied [26-29].  Temperature 
is one of the driving factors of the Fenton-like reaction up to about 40 °C [30].  Above this 
temperature, hydrogen peroxide begins to degrade into oxygen and water limiting the 
reaction.  To date, no one has studied the effect of AMF exposure on the generation of free 
radicals from iron oxide nanoparticles.   
The main objective of this study is to determine the influence of AMF exposure on 
the degradation of methylene blue by magnetite nanoparticles (Fe3O4) and hydrogen 
peroxide.  Three iron oxide concentrations were selected based on their ability to heat the 
surrounding media.  The low concentration of iron oxide nanoparticles did not heat the 
solution above the radiant heat from the inductive source coil; whereas the high 
concentration actively heated the solution.  The kinetic behavior was first determined using 
temperature controlled water baths.  This data was used to extrapolate an Arrhenius 
73 
 
relationship which provided theoretical values based on the temperature achieved during 
AMF exposure.  The reported enhancement was defined as the ratio of the experimental 
degradation observed compared to the theoretical value. 
5.2. Materials and Methods 
5.2.1 Materials 
 Iron (III) chloride hexahydrate (FeCl3•6H2O); iron (II) chloride tetrahydrate 
(FeCl2•4H2O); hydrogen peroxide (H2O2); and methylene blue (MB) were obtained from 
Sigma Aldrich (St Louis, MO).  Ammonium hydroxide (NH4OH) was obtained from EMD 
Chemicals (Gibbstown, NJ).  All materials were used as received. 
5.2.2 Iron Oxide Nanoparticle Synthesis 
 A one-pot co-precipitation method was used to prepare the iron oxide nanoparticles 
as similarly reported previously [31].  Briefly, aqueous solutions of FeCl3•6H2O and 
FeCl2•4H2O were combined in a 2:1 molar ratio in a sealed three-neck flask under vigorous 
stirring and an inert N2 environment.  Once 85 °C was reached, a 1.5 M solution of NH4OH 
was injected into the vessel and the reaction was carried out for 1 hour.  The nanoparticles 
were initially decanted via magnetic decantation to remove majority of the impurities.  
After, they were resuspended in water and transferred to a dialysis bag for 48 hours of 
dialysis.  Following the washing steps, the particles were stored in suspension. 
5.2.3 Nanoparticle Characterization 
Dynamic Light Scattering (DLS).  DLS measurements were obtained using a Malvern 
Zetasizer, Nano ZS90 instrument.  Nanoparticles were diluted in DI water to a 
concentration of 200 μg/mL and dispersed using ultrasonication.  
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Alternating Magnetic Field heating.  The AMF heating profile was observed using a 
custom made Taylor Winfield magnetic induction source and temperature was measured 
with a Luxtron FOT Lab Kit.  Nanoparticles were diluted in DI water to a concentration of 
5 mg/mL.  One ml of solution was placed in a 2 ml centrifuge tube and placed in the center 
of the coil.  The solution was heated in a field of approximately 60 kA/m in strength at 292 
kHz frequency for 5 minutes.  
5.2.4 Methylene Blue Degradation  
 The methylene blue degradation experiments were performed in 2 ml 
microcentrifuge tubes in either temperature controlled water baths or exposed to an AMF.  
One ml samples were prepared by diluting stock concentrations of methylene blue to 5 
µg/ml and iron oxide nanoparticles to 37.5, 75, and 150 µg/ml.  The samples were placed 
in the water bath for 10 min to equilibrate to the set temperature.  The degradation was 
initiated by spiking the samples with 25 µl of 30% H2O2 to a working concentration of 245 
mM.  After given time intervals the samples were centrifuged for 30 s using a Phenix 
Quickspin Centrifuge, magnetically decanted, and measured using UV-visible 
spectroscopy (maximum absorbance at 665 nm) with a Varian Cary.  To account for 
nanoparticle scattering from the nanoparticles that remain in suspension, samples 
containing only nanoparticles were measured and subtracted out from the sample 
absorbance. 
 Samples exposed to the AMF were prepared as described above.  They were placed 
in water baths which corresponded to the expected steady state temperature as a result of 
field exposure.  The samples were exposed to a magnetic field of approximately 51.0 kA/m  
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Scheme 5.1. Molecular structure of methylene blue. 
 
 
 
 
 
Scheme 5.2. Diagram of potential Fenton/Haber Weiss reactions initiated by iron oxide 
nanoparticles. 
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Figure 5.1.  ΔT heating profile uncoated iron oxide a nanoparticle where starting 
temperature was room temperature.  The tangent line indicated the slope used in the SAR 
calculations. 
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in strength at 292 kHz frequency while temperature was measured with a Luxtron FOT 
Lab Kit. 
5.2.5 Statistical Analysis 
 Statistical analysis of the enhancement factor was determined using a one sample 
t-test where the hypothetical mean was set to 1.  To indicate significant enhancement a 
single, double, or triple asterisk corresponding to p < 0.05, 0.01, and 0.001 respectively 
were included in the figure. 
5.3. Results and Discussion 
5.3.1 Nanoparticle Characterization 
The hydrodynamic size of the particles was determined with DLS and reported as 
Z-average.  Iron oxide nanoparticles were 107 nm with a PDI of 0.176 when dispersed in 
water.  Previous work with TEM has determined the core nanoparticles to be on the order 
of 10 nm.  As these are uncoated nanoparticles with no stabilizing group, agglomerates are 
likely contributing the in the increase in hydrodynamic size compared to the crystal size 
observed in TEM. 
The heating characteristics of the nanoparticle systems in an AMF were examined, 
and the heating profiles can be seen below in Figure 5.1.  The specific absorption ratio 
(SAR) was calculated: 
SAR = (∑iCimi)/m * (ΔT/Δt)    Equation 5.1 
where Ci is the heat capacity, mi is the individual mass of the components heated (in this 
case water and iron oxide nanoparticles), m is the mass of the component generating heat 
(iron oxide), and ΔT/Δt is the initial slope of the heating profile (the 25 and 35 second time 
points were used to calculate the slope).  Calculations were based on specific heat 
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capacities of 0.65 and 4.18 J/g*K for iron oxide and water respectively.  The SAR value 
was determined to be 535.5 ± 25.8 W/g at an AMF of approximately 60 kA/m in strength 
at 292 kHz frequency. 
5.3.2 Methylene Blue Degradation  
 The rate of radical generation was determined by analyzing the rate of methylene 
blue (Scheme 5.1) degradation.  In a Fenton-like system, as illustrated in scheme 5.2, iron 
ions react with hydrogen peroxide to generate highly reactive hydroxyl and superoxide 
radicals.  These radicals attack bonds on methylene blue fracturing the molecule into 
colorless intermediates.  Possible splitting sites include the C-S+=C and the C-N=C of the 
central ring or hydroxylation of the aromatic side rings [32, 33].  It was determined that the 
degradation of methylene blue was catalyst driven, as there were negligible effects of 
hydrogen peroxide alone or adsorption onto the nanoparticle surface on measured 
absorbance.  
 The kinetic data was initially fit to a pseudo-first-order and second-order models as 
explored previously in literature [34, 35].  Relating concentration as a function of relative 
absorbance, we had the following rate models: 
d(At/Ao)/dt = -k1(At/Ao)    Equation 5.2 
d(At/Ao)/dt = -k2(At/Ao)2    Equation 5.3  
Where k1 and k2 are the first and second order rate constants, and At is the measured 
absorbance at a given time normalized to the initial absorbance, Ao.  Integrating equations 
2 and 3 results in the following: 
ln(At/Ao) = k1t     Equation 5.4  
1/(At/Ao) = k2t + 1     Equation 5.5  
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Figure 5.2. Second-order kinetic plots of methylene blue degradation at 37.5 µg/ml (a), 75 
µg/ml (b), and 150 µg/ml (c) iron oxide concentration. 
a) 
b) 
c) 
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The methylene blue degradation data was fit using the above equations to determine the 
respective rate constants using a linear regression.  The pseudo-first-order model was 
rejected because the y-intercept never approached 0 for any of the concentrations or 
temperatures tested.  The second-order model, seen in Figure 5.2, fit the methylene blue 
degradation as observed previously [35].  The linear correlation coefficients (R2) were in 
the neighborhood of 0.95 again confirming the accuracy of the linear model. 
 By studying methylene blue degradation at various temperatures, an Arrhenius type 
relationship was determined.  Based on the slopes observed in Figure 5.2 the reaction was 
temperature dependent where there was an increase in reaction with increased temperature 
as expected by Fenton-like chemistry.  Using the Arrhenius equation: 
 k = Aexp(-Ea/RT)     Equation 5.6  
where A is the pre-exponential factor, Ea is the activation energy, R is the ideal gas constant, 
and T is the reaction temperature.  Converting Equation 5.6 into a linear relationship 
between ln(k) and 1/T, the previously determined reaction rates were plotted into Figure 
5.3.  The derived activation energy and pre-exponential factor are listed in Table 5.1 for 
the given concentration of iron oxide studied. 
Deriving an Arrhenius relationship was essential to provide a comparative basis for 
the AMF studies.  The three iron oxide concentrations studied were selected based on their 
ability to heat the surrounding media.  When the AMF source is activated, the copper coil 
heats instantaneous and begins to radiate heat to the sample.  At the AMF field amplitude 
used, a solution of methylene blue would heat to 32-32.5 °C.  At 37.5 µg/ml iron oxide 
concentration, the measured solution temperature never exceeded this range with 15 
minutes of heating.  This implies that the amount of heat generated from the nanoparticle 
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surface is insufficient to significantly heat the surrounding volume of water.  At 75 µg/ml 
iron oxide, the measured solution temperature was 33.5-34 °C, and at 150 µg/ml, the 
measured temperature was 36-36.5 °C resulting in a 1.5 and 4 °C temperature rise 
respectively.  At these concentrations the heat generated from the nanoparticle surface 
actively heated the solution temperature.  From the measured steady state temperature of 
each sample, a theoretical concentration was calculated using the Arrhenius relationship.  
This value was compared to the experimentally measured absorbance through the 
following enhancement factor (EF) equation: 
EF = (1-(At/Ao)exp) / (1-(At/Ao)theo)   Equation 5.7 
Where (At/Ao)exp is the experimental concentration and (At/Ao)theo is the theoretical 
concentration of methylene blue.  The enhancement factor results are displayed in Figure 
5.4.  The lowest concentration, 37.5 µg/ml, displayed very significant ROS enhancement 
over the three time periods studied.  At 5 minutes of exposure, 75 µg/ml was significant, 
but the enhancement decreased to no measurable enhancement by 15 minutes.  The highest 
concentration never displayed a significant enhancement.  
 At the lower concentrations of nanoparticles, the local nanoscale heating effects 
would be more pronounced than at the highest concentration.  At these concentrations, 
energy would be dispersed to the local area driving the catalytic degradation of methylene 
blue.  This energy, however, is insufficient to heat the surrounding volume resulting in no 
measurable temperature rise.  Thus, we would expect the kinetic behavior to be similar to 
the temperature elevated a few degrees resulting in the observed enhancement.  At the 
highest concentration the measured temperature corresponds closer the local surface 
temperature and hence no enhancement. 
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Figure 5.3. Arrhenius plots derived from second order kinetic model from methylene blue 
degradation at 37.5 µg/ml (a), 75 µg/ml (b), and 150 µg/ml (c) iron oxide concentration. 
a) 
b) 
c) 
83 
 
Table 5.1. Arrhenius constants of methylene blue degradation at various concentrations of 
iron oxide nanoparticles. 
Concentration -Ea (J/mol) A (s-1) 
37.5 µg/ml 7.15e4 8.79e8 
75 µg/ml 9.91e4 1.05e14 
150 µg/ml 8.48e4 7.27e11 
 
 
 
 
 
Figure 5.4. Enhancement factor comparing extent of methylene blue degradation based on 
experimental and theoretical values at different concentrations of iron oxide nanoparticles 
and length of AMF exposure. 
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 When enhancement was observed, the degree of enhancement declined with length 
of AMF exposure.  One possible explanation is the reversible agglomeration of the 
nanoparticles induced by the magnetic field.  Being paramagnetic, the nanoparticles would 
be attracted to each other resulting in aligned chains or clusters [36, 37].  In this 
agglomerated state, the available surface area of the nanoparticles would be reduced 
affecting the catalyst potential.  This further confirms a recent observation made by Sharma 
et al. where the degree of cellular oxidative stress was a function of iron oxide nanoparticle 
surface area as opposed to mass delivered [38].  Nanoparticle concentration is one of the 
hallmark factors of colloidal stability and could explain why no enhancement was observed 
at the highest concentration.  Elevated concentrations of magnetic nanoparticles display 
observable changes in colloidal stability when exposed to the AMF.  While not significant, 
the enhancement factor of the 150 µg/ml system was below 1 at the 10 and 15 minute 
exposure times.  Future experiments investigating the role of aggregation state on the 
magnetic field heating enhancement factor are warranted.  
 This study provides a direct example of utilizing the accelerated surface reactivity 
with AMF exposure for the degradation of a model pollutant.  When translating this 
material property to a biological system such as within the cellular environment, however, 
there is room for scholarly debate.  For starters, the intracellular concentration of H2O2 is 
typically around 0.5-0.7 µM but can be as high as 1 µM during proliferation signaling [39].  
Cancer cells are known to have higher levels of H2O2 due to erratic signaling, so the 
intracellular level could conceivably be even higher than 1 µM, but these levels are 
significantly lower than the levels used in this study.  With the decrease in relative 
concentrations of reactants, the reaction rates would predictably be slower.  Most cancer 
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cells display an overexpression of Akt which causes them to be more susceptible to 
oxidative stress induced apoptosis [40].  Thus, even acute fluctuations of ROS levels from 
iron oxide catalyzed Fenton chemistry could have a detrimental effect on cancer cells.  Here 
in the best case, we have demonstrated upwards of a two fold increase in ROS generation 
with AMF exposure.  Future research should investigate whether this ROS generation 
corresponds with an effective concentration of iron oxide nanoparticles triggering a 
cytotoxic event. 
5.4. Conclusions  
 This study reports the observed enhanced degradation of methylene blue by free 
radicals generated by iron oxide nanoparticles heated in an alternating magnetic field.  The 
kinetic behavior of methylene blue degradation was modeled using a second-order 
reaction, and an Arrhenius relationship was extrapolated from the temperature dependence.  
When exposed to an alternating magnetic field, the nanoparticles at lower concentrations 
and exposure time are capable of degrading methylene blue at a greater extent than 
predicted by the Arrhenius relationship.  This observation has multiple future applications, 
such as improving intracellular hyperthermia processes and reaction rates in advanced 
oxidation processes. 
5.5 References 
References are located at the end of the dissertation subdivided by chapters. 
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Chapter 6: The Role of ROS Generation from Magnetic Nanoparticles in an 
Alternating Magnetic Field on Cytotoxicity 
Monosaccharide coated iron oxide nanoparticles were developed to selectively target colon 
cancer cell lines for magnetically mediated energy delivery therapy.  The nanoparticles 
were prepared using a coupling reaction to attach the glucose functional group to the iron 
oxide core, and functionality was confirmed with physicochemical characterization 
techniques.  The targeted nanoparticles were internalized into CT26 cells at a greater extent 
than non-targeted nanoparticles, and the nanoparticles were shown to be localized within 
lysosomes.  Cells with internalized nanoparticles were exposed to an alternation magnetic 
field (AMF) to determine the potential to delivery therapy.  Cellular ROS generation and 
apoptotic cell death was enhanced with field exposure.  The nanoparticle coatings inhibit 
the Fenton-like surface generation of ROS suggesting a thermal or mechanical effect is 
more likely the source of the intracellular effect.  The information included here is adapted 
or directly taken from work submitted for publication: 
Robert J. Wydra, Piotr Rychahou, B. Mark Evers, Kimberly W. Anderson, Thomas 
D. Dziubla, J. Zach Hilt. The role of ROS generation from magnetic nanoparticles 
in an alternating magnetic field on cytotoxicity. Acta Biomaterialia. (In review). 
 
6.1. Introduction 
Magnetic nanoparticles are being studied for a wide range of biomedical 
applications such as diagnostic imaging, drug delivery, and thermal therapy of cancer [1-
4].  In the case of thermal therapy, the particles absorb the energy from the magnetic field 
and convert it into heat through the Brownian and Neel relaxation [5].  In most cases, the 
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nanoparticles rely on passive targeting to systemically circulate and accumulate in tumors 
via the phenomenon known as the enhanced permeability and retention effect [6].  To 
increase specific interactions with cells, nanoparticles can be functionalized with 
appropriate targeting ligands such as peptides, antibodies, and carbohydrates [7-9].  It has 
recently been demonstrated that targeted nanoparticles are not only capable of reaching the 
primary tumor but micrometastatic sites as well [10].  Coupled with the ground breaking 
work by Creixell et al. demonstrating that internalized targeted nanoparticles can induce 
cellular death when exposed to an alternating magnetic field without a measurable 
temperature rise, there is great interest to develop targeted nanoparticles for the treatment 
of metastatic cancer [11].  This intracellular effect, where the internalized nanoparticles 
deliver therapeutic gains without perceived temperature rise, has been coined as 
‘magnetically mediated energy delivery’ (MagMED) represents a promising field of 
therapeutics but the exact mechanism of cytotoxicity still needs to be explored [12]. 
Intracellular hyperthermia was previously considered improbable due to heat 
transport calculations by Rabin that demonstrated theoretically the heat generated from a 
single nanoparticle or cluster of nanoparticles would be negligible to the cell or surrounding 
tumor [13].  However, it has been observed that the surface temperature of the nanoparticles 
is able to significantly exceed the solution temperature suggesting that a localized heating 
effect may attribute to the toxicity of the therapy [14].  In addition to a heating effect, 
chemical effects or mechanical damage from the physical rotation and vibration of the 
nanoparticles may induce toxicity.  One potential chemical effect would be the result of 
surface mediated production of reactive oxygen species (ROS) from the iron oxide 
nanoparticles [15].  Free radical generation results in cellular oxidative stress which is 
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believed to be one of the key underlying mechanisms of cytotoxicity [16, 17].  When 
temperatures are raised to the hyperthermia range, ROS levels are amplified resulting in 
long-term cellular death [18].  This observation can be attributed to increased kinetic 
activity of the Fenton-like reaction with temperature or the decreased ability of cancer cells 
to scavenge ROS at the elevated temperature [18-20].  Recently, we have demonstrated 
that the generation of ROS is enhanced in presence of an alternating magnetic field [21].  
At nanoparticle concentrations where there was no observable temperature rise, we 
observed a significant increase in ROS generation compared to the Arrhenius prediction. 
Carbohydrate coated nanoparticles, or glyconanoparticles, are an attractive 
functionality in order to study molecular and cellular targeting by combining the 
physicochemical properties of the core nanoparticle with receptor interaction, stabilization, 
and relatively inexpensive compared to other targeting ligands (i.e. antibodies) advantages 
from carbohydrates [22-26].  Functionalizing nanoparticles with monosaccharides can 
provide similar passivation to poly(ethylene glycol) (PEG) while at the same time 
providing a targeting strategy for cells overexpressing glucose transporters [27-29].  
Demonstrating therapeutic potential, gold nanoparticles functionalized with glucose were 
internalized at a greater rate by ovarian cancer cells and used as a sensitizer to enhance 
radiation therapy [30].  Specifically, we were interested in designing a nanoparticle system 
to target colon cancer liver metastasis.  To date, fluorine-18-deoxyglucose has been 
successful in the accurate detection of colon cancer liver metastases with positron emission 
tomography suggesting glucose may be an interesting ligand to study [31].   
In this paper, monosaccharide targeted nanoparticles were developed and assessed 
for their ability to be selectively internalized by colon cancer cell lines.  Glucose coated 
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nanoparticles were synthesized using a two-step process (Scheme 6.1).  Iron oxide core 
nanoparticles, selected for their ability to remotely heat in an AMF, were prepared utilizing 
a facile one-pot co-precipitation technique where a citric acid stabilizer was added during 
the core synthesis.  Next, glucose functionality was attached to the surface through an 
amine-carboxyl coupling reaction involving D-glucosamine and the citric acid stabilizer.  
Once internalized, the cells containing nanoparticles were exposed to an alternating 
magnetic field and cellular ROS was measured.  After exposure, we observed a significant 
increase in cellular ROS and an associated increased level of apoptotic cells. 
6.2. Materials and Methods 
6.2.1 Materials  
Iron (III) chloride hexahydrate (FeCl3•6H2O), iron (II) chloride tetrahydrate 
(FeCl2•4H2O), D-(+)-glucosamine, and fluoresceinamine isomer I were obtained from 
Sigma Aldrich (St Louis, MO).  Ammonium hydroxide (NH4OH) was obtained from EMD 
Chemicals (Gibbstown, NJ).  Citric acid monohydrate (CA) was obtained from Fisher 
Scientific and N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) were obtained from Thermo Scientific (Waltham, MA).  All materials 
were used as received.  
6.2.2 Synthesis of Iron Oxide Nanoparticles  
A one-pot co-precipitation method was used to prepare the core citric acid coated 
iron oxide nanoparticles as reported previously [32].  Briefly, aqueous solutions of 
FeCl3•6H2O and FeCl2•4H2O were combined in a 2:1 molar ratio in a sealed three-neck 
flask under vigorous stirring and an inert N2 environment.  Once 85 °C was reached, 5 mL 
of NH4OH was injected into the vessel followed by 4 ml of 2 M citric acid.  The reaction  
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Scheme 6.1. Reaction schematic of monosaccharide coating of iron oxide nanoparticles 
displaying the attachment of the citric acid stabilizer and subsequent addition of D-
glucosamine via amine-carboxyl coupling reaction. 
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was carried out for 1 hour.  The particles were transferred to a dialysis tube for 24 hours of 
dialysis to remove unreacted chemicals. 
6.2.3 Glucose Functionalization  
Monosaccharide functional groups were attached to the nanoparticle surface 
through an amine-carboxyl coupling reaction utilizing NHS/EDC.  A molar ratio of 10:1 
molar EDC to carboxyl groups was used where the amount of citric acid per nanoparticle 
was estimated from TGA data.  The NHS to EDC ratio was 5:2 molar and glucosamine 
was used in 10 fold by mass excess to the amount of nanoparticles.  In a typical reaction, a 
stock 10 mg/ml suspension of citric acid coated nanoparticles was mixed with EDC/NHS 
in aqueous solution to facilitate activation of the carboxyl groups for 30 minutes.  
Glucosamine solution was prepared in PBS and added to the work up for a final working 
concentration of 5 mg/ml nanoparticles and allowed to react for 6 hours.  Following the 
reaction, the nanoparticles were washed with dialysis. 
6.2.4 Particle Characterization 
Fourier Transform infrared (FTIR) spectra.  Attenuated total reflectance FTIR (ATR-
FTIR) was used to determine surface functionalization with a Varian Inc. 7000e 
spectrometer.  Dried samples were placed on the diamond ATR crystal and the spectrum 
was obtained between 700 and 4000 cm−1 for 32 scans. 
Thermal gravimetric analysis (TGA).  TGA was used to quantify the mass percent of the 
iron oxide core particle.  Measurements were performed using a TA Instruments SDT Q600 
TGA/DSC instrument (New Castle, DE).  Approximately 10 mg of dried sample was 
loaded and a heat rate of 5 °C/min under constant nitrogen flow was used.  At 120 °C, the 
sample was held isothermal for 10 minutes to vaporize residual solvent and potential water 
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vapor from the atmosphere.  The sample continued to heat at 5 °C/min until 450 °C.  The 
presented values are normalized to the mass at 120 °C. 
Dynamic Light Scattering (DLS) and zeta potential.  DLS and zeta potential measurements 
were obtained using a Malvern Zetasizer, Nano ZS90 instrument (Westborough, MA).  
Nanoparticles from stock suspensions were diluted in DI water for DLS and 10 mM NaCl 
to a concentration of 200 μg/mL and dispersed via probe sonication. 
6.2.6 Uptake and Localization  
CT26 colorectal cancer cells were cultured in Dulbecco’s Modified Eagle’s 
Medium supplemented with 10 % v/v calf bovine serum, 10 μg/mL Fungizone (Invitrogen, 
Carlsbad, CA), and 2 μg/mL Penicillin-Streptomycin-Glutamine (ATCC) in an incubator 
at 37°C and 5% CO2.  The cells were seeded in a 35 mm culture dishes at 15000 cells/cm2 
and were allowed to become confluent.  Dehydrated nanoparticles were suspended in 
DMSO at 5 mg/ml stock concentration.  The nanoparticles were diluted to 200 µg/ml in 
cell media prior to exposure.  The cells were exposed to nanoparticles for 0.5, 1, and 2 
hours.  After, the cells were washed 2x with warm DPBS, trypsinized, counted, and 
dehydrated prior to the Prussian Blue colorimetric assay.  100 µl HCl was used to digest 
the dry cell pellet and 10 µl of the digested pellet was transferred to a microcentrifuge tube 
where the reducing agent, hydroxylamine, was added for at least 8 hours.  Finally, the iron 
ions were stained with a 5% potassium ferricyanide solution for 1 hour.  Absorbance at 700 
nm was measured with a GENios Pro fluorescence spectrophotometer (Tecan, 
Switzerland).  Iron concentration standard curves were prepared using ferrous and ferric 
chloride salts. 
93 
 
To visualize the nanoparticle internalization a co-localization technique was 
utilized.  First, the nanoparticles were fluorescently tagged with fluoresceinamine, isomer 
I through a competitive carboxyl-amine coupling reaction.  The reaction work-up and 
purification was the same as the glucose functionalization step described above with a 
fluoresceinamine isomer I to glucosamine ratio of 0.02:1.  The fluorescently tagged 
nanoparticles were diluted to 50 µg/ml and incubated with CT26 cells overnight.  The cells 
were washed 2x with DPBS and stained with DAPI and Lysotracker Red.  Post staining, 
the cells were imaged utilizing a fluorescent microscope and analyzed for internalization 
(Nikon Elements 4.2). 
6.2.7 Cellular Response to Alternating Magnetic Field 
Similar to above, CT26 cells were seeded in a 35 mm culture dishes at 15000 
cells/cm2 and were allowed to become confluent.  The cells were doped with iron oxide 
nanoparticles from 5 mg/ml DMSO stocks and incubated for an additional 1 hour.  The 
media was removed, washed 2x with warm DPBS, and cells were detached using trypsin.  
Cells were split into samples with and without field exposure and doped with 50 mM 6-
carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-DCFDA) (Invitrogen).  Cells 
were incubated at 37 °C for 30 minutes to facilitate stain internalization, exposed to the 
field for 30 minutes (Taylor Winfield magnetic induction source; approximately 60 kA/m 
in strength at 292 kHz frequency), and returned to the incubator for 30 minute post 
incubation.  Cells were analyzed using an Accuri C6 flow cytometer (BD Biosciences, San 
Jose, CA).  A ratio of the mean fluorescence between samples exposed to the AMF and the 
samples that remained in the incubator was used to determine the enhanced ROS generation 
attributed to the nanoparticles in the AMF. 
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To determine the effects of the treatment, a Caspase 3/7 Apoptosis assay 
(Invitrogen) was utilized.  Following the intracellular procedure described above, the cells 
were stained with the reagent per the manufactures protocol immediately following the 
AMF exposure and allowed to incubate for 30 minutes.  After the incubation period the 
cells were analyzed with flow cytometry.  A ratio of the mean fluorescence between 
samples exposed to the AMF and the samples that remained in the incubator was used to 
assess the effects of the field exposure. 
6.2.8 Surface ROS Generation 
 To determine the amount of ROS generated from the surface the nanoparticles a 
methylene blue degradation assay was used.  The degradation experiments were performed 
in 2 ml microcentrifuge tubes where one ml samples were prepared by diluting stock 
concentrations of methylene blue to 5 µg/ml and iron oxide nanoparticles to 75 µg/ml.  The 
samples were placed in the water bath for 10 min to equilibrate to the expected steady state 
temperature as a result of field exposure.  The degradation was initiated by spiking the 
samples with 25 µl of 30% H2O2 to a working concentration of 245 mM.  The samples 
were exposed to a field of approximately 51.0 kA/m in strength at 292 kHz frequency while 
temperature was measured with a Luxtron FOT Lab Kit.  After given time intervals the 
samples were centrifuged for 30 s using a Phenix Quickspin Centrifuge, magnetically 
decanted, and measured using UV-visible spectroscopy (maximum absorbance at 665 nm) 
with a Varian Cary.  To account for nanoparticle scattering from the nanoparticles that 
remain in suspension, samples containing only nanoparticles were measured and subtracted 
out from the sample absorbance. 
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Figure 6.1.  FTIR spectra of citric acid coated iron oxide and glucose coated samples.  The 
vertical line at 1088 cm-1 indicates the location of a C-N vibration and at 1040 cm-1 
indicated the location of C-O stretch peak attributed to the D-glucosamine.  The vertical 
lines 1560 cm-1, 1360 cm-1, and 1250 cm-1 indicate the location of the C=O stretch, O-H 
bend, and C-O stretch bonds, respectively, typically attributed to citric acid coated 
particles. 
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Figure 6.2. Mass loss profile of citric acid and glucose coated iron oxide. 
 
 
 
Table 6.1. Results from DLS and Zeta potential measurements of coated nanoparticles. 
 Zavg (nm) PDI Zeta (mV) 
Citric Acid  75.36 0.207 -34.7 
Glucose  70.06 0.193 -20.3 
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6.2.9 Statistical Analysis  
 Statistical analysis of the ROS generation and apoptosis assay were performed 
using a two sample Student’s t-test comparing viability to the control.  To indicate 
significant differences defined by the following ranges: p < 0.05, p < 0.01 and p < 0.001, a 
single, double, or triple asterisk was included in the figures. 
6.3. Results and Discussion 
6.3.1 Characterization of Nanoparticles  
Following the reaction, the nanoparticles were characterized to confirm the success 
of the functionalization.  FTIR was utilized as an initial screen to verify the presence of 
predicted functional groups.  In Figure 6.1, there is a change in signature between the citric 
acid and the glucose coated nanoparticles with the key peaks of interest being a shoulder 
at 1088 cm-1 attributed to the C-N vibration and a pronounced peak at 1040 cm-1 indicating 
the location of C-O stretch peak attributed to the glucosamine.  It should be noted that the 
loss of the primary amine peak from glucosamine further confirms a covalent bond instead 
of electrostatic interactions between the carboxyl and amine groups. 
In Figure 6.2, TGA indicated similar mass loss for both citrate and glucose coated 
particles, approximately 10 and 12% respectively, however a change in the profile was 
observed indicating different compounds.  The citrate coating displayed its greatest mass 
loss between 150 and 200 °C which is similar to the values reported by Frimpong et al. 
[32].  Glucose coated particles saw its greatest mass loss shift to between 200 and 300 °C.   
The nanoparticle systems were further characterized with DLS and Zeta Potential 
to determine the hydrodynamic size of the particles and surface charge (Table 6.1).  Citrate 
coated nanoparticles were 75 nm in diameter with a PDI of 0.207 and glucose 
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functionalized particles were 70 nm with a PDI of 0.193.  The addition of the 
monosaccharide functional group resulted in no increase in hydrodynamic size.  This result 
also indicated that there was no aggregation induced during the additional synthesis and 
washing steps.  Previous work with TEM has determined the core iron oxide crystal size 
to be on the order of 10 nm.  The zeta potential displays a distinct shift from -34.7 to -20.3 
mV.  During the functionalization step, carboxyl groups from the stabilizing agent are 
being partially replaced by the monosaccharide molecules resulting in a diminished surface 
charge. 
6.3.2 Uptake and Localization  
 A Prussian blue colorimetric assay was used to quantify cellular uptake of uncoated, 
citric acid coated, and glucose coated iron oxide nanoparticles into CT26 cells.  In Figure 
6.3, the glucose coated nanoparticles display a greater extent of internalization compared 
to the non-targeted nanoparticles.  Over the three time points measured, glucose coated 
nanoparticles display a 2-3 fold increase over the citric acid coated nanoparticles.  
Internalization of the glucose coated nanoparticles increased with time and slightly more 
than doubles between 0.5 and 2 hours.  The internalization of the uncoated nanoparticles 
remains relatively constant between 5-8 pg iron per cell.  Citric acid coated nanoparticle 
internalization doubles between 0.5 and 1 hour but then remains constant. 
To visualize the location of the nanoparticles in CT26 cells, the glucose coated iron 
oxide nanoparticles were functionalized with a green fluorescent tag.  Co-localization 
studies were performed with the addition of DAPI blue and Lyso-tracker red stains to 
visualize the location of the nucleus and lysosomes respectively.  Representative images 
can be found below in Figure 6.4.  In the control figure, there is a diminished presence of  
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Figure 6.3. Iron content in CT26 cells when exposed to 200 µg/ml of nanoparticles over 
0.5, 1, and 2 hours of incubation.  Control group consists of cells never exposed to 
nanoparticles but underwent similar culturing conditions. 
 
 
 
Figure 6.4. Representative localization images of control (a) and 50 μg/ml fluorescently 
tagged glucose coated nanoparticles (b) incubated with CT26 cells.  
  
a) b) 
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naturally occurring lysosomes.  In the case of nanoparticle exposure, there are areas of 
yellow-orange overlap from the green nanoparticles and red lysosomes suggesting the 
nanoparticles are being internalized in lysosomes.  Previously, it was determined that 
glucose coated iron oxide nanoparticles were internalized by cells via a caveolae dependent 
pathway culminating in lysosomes [33].  While working with similarly designed glucose 
functionalized nanoparticles, Shan et al. studied the effects of using a GLUT-1 inhibitor on 
the rate of internalization [28].  They determined that the internalization was retarded to 
rates similar to control nanoparticle system.  However, glucose transporters are more 
attuned to transporting small molecules across the cell membrane, not nanoparticles on the 
order of 70 nm.  We picture that the glucose functionalized nanoparticles are sticking to 
the cell surface via glucose transporters, internalized via caveolae, and eventually 
compartmentalized into lysosomes. 
6.3.3 Alternating Magnetic Field Response 
 After determining the selectivity of the glucose coated nanoparticles, cells with 
internalized nanoparticles were exposed to the AMF to demonstrate the potential of the 
system to deliver MagMED therapy.  To study the changes in cellular ROS levels, a 
DCFDA assay was used.  In the presence of ROS, the acetate groups are cleaved converting 
the molecule from non-fluorescent to fluorescent.  The cells were exposed to the AMF for 
30 minutes while the temperature was measured with a Luxtron FOT Lab Kit.  At the power 
setting used (approximately 60 kA/m in strength at 292 kHz frequency), the radiant heat 
from the copper coil heated cellular media to 37-38.5 °C, and there was no difference in 
heating profile between the control group and the nanoparticle systems.  The presence of 
nanoparticles altered the absolute measured fluorescent value, so a ratio of samples 
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exposed to the AMF and the samples that remained in the incubator was used.  Figure 6.5 
displays the field enhancement ratio of the various systems tested with CT26 cells.  There 
is negligible enhancement in the control group, and any minor increase was attributed to 
deviation away from ideal culture conditions.  Significant enhancement was observed with 
nanoparticle exposure.  Glucose coated nanoparticles displayed an additional enhancement 
compared to the other non-targeted nanoparticle systems.  The increase in ROS 
enhancement is thought to be associated with the amount of nanoparticles internalized by 
the cells. 
 Increased intracellular ROS generation from engineered nanomaterials typically 
leads to a cytotoxic event.  A Caspase 3/7 Apoptosis assay was utilized to determine the 
effects of the increased ROS enhancement and to demonstrate the potential as a therapeutic.  
Through the activation of caspase 3/7 in apoptotic cells, the reagent is activated and 
becomes fluorescent when bound with cellular DNA.  Similar to above, Figure 6.6 displays 
the ratio of fluorescent values between exposed to the AMF, and the samples that remained 
in the incubator.  Only the glucose coated nanoparticles displayed a significant increase in 
caspase 3/7 activity compared to the control and the non-targeted nanoparticle systems.  
The increase in ROS generation during AMF exposure is capable of the triggering the 
apoptotic pathway leading the cellular death. 
To determine the source of the ROS generation, we examined the surface 
generation through a methylene blue dye degradation assay.  The surfaces of iron oxide 
nanoparticles are capable of catalytically generating ROS through the Fenton and Haber-
Weiss reactions.  In a Fenton-like system, iron ions react with hydrogen peroxide to 
generate highly reactive hydroxyl and superoxide radicals which in turn attack bonds on  
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Figure 6.5. Measured ROS enhancement with field exposure determined by dividing the 
relative fluorescent means from the samples with field exposure by no field exposure.  
Significant differences between groups are indicated as *p < 0.05, **p < 0.01. 
 
 
Figure 6.6. Ratio of Caspase 3/7 fluorescence of cells with and without field exposure 
when exposed to various nanoparticle systems.  Significant differences between groups are 
indicated as *p < 0.05. 
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Figure 6.7. Fenton-like generation of ROS by nanoparticle systems measured by 
methylene blue dye degradation.   75 µg/ml nanoparticles were exposed to the AMF for 5 
and 15 minutes in the presence of 0.75% H2O2. 
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methylene blue fracturing the molecule into colorless intermediates.  By measuring 
methylene blue colorimetrically, the amount of degradation can be determined.  Figure 6.7 
below displays the amount of methylene blue degraded by the various nanoparticle systems 
when exposed to the AMF for 5 or 15 minutes.  The concentration of nanoparticles selected 
was 75 µg/ml where there is minimum, 1.5 °C, temperature rise of the solution attributed 
to nanoparticle heating.  Previously at this concentration we observed a statistical 
enhancement in ROS generation with uncoated nanoparticles compared with the Arrhenius 
prediction [21].  The uncoated nanoparticles display significant degradation on the order 
of 40-60%.  However, the coated systems display negligible degradation indicating our 
coating inhibits the Fenton-like reaction.   
Toxicity associated with iron oxide nanoparticles is typically attributed to Fenton-
like catalytic generation of free radicals with endogenous hydrogen peroxide [34, 35].  
Based on previous results, our initial hypothesis was cellular ROS generation would be 
enhanced through the local heating of the nanoparticles driving the Fenton-like chemistry.  
Since our coated systems do not display this behavior suggests that another mechanism is 
at play beyond a chemical effect.  In the presence of the alternating magnetic field, the 
nanoparticles would be physically rotating and realigning themselves with the field.  If 
bound to the cell membrane or internalized within lysosomes these physical motions would 
induce stress within the cell.  The ROS generation in response to these physical stresses 
would correspond with the amount of nanoparticles internalized.  In the case of EGFR 
targeted iron oxide nanoparticles, Domenech et al. observed an increase in lysosomal 
permeability correlating with increased ROS generation and decreased viability as a result 
of their intracellular treatment [36].  They attributed this observation to heat dissipation or 
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mechanical disruption of the lysosomes.  Similarly, iron oxide nanoparticles were coated 
with lysosomal protein marker antibodies to specifically accumulate along the lysosome 
membrane [37].  In this case, the alternating magnetic field applied was at 20 Hz where 
only physical rotations by the nanoparticles would be actuated.  The resulting cellular 
apoptosis occurred due to the lysosomal disruption from the rotational forces.   
Accounting for the location of the nanoparticles in lysosomes, the shift in pH (~4.5) 
would result in some dissolution of iron oxide to iron ions.  These free ions have the 
potential to leave the lysosome to the cytosol, mitochondria, or endoplasmic reticulum 
where they would encounter conditions more favorable to Fenton-like chemistry in terms 
of available hydrogen peroxide [34, 38-41].  The toxicity of iron oxide nanoparticles has 
been directly tied to intracellular release of iron ions which would react with mitochondrial 
hydrogen peroxide [42].  Considering the theoretical heating calculations, there remains 
doubt whether the nanoscale heating isolated in lysosomes would be able to effect the 
kinetics in neighboring organelles [13, 43].  Experimental evidence demonstrating 
nanoscale heating involves changes in a fluorescent polymeric shell or nanoparticles in the 
direct vicinity of a liposomal carrier increasing the permeability of the bilayer [14, 44, 45].  
Lysosomal membrane permeabilization from free radicals has been demonstrated by 
elevating the intralysosomal iron content through iron loaded silica particles [46, 47].  The 
source of the intralysosomal hydrogen peroxide is a direct result of membrane bound 
NADPH oxidase stimulation by the silica particles [48].  However, uncoated iron oxide 
nanoparticles do not similarly stimulate NADPH oxidase with endocytosis [49].  Thus in 
our case, even if the coating is displaced, the only potential source of lysosomal hydrogen 
peroxide available would have to escape catalase degradation and freely diffuse into the 
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compartment.  With our specific nanoparticle systems, we can likely eliminate a chemical 
effect and point to either a thermal or mechanical effect disrupting the lysosomal membrane 
as the source of enhanced ROS generation and associated apoptosis.   
6.4. Conclusions 
 This study reports the use glucose coated iron oxide nanoparticles for the selective 
internalization and assessed for their potential to deliver MagMED therapy to a colorectal 
cancer cell line.  The targeted nanoparticles displayed increased internalization compared 
to non-targeted nanoparticles, and co-localization suggests the nanoparticles are 
internalized into lysosomes.  With exposure of an alternating magnetic field, the glucose 
coated nanoparticles displayed a significant increase in cellular ROS and apoptotic cell 
death with no measurable increase in media temperature.  To determine if the mechanism 
of toxicity was attributed to a chemical effect, we investigated the surface generation of 
ROS through Fenton-like chemistry.  The coated systems displayed negligible ROS 
generation compared to uncoated nanoparticles.  These observations suggest the cellular 
ROS measured is attributed to a thermal or mechanical effect of the internalized 
nanoparticles. 
6.5. References 
References are located at the end of the dissertation subdivided by chapters. 
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Chapter 7: Synthesis and Characterization of Magnetic Nanoparticles with 
Biodegradable Polymer Coatings for the Treatment of Cancer  
Iron oxide nanoparticles provide theranostic capabilities through alternating magnetic field 
(AMF) mediated therapy and enhanced contrast in magnetic resonance imaging.  The 
enhanced local generation of reactive oxygen species (ROS) with AMF exposure has the 
potential to be a direct toxic effect associated with magnetically mediated energy delivery 
(MagMED) therapy or can work in conjunction with chemotherapeutics to enhance the 
drug efficacy.  However, coatings essential to the delivery of the nanoparticles can retard 
the surface generation of ROS, which occurs at the surface through Fenton-like chemistry.  
To circumvent this issues, we developed a biodegradable coating based on a poly(beta-
amino ester) macromer.  The reactivity of the nanoparticles was assessed using a methylene 
blue degradation assay.  Unfortunately, with the coating degraded, the nanoparticles did 
not improve in reactivity and future work is warranted to determine the role of surface 
anchoring groups. 
7.1. Introduction 
With their unique physical properties, magnetic nanoparticles are of great interest 
to nanomedicine researchers with applications in diagnostic imaging, drug delivery, and 
thermal therapy of cancer [1-4].  Traditionally, nanoparticles often relied on passive 
targeting to systemically circulate and accumulate in tumors via the phenomenon known 
as the enhanced permeation and retention effect [5].  Current nanoparticle research has 
looked to functionalize the surface with appropriate targeting ligands such as peptides, 
antibodies, and carbohydrates to increase cellular interaction and even target intracellular 
organelles such as the lysosome [6-10].  The therapeutic potential of magnetic 
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nanoparticles stem from their ability to remotely heat when subjected to an AMF.  
Magnetic fluid hyperthermia has been studied for decades, but recent advances with 
intracellular energy delivery has become an area of interest to researchers [11].  Targeted 
magnetic nanoparticles can combine their therapeutic potential and enhanced contrast 
properties as theranostics particles. 
MagMED builds off the work established by Creixell et al. demonstrating that 
internalized targeted nanoparticles can induce cellular death when exposed to an AMF 
without a measurable temperature rise [11, 12].  In follow-up work, with the specific 
targeting ligands utilized, local delivery of heat or physical/mechanical forces was shown 
to disrupt lysosomes and trigger cellular death [13-15].  Beyond these mechanisms, a third 
potential effect of the local energy delivery involves the generation of reactive oxygen 
species (ROS).  We have recently demonstrated the generation of ROS from the surface of 
uncoated iron oxide nanoparticles is enhanced in presence of an alternating magnetic field 
[16].  However, in follow up work, we studied the role of nanoparticle coatings and 
observed the ROS generation was significantly impaired (submitted to Acta Biomaterialia).  
One of the coated systems involved glucose functionalization, and it was efficiently 
internalized into lysosomes and induced significant apoptosis compared to the other 
nanoparticles, reinforcing the physical or thermal mechanisms discussed above.  Building 
off this research, a potential next generation strategy is to develop a biodegradable coating 
with a targeting strategy to locate bare nanoparticles next to a biological relevant source of 
hydrogen peroxide [17-21].  An interesting targeting candidate would be lipophilic 
triphenylphosphonium (TPP) [22, 23].  Due to its cationic head group, targeted 
nanoparticles have been observed to escape endosomes and lysosomes and cross into the 
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mitochondria matrix from charge gradients.  We hypothesize that through mitochondrial 
targeting the chemical effect would be most pronounced.  Heterogeneous catalysis coupled 
with the enhanced reactivity though nanoscale heating is another route of MagMED worth 
exploring. 
Beyond being a direct toxic effect, the enhanced ROS generation can be used to 
enhance chemotherapeutics [24].  For example, Huang et al. developed iron oxide loaded 
pH responsive micelles loaded with the anticancer drug β-lap [25].  They determined that 
iron ions were released and further reacted with hydrogen peroxide generated from the β-
lap.  The surface of iron oxide nanoparticles can catalytically generate radicals at a 50-fold 
rate compared to iron ions [26].  Thus, if a biodegradable coating were utilized and the 
surface of the iron oxide nanoparticles were made available for this above therapy, the 
efficacy could greatly be improved. 
 Poly(beta-amino esters) (PBAEs) are a class of biodegradable polymers extensively 
studied due to their tunable physical properties [27, 28].  For example, by varying the 
hydrophilic/hydrophobic contributions in the form of the ratios of poly(ethylene glycol) 
diacrylate (PEGDA) and diethylene glycol diacrylate (DEGDA), significantly different 
degradation profiles can be achieved [29].  In terms of composite nanoparticle work, Fang 
et al. provides an interesting example of iron oxide nanoparticles coated with a PBAE 
copolymer containing doxorubicin [30].  The doxorubicin is released as the PBAE is 
degraded resulting in a novel theranostic system.  By utilizing a PEG-based PBAE polymer 
coating, the nanoparticles will avoid reticuloendothelial system clearance, increasing their 
circulation time [31]. 
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In this paper, biodegradable PBAE coated nanoparticles were synthesized and 
assessed for their ability to catalytically generated ROS.  Iron oxide core nanoparticles, 
selected for their ability to remotely heat in an AMF, were prepared utilizing the facile co-
precipitation technique.  A PEG-based PBAE polymer with varying amount of anchoring 
group will be added the nanoparticle surface.  This coating would degrade and would re-
expose the iron oxide surface to the surrounding environment.  We hypothesize that, once 
the coating is degraded, the nanoparticles will display similar reactivity to the uncoated 
nanoparticles. 
7.2. Materials and Methods 
7.2.1 Materials 
 Iron (III) chloride hexahydrate (FeCl3•6H2O); iron (II) chloride tetrahydrate 
(FeCl2•4H2O); and isobutylamine (IBA) were obtained from Sigma Aldrich (St Louis, 
MO).  Ammonium hydroxide (NH4OH) was obtained from EMD Chemicals (Gibbstown, 
NJ).  3-aminopropyl trimethoxysilane (APTMS) was obtained from Gelest Inc. 
(Morrisville, PA).  Diethylene glycol diacrylate (DEGDA) and poly(ethylene glycol) (N = 
400) diacrylate (PEG400DA) was obtained from Polysciences Inc. (Warrington, PA).  All 
materials were used as received. 
7.2.2 Synthesis of Iron Oxide Nanoparticles  
 A one-pot co-precipitation method was used to prepare the iron oxide nanoparticles 
as similarly reported previously [32].  Briefly, aqueous solutions of FeCl3•6H2O and 
FeCl2•4H2O were combined in a 2:1 molar ratio in a sealed three-neck flask under vigorous 
stirring and an inert N2 environment.  Once 85 °C was reached, a 1.5 M solution of NH4OH 
was injected into the vessel and the reaction was carried out for 1 hour.  The nanoparticles 
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were initially decanted via magnetic decantation to remove majority of the impurities.  
After, they were resuspended in water and transferred to a dialysis bag for 48 hours of 
dialysis.  Following the washing steps, the particles were stored in suspension. 
7.2.3 PBAE Macromer Synthesis  
Macromers were synthesized similar to a method and nomenclature previously 
described [33].  The diacrylate and amine were used in a molar ratio of 1.2:1.  The 
diacrylates consisted of DEGDA (A) and PEGDA (H) kept in a 1:2 molar ratio.  The amines 
consisted of IBA (6) and APTMS (9) in two different ratios based on amount of APTMS 
anchoring group.  Each chemical was pipetted into a 20 mL glass vial with magnetic stirrer.  
Once the chemicals were added, the vial was transferred to an oil bath set to a temperature 
of 85°C.  The synthesis time period of 48 hours is defined as the point where the chemicals 
are first mixed at room temperature.  The macromer was labeled AH69 10% and AH69 
2.5% with the percentages indicating the amount of anchoring group.  
7.2.4 Synthesis of PBAE Coated Iron Oxide and Degradation 
 AH69 coated Fe3O4 composite nanoparticles were synthesized via a surface 
addition reaction.  Dried uncoated iron oxide nanoparticles were suspended in anhydrous 
DMSO at a concentration of 5 mg/ml through probe sonication.  Once dispersed, AH69 
was added directly to the nanoparticle suspension in a 10:1 mass ratio.  The mixture was 
vigorously mixed for 24 hours to facilitate the macromer addition.  The nanoparticles were 
washed via magnetic decantation with the initial precipitation in ether and then washed 
three times with acetone.  The particles were dried in a vacuum oven and the dry powder 
was stored under desiccation. 
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 Following the synthesis, AH69 coated Fe3O4 were suspended in water at a 
concentration of 5 mg/ml.  The nanoparticle suspension was transferred to a dialysis bag 
and dialyzed against water for 72 hours.  After dialysis, the nanoparticles were 
magnetically decanted and washed with water.  The particles were dried in a vacuum oven 
and the dry powder was stored under desiccation. 
7.2.5 Particle Characterization 
Fourier Transform infrared (FTIR) spectra.  Attenuated total reflectance FTIR (ATR-
FTIR) was used to determine surface functionalization with a Varian Inc. 7000e 
spectrometer.  Dried samples were placed on the diamond ATR crystal and the spectrum 
was obtained between 700 and 4000 cm−1 for 32 scans. 
Thermal gravimetric analysis (TGA).  TGA was used to quantify the mass percent of the 
iron oxide core particle.  Measurements were performed using a TA Instruments SDT Q600 
TGA/DSC instrument (New Castle, DE).  Approximately 10 mg of dried sample was loaded 
and a heat rate of 5 °C/min under constant air flow was used.  At 120 °C, the sample was 
held isothermal for 10 minutes to vaporize residual solvent and potential water vapor.  The 
sample continued to heat at 5 °C/min until 500 °C.  The presented values are normalized 
to the mass at 120 °C. 
Dynamic Light Scattering (DLS).  DLS measurements were obtained using a Malvern 
Zetasizer, Nano ZS90 instrument.  Nanoparticles were diluted in DI water to a 
concentration of 200 μg/mL and dispersed using ultrasonication.  
Alternating Magnetic Field heating.  The AMF heating profile was observed using a 
custom made Taylor Winfield magnetic induction source and temperature was measured 
with a Luxtron FOT Lab Kit.  Particles were diluted in DI water to a concentration of 2 
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mg/mL.  One ml of solution was placed in a 2 ml centrifuge tube and placed in the center 
of the coil.  The solution was heated in a field of approximately 58.1 kA/m in strength at 
292 kHz frequency for 5 minutes.  
7.2.6 Surface ROS Generation 
 To determine the amount of ROS generated from the surface the nanoparticles a 
methylene blue degradation assay was used.  The degradation experiments were performed 
in 2 ml microcentrifuge tubes where one ml samples were prepared by diluting stock 
concentrations of methylene blue to 5 µg/ml and nanoparticles to 75 µg/ml.  The samples 
were placed in the water bath at 34 °C for 10 min to equilibrate to the expected steady state 
temperature as a result of field exposure.  The degradation was initiated by spiking the 
samples with 25 µl of 30% H2O2 to a working concentration of 245 mM.  After given time 
intervals the samples were centrifuged for 30 s using a Phenix Quickspin Centrifuge, 
magnetically decanted, and measured using UV-visible spectroscopy (maximum 
absorbance at 665 nm) with a Varian Cary.  To account for nanoparticle scattering from 
the nanoparticles that remain in suspension, samples containing only nanoparticles were 
measured and subtracted out from the sample absorbance. 
7.3. Results and Discussion 
7.3.1 Characterization of Nanoparticles  
The PBAE is synthesized through a Michael addition reaction between the amine 
and acrylate groups resulting in a covalent linkage of amines and esters (Scheme 7.1.a).  
The inclusion of APTMS into the PBAE backbone provides an anchoring group to the 
nanoparticle surface through siloxane bonds.  The ester groups of the PBAE backbone are 
susceptible to hydrolysis into diols and β-amino acids.  These smaller degradation products  
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Scheme 7.1. Reaction schematic of the AH69 macromer synthesis (a) and subsequent 
nanoparticle coating (b).  The macromer was made using a 1.2:1 ratio of diacrylate to 
amine, 1:2 molar ratio of DEGDA to PEG400DA, and 10 or 2.5 mol% APTMS.  AH69 
attachment was facilitate through siloxane bonding of the anchoring group to the iron oxide 
surface.  
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are washed out during dialysis leaving behind a small fraction of the original PBAE as 
anchoring groups on the nanoparticle surface.  Following the reaction and degradation, the 
nanoparticles were characterized to confirm the successful addition and removal of AH69.  
FTIR was utilized as an initial screen to verify the presence of predicted functional groups.  
The spectra of the core uncoated nanoparticles and AH69 coated and degraded 
nanoparticles with 10 and 2.5% anchor groups are displayed in Figure 7.1.  Key peaks of 
interest are indicated by vertical lines at 1715 cm-1 and 1110 cm-1 corresponding to the 
carbonyl (C=O) stretch band and ether (C-O-C) stretch band from the PBAE background 
and at 1015 cm-1 corresponding to the siloxane anchoring group.  After degradation, the 
indicative peaks are diminished, and the spectra resembles that of uncoated iron oxide.  
Figure 7.2 displays the TGA thermograms of the various nanoparticle systems 
tested.  The uncoated nanoparticles display a 3.1% loss in mass, which can be attributed to 
chemically adsorbed water and iron oxide hydroxyl groups.  With the addition of AH69, 
the mass loss approaches 10% and occurs in two stages: 250-300 °C and 350-400 °C.  The 
first stage closely corresponds to the elimination of poly(ethylene glycol) previously 
observed by us in a cross-linked hydrogel coated system [34].  The second stage, around 
400 °C, corresponds to the range observed by Galeotti et al. studying a variety saline 
grafting agents [35].  After degradation, the amount of mass loss decreases to 93.8 and 
95.1% for the 10 and 2.5% anchor group systems respectively, confirming the loss of the 
PBAE backbone.  However, the anchoring groups remain as the profile displays the similar 
elimination range between 350-400 °C.  The differences in mass loss profile corresponds 
the amount of anchoring groups involved in the initial macromer synthesis. 
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Figure 7.1. FTIR spectra of functionalized nanoparticles.  Vertical lines at 1715 cm-1 and 
1130 cm-1 indicate the location of the C=O and C-O-C bonds from the PBAE backbone; 
1015 cm-1 attributed to the Si-O bond from the anchor molecule. 
 
 
 
Figure 7.2. Mass loss profile of uncoated iron oxide and AH69 coated iron oxide before 
and after degradation with different amount of anchoring group. 
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Table 7.1. Results from DLS measurements over 40 minutes, the equivalent time involved 
in the methylene blue assay. 
Sample Time Zavg (D-nm) PDI % change 
Fe3O4 UC Initial 94.69 0.172 106.2 
40 min 100.6 0.179 
AH69 10% Initial 126.7 0.358 110.1 
40 min 139.5 0.317 
AH69 10% 
Degraded 
Initial 88.01 0.315 108.7 
40 min 95.63 0.251 
AH69 2.5% Initial 109.2 0.373 111.9 
40 min 122.2 0.292 
AH69 2.5% 
Degraded 
Initial 86.02 0.263 116.6 
40 min 100.3 0.252 
 
 
 
 
Figure 7.3. Extent of methylene blue degradation over different reaction times of 75 µg/ml 
nanoparticles at 34 °C.  Initial concentration of methylene blue was 5 µg/ml and H2O2 was 
used at 245 mM. 
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The hydrodynamic size of the particles was determined with DLS and reported as 
Z-average in Table 7.1.  The core uncoated nanoparticle are on the order of 100 nm in 
diameter with a PDI of 0.172%.  The nanoparticles increase 20-30 nm with the addition of 
AH69 as further evidence of the successful coating.  With coating degradation, the increase 
in hydrodynamic size recedes, and the nanoparticles loses close to 8 nm in size compared 
to the core uncoated nanoparticles.  While not significant, it is an interesting result as one 
would expect the potential for agglomeration with the additional dialysis and handling 
steps.  A possible explanation would be an etching of the outer layer of iron oxide by the 
local acidic environment created during the PBAE degradation.  Over the course of 40 
minutes, corresponding to the length of the methylene blue degradation assay, all samples 
experience a similar ~10% increase in size due to agglomeration. 
7.3.2 Surface ROS Generation 
 After determining the addition and degradation of the AH69 coating, the 
nanoparticles were tested for their reactivity with a methylene blue degradation assay.  In 
the presence of hydrogen peroxide, the surfaces of iron oxide nanoparticles are capable of 
catalytically generating highly reactive hydroxyl and superoxide radicals through the 
Fenton and Haber-Weiss reactions.  These radicals attack bonds on methylene blue 
fracturing the molecule into colorless intermediates which can be measured 
colorimetrically.  Figure 7.3 below displays the reactivity of the various systems at 75 
µg/ml at 34 °C.  Without any functionalization, the uncoated nanoparticles are the most 
reactive displaying 38% degradation over 30 minutes of reaction.  The AH69 coated Fe3O4 
nanoparticles were still reactive but at a diminished 25% over 30 minutes.  Previously, with 
citric acid stabilized nanoparticles, the reactivity was completely inhibited (submitted to 
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Acta Biomaterlia).  In this case, the nanoparticle system involves coating with semi-mobile 
polymeric chains as opposed to a monolayer of stabilizing groups.  The mobility of the 
coating would facilitate diffusion of the reactants to the catalytic surface allowing the 
reaction to occur.   
However, with degradation of the AH69 coating, there was no improvement in 
reactivity.  Recall, the initial hypothesis was that with degradation the nanoparticle system 
should return to similar behavior of the uncoated nanoparticles allowing these 
nanoparticles a range of therapeutic applications.  When observing concentrated 
suspensions of nanoparticles, the degraded samples had a slight brown hue compared to 
the black suspension of uncoated Fe3O4.  A brown shift would be indicative of oxidation 
of the nanoparticles to Fe2O3.  Fe2O3 is less reactive than Fe3O4 as a Fenton-like catalyst, 
since only Fe3+ ions are initially present on the particle surface [36].  When diluted to a 
transmittable concentration, there is no measurable shift in UV-vis absorbance to quantify 
this observable color change.  An alternative approach is to study the inductive heating 
property of the nanoparticles.  If there is a measurable surface oxidation, the nanoparticle 
systems would heat less than uncoated Fe3O4.  Figure 7.4 displays the heating profile of 
uncoated and degraded nanoparticle systems and specific absorption ratio (SAR) values 
were tabulated in Table 7.2.  SAR is a means of quantifying the heat generated per mass 
of nanoparticle and is calculated using the following equation: 
SAR = (∑iCimi)/m * (ΔT/Δt)   Equation 7.1 
where Ci is the heat capacity, mi is the individual mass of the components heated (water 
and iron oxide nanoparticles), m is the mass of the component generating heat (iron oxide), 
and ΔT/Δt is the initial slope of the heating profile (the 25 and 35 second time points were 
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used to calculate the slope).  Based on the results in Figure 7.4 and Table 7.2, there is 
negligible differences between the various nanoparticle systems tested suggesting 
whatever surface oxidation is present does not affect the physical properties of the 
nanoparticles.  Future work is warranted to investigate potential surface oxidation.  
Additionally, the 10 and 2.5% anchoring group was selected relatively arbitrarily, and 
based on the TGA evidence future work should investigate lowering the amount to 
determine the role of the residual β-amino acid-silane on the nanoparticle surface. 
7.4. Conclusion 
 This study explores the use of PBAE coated nanoparticles for biological enhanced 
ROS generation.  Biodegradable AH69 macromer was successfully added to and 
subsequently degraded from iron oxide nanoparticles.  However, when determining the 
reactivity, the degraded nanoparticles did not return to the performance of uncoated iron 
oxide as expected.  The macromer system can further be modified to incorporate targeting 
ligands.  To date, we have incorporated amine-PEG-carboxyl spacers into the PBAE 
backbone.  The intent was to functionalize the carboxyl groups with epithelial cell adhesion 
molecule (EpCAM) antibodies via an amine-carboxyl coupling reaction.  EpCAM was 
selected since it has been observed to be over expressed in majority of colorectal cancer 
cell lines [37, 38].  By comparison it has also been documented that adult, non-regenerating 
hepatocytes do not express EpCAM [39].  Thus, EpCAM is an attractive target for 
colorectal cancer liver metastases, however local delivery through hepatic perfusion must 
be considered to prevent unintended delivery to healthy epithelium.  If future work 
overcomes the obstacles of decreased reactivity, this novel nanoparticle system has 
promising applications to detect and treat cancer through enhanced ROS generation. 
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Figure 7.4. Heating profile of various systems tested 
 
 
 
Table 7.2. Calculated SAR values using the estimated slope between 25 and 35 second 
time points. 
System SAR (W/kg) 
Fe3O4 UC 317.8 
AH69 10% Degraded 319.9 
AH69 2.5% Degraded 309.4 
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Chapter 8: Conclusion  
 In this dissertation, the use of iron oxide nanoparticles for cancer therapy 
applications was explored.  When exposed to an alternating magnetic field (AMF), iron 
oxide nanoparticles absorb energy from the magnetic field and convert it into heat.  
Traditionally, this energy was used to heat the bulk surroundings for thermal therapy.  As 
explored in the first section of this dissertation, poly(ethylene glycol)-coated nanoparticles 
were able to heat cancer cells to the thermoablation range inducing necrosis.  While 
effective in the lab, there are major translational hurdles for implementing thermoablation 
or magnetic fluid hyperthermia in the clinic.  Current research focuses on targeted 
nanoparticles and their intracellular nanoscale effects to treat metastatic lesions previously 
considered untreatable.  Now instead of heating the bulk surrounding, the energy is 
dissipated locally to eliminate individual cancer cells.  Possible mechanisms of cytotoxicity 
at play are local heating effects, physical-mechanical effects (rotational or vibrational 
movements), or chemical effects (e.g., the generation of reactive oxygen species, ROS)).  
When exposed to an AMF, the Fenton-like generation of ROS was enhanced.  To our 
knowledge, this is the first time Fenton-like reaction kinetics were studied with AMF 
exposure and adds relevant literature to the ongoing controversy over the existence of 
nanoscale heating effects.  With biological applications, nanoparticle coatings are essential, 
and thus far these coatings either inhibit or retard the generation of ROS.  Using enhanced 
ROS is an intriguing new route of therapy, and the work described here lays the 
groundwork for exciting future studies. 
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8.1. Significant Findings 
 There are several findings in this work that contribute to the scientific community’s 
understanding of iron oxide nanoparticles for biomedical applications.  The focus here was 
on cancer therapy, but the knowledge can be extended to other diseases or fields such as 
environmental remediation.  Magnetically mediated energy delivery is a relatively new 
concept in the literature, and thus, our findings contribute directly to a growing field.   The 
specific conclusions and relevance of this work is presented below. 
 The successful thermoablation of A549 demonstrates the potential use of polymer 
coated particles for thermal therapy 
 Uncoated nanoparticles display enhanced ROS generation with AMF compared 
with the Arrhenius prediction due to nanoscale heating effects 
 Cyclical field exposure prevents nanoparticles from agglomerating allowing for 
sustained ROS enhancement 
 Glucose coated iron oxide nanoparticles are internalized at a greater rate than non-
targeted nanoparticles and induce enhanced cellular ROS with AMF exposure 
leading to apoptosis  
 Stabilizing groups can inhibit the surface generation of ROS suggesting a thermal 
or mechanical effect is more likely the source of observed toxicity 
 Residual anchoring groups from a bio-degradable poly(beta-amino ester) coating 
retards the surface generation of ROS 
 Composite monoglyceride-based thermo-responsive cubosomes release a model 
protein when heated past their transition temperature 
Copyright © Robert John Wydra 2015   
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Appendix 1: Co-delivery of Heat Shock Protein 90 Inhibitors and Iron Oxide 
Nanoparticle Induced Hyperthermia for Dual Cancer Therapy 
In this study, iron oxide nanoparticles were prepared to concurrently deliver a heat shock 
protein (HSP) inhibitor to cancer cells for chemotherapeutic/hyperthermic dual cancer 
therapy.  The dual cancer therapy involves the use of magnetic nanoparticles raising the 
temperature of a tumor between 40-45°C through energy dissipation in an alternating 
magnetic field (AMF), while HSP inhibitors down-regulate chaperoning signal 
transduction for cancer cell survival under heat-mediated stress.  We hypothesized that 
HSP inhibition prior to hyperthermia would make cancer cells more susceptible to thermal 
damage delivered by the nanoparticles.  The nanoparticles utilized were citric acid coated 
with the intent to study core-shell nanoparticles that were prepared using atomic transfer 
radical polymerization as described in Chapter 4.  In our preliminary study, 90 kDa heat 
shock protein (HSP90) was targeted by using the chemotherapeutics geldanamycin and 17-
N-Allylamino-17-demethoxygeldanamycin.  Combinational therapy of HSP90 inhibitors 
and hyperthermia on lung carcinoma cells was then investigated to explore potential 
enhancements in therapeutic effect.  This work was done in conjunction with Sarah E. 
Seger as part of her NSF-REU research. 
A1.1. Introduction  
 Thermal therapy is the process of elevating tumor tissue temperature for therapeutic 
gains and is traditionally divided into two regimes, hyperthermia and thermoablation, based 
on temperature achieved.  Hyperthermia therapy, heating tumor tissue to 40-45 °C, is of 
interest in conjunction with traditional therapies for enhanced efficacy as opposed to a 
stand-alone treatment [1, 2].  Increasing the temperature of tumor tissue can be done with 
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focused ultrasound waves, warmed chemotherapy or blood perfusion, and magnetic fluid 
hyperthermia [3].  Magnetic fluid hyperthermia involves the introduction of magnetic 
nanoparticles to a tumor site that remotely heated when exposed to an alternating magnetic 
field (AMF) by dissipating the absorbed energy as heat through Neel and Brownian 
relaxations [4-6].  This approach avoids causing damage to surrounding tissue by localizing 
the heat delivery within the tumor and opens the possibility to treat tumors that are deep 
within the body and unreachable with current techniques.  Numerous clinical trials have 
demonstrated that hyperthermia has additive and sometimes synergistic effects when 
combined with conventional radiotherapy or chemotherapy [7].  Elevated temperatures can 
increase the effects of chemotherapy by increasing rates of alkylation by alkylating agents, 
increasing drug uptake into tumor tissue, and inhibiting DNA repair mechanisms [8]. 
While hyperthermia has been proven beneficial in numerous trials, it can also be 
antagonistic by inducing cell-protective mechanisms.  The dominant response depends on 
the magnitude of the temperature change, the resulting levels of denatured proteins, and 
the order of therapy delivered [9].  Activating cell-protective responses to hyperthermia 
include increased enzyme activity and induction of the heat shock response. The heat shock 
response is the increased expression of various heat shock proteins (HSPs) or molecular 
chaperones within the cell [10]. These proteins can re-fold denatured proteins, prevent 
proteasomal degradation of proteins, and protect the cell from subsequent stresses, leaving 
the cell in a transient thermotolerant state.   
Of the HSPs identified, HSP90 is the most abundantly expressed stress protein in 
the eukaryotic cytosol and has been highly studied [11].  Included in HSP90’s client 
proteins are signal transduction molecules related to cell growth and nuclear receptors of 
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steroid hormones [12].  Signal transduction clients are significant because cancer cells 
express altered signal transduction pathways that enable the avoidance of apoptosis and 
unlimited cell division.  Additionally, HSP90 is involved with the heat shock response 
protecting the cell from stress- induced death.  Many tumor environments are acidic, 
hypoxic, and nutrient deprived, therefore the HSP90 are overexpressed in cancer cells 
relative to normal tissue cells [13, 14].  Already being overexpressed, HSP90 can protect 
cells from traditional cancer therapies.  Thus, targeting HSP90 for cancer therapy provides 
a way of sensitizing cancer cells to therapy [15, 16]. 
This study investigated co-delivery of hyperthermia and the HSP90 inhibitors, 
geldanamycin (GA) and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) on lung 
carcinoma cells.  Cytotoxicity studies were carried out to determine the concentrations of 
the HSP90 inhibitors required to sensitize lung carcinoma cells to subsequent a 
hyperthermia treatment.  Hyperthermia was delivered to the cells in two different ways.  
Ambient incubation was used to create bulk heating of the media, and magnetic fluid 
hyperthermia was used to create localized heating of the cells.  It was expected that pre-
incubation of cells with the inhibitors, in addition to hyperthermia, would be more 
cytotoxic than each treatment alone, and that magnetic fluid hyperthermia would be more 
toxic than incubator-mediated hyperthermia. 
A1.2. Materials and Methods 
A1.2.1 Materials  
Iron (III) chloride hexahydrate (FeCl3•6H2O) and iron (II) chloride tetrahydrate 
(FeCl2•4H2O) were obtained from Sigma Aldrich (St Louis, MO).  Citric acid monohydrate 
(CA) was obtained from Fisher Scientific and ammonium hydroxide (NH4OH) from EMD 
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Chemicals (Gibbstown, NJ).  Geldanamycin (GA) and 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) were purchased from LC Laboratories (Woburn, 
MA).  Both drugs were dissolved in dimethyl sulfoxide at a concentration of 500 µM and 
stored at -20 °C. For experimentation, the stock solutions were diluted to the desired 
concentrations in A549 cell medium immediately before use.  Unless noted, all materials 
were used as received. 
A1.2.2 Iron Oxide Nanoparticle Synthesis  
A one-pot co-precipitation method was used to prepare the core citric acid coated 
iron oxide nanoparticles [17].  Aqueous solutions of FeCl3•6H2O and FeCl2•4H2O were 
combined in a 2:1 molar ratio in a sealed three-neck flask under vigorous stirring and an 
inert N2 environment.  Once 85 °C was reached, 5 mL of NH4OH was injected into the 
vessel followed by 4 ml of 2 M citric acid.  The reaction was carried out for 1 hour.  The 
particles were washed with ethanol and retrieved with magnetic decanting.   Following the 
wash the particles were dried and stored under vacuum. 
A1.2.3 Cell culture  
All cell culture reagents were purchased from American Type Culture Collection 
(ATCC).  A549 and PC-9 lung carcinoma cells at passages 4-13 were cultured in F-12K 
medium supplemented with 10% fetal bovine serum, 10 μg/ml Fungizone, and 2 μg/ml 
Penicillin-Streptomycin-Glutamine at 37 °C under an atmosphere of 5% CO2 humidified 
incubator. Confluent (80% confluence) cells were detached with a Trypsin-EDTA solution 
(0.05% Trypsin and 0.02% EDTA; ATCC) and subcultured at least once prior to seeding. 
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A1.2.4 HSP90 Inhibitor Therapy Combined with Incubator-mediated Hyperthermia 
Lung carcinoma cells were seeded in 6-well plates and 96-well plates at 6000 
cells/cm2 and were incubated overnight to facilitate attachment.  After, the cell culturing 
medium was removed and replaced with 2 mL or 180 µL of the drug-containing medium.  
Two 6-well plates and two 96-well plates were prepared identically.  One plate from each 
set was kept at 37°C for the entire study, and the other plates were exposed to 30 minutes 
of 43 °C hyperthermia treatment in an incubator at elevated temperature after 48 hours of 
drug exposure.  The viability of the cells was assessed immediately after treatment. The 6-
well plates were assessed using the Live/dead assay, and the 96-well plates were assessed 
using the resazurin blue assay. 
The Molecular Probes Live/Dead Cytotoxicity kit used to assess 6-well plate 
viability was purchased from Invitrogen (Carlsbad, CA).  This assay was chosen to 
determine changes in cellular morphology, cell count, and number of necrotic cells present 
within each sample.  After the 48 hour exposure to drug or directly after the 30 minute 
hyperthermia treatment, the culture medium was removed and discarded.  A 2 ml DPBS 
wash was performed to ensure the removal of residual medium.  Then 1 ml of live/dead 
assay solution was added to each well, and the plates were incubated for 20 minutes.  Five 
image sights (live and dead) were taken of each well using a fluorescence microscope 
(Nikon Eclipse LV 100, Melville, NY).  The number of live and dead cells in each image 
were counted using NIS-Elements BR 3.0 imaging software.  All 6-well experiments were 
performed in triplicate.  Viability was determined by dividing the average number of live 
cells by the total number of cells in each cohort.  Normalized concentration was determined 
as average live number of cells divided by the seeding density of the picture area.  
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The resazurin sodium salt used for the resazurin blue assay of the 96-well plates 
was purchased from Sigma-Aldrich (Milwaukee, WI).  This assay was chosen to evaluate 
mitochondrial activity as a means of quantifying viability.  The resazurin sodium salt was 
dissolved in 1x PBS to a 10 mM concentration and stored at -20 °C. After the 48 hour drug 
exposure or directly after the 30 minute hyperthermia treatment, culture medium was 
removed and discarded.  A 180 µl DPBS wash was performed to remove residual drug 
medium prior to adding 90 µl fresh drug-free medium and 10 µL resazurin solution to each 
well.  The plates were incubated for 3 hours before reading fluorescence.  The fluorescence 
was read with a Cary Eclipse bottom-reading fluorescence spectrophotometer (5 nm slit; 
560ex/590em wavelength).  Data from this assay is presented as percent mitochondrial 
activity compared to the control. 
A1.2.5 HSP90 Inhibitor Therapy Combined with AMF-mediated Hyperthermia 
 A549 lung carcinoma cells were seeded in 35 mm dishes (2 mL cell culture 
medium) at 6000 cells/cm2.  Cells were cultured and doped with drug containing media as 
above. 6-well plates were prepared identically but were kept at 37 °C for the entire study.  
After 48 hours of drug exposure, the medium in the 35 mm dishes was removed and 
replaced with medium containing 5 mg/ml suspended citric acid coated iron oxide 
nanoparticles.  The dishes were placed on the stage, centered on the coil, and exposed to 
the alternating magnetic field for 30 minutes.  After termination of the alternating magnetic 
field, the dishes were stained and imaged with the live/dead assay described above.   
131 
 
A1.3. Results and Discussion 
A1.3.1 A549 HSP90 Efficacy Screen 
This study was utilized to determine an effective concentration of each inhibitor 
that would sensitize the A549 cells to hyperthermia. Viability was assessed with resazurin 
blue stain which is reduced within metabolically active cells producing the highly 
fluorescent resofurin.  The results from the assay can be found below in Figure A1.1 for 
both GA (Figure A1.1a) and 17-AAG (Figure A1.1b).  Based on these results, 125 nM 
concentrations of both GA and 17-AAG were selected for future studies.  At this 
concentration, there was the most dramatic decrease in mitochondrial activity after the cells 
were exposed to 30 minute of 43 °C hyperthermia treatment indicating sensitization to 
hyperthermia. 
A1.3.2 A549 Cytotoxicity with Active Agents  
 Following the selection of a working concentration, A549 cells were exposed to 
every combination of variables.  Based on previous working knowledge of citric acid 
coated iron oxide, a 5 mg/ml concentration was selected [18].  This concentration is capable 
of heating to the hyperthermia range while having minimal toxicity over the short time 
frame selected.  To facilitate the AMF-induced studies, the viability assay was changed 
from resazurin to live/dead.  Since the 35 mm dishes utilized are larger than the 0.625”ID 
coil, there will be a distinct region in the center of the well where the field was the strongest 
and the particles heat more [19].  When determining the viability, images were taken from 
both the periphery and the center to distinguish between the two regions.  Live/dead also 
provides representational images allowing for discussion on the morphology of the cells.  
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A normalized live cell concentration was also calculated to give insight on the proliferation 
potential of the cells instead of only absolute live/dead viability. 
 The percent viability and normalized cell concentration for A549 cells exposed to 
125 nM concentrations of GA or 17-AAG with or without a 45 min exposure to citric acid 
coated Fe3O4 nanoparticles are displayed in Figure A1.2.  By initially only calculating the 
percent viability, it appeared that 125 nM no longer has an effect on the cells despite the 
resazurin results discussed above.  By including a normalized cell concentration, we in part 
calculated a proliferation potential of the cells.  Here, 17-AAG and peripheral GA display 
minimal cell proliferation as the relative concentration only increases 1-2 fold over the 
seeding density, confirming the inhibitory concentration selected.  The representative 
images from this assay are displayed in Figures A1.3 and A1.4 where Figure A1.4 
contains the cells exposed to 5 mg/ml citric acid coated iron oxide nanoparticles.  Based 
on these images and the results above, the nanoparticles have negligible effect on A549 
cells.  Compared to the control group, cells receiving 125 nM of inhibitor displayed an 
altered morphology.  The cells are sparsely packed and some examples seem bloated with 
a larger cell radius.  Parallel results were displayed in Figures A1.5-7 where a 30 minute 
exposure to 43 °C incubator-mediated hyperthermia was applied in combination with 125 
nM GA or 17-AAG and 45 min exposure to citric acid coated Fe3O4 nanoparticles.  
Similarly, we observed minimal change in percent viability.  However, with the inclusion 
of hyperthermia all samples exposed to the inhibitor displayed minimal cell proliferation 
as the relative concentration only increased 1-3 fold over the seeding density.  In the case 
of GA, this would add support to the increased sensitivity of the cells to hyperthermia.  
Similar altered morphologies appear in the representative cell images.   
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Figure A1.1. Relative mitochondrial activity of A549 cells after exposure to GA (a) and 
17-AAG (b) with or without hyperthermia treatments. Results are presented as means ± SE 
(n = 6). 
  
a
) 
b) 
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Figure A1.2. Percent Viability (a) and normalized cell concentration of A549 cells after 
48 h exposure to 125 nM concentrations of GA or 17-AAG with or without a 45 min 
exposure to citric acid coated Fe3O4 nanoparticles.  Results are presented as means ± SE 
(n=3). 
 
 
a
) 
b) 
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Figure A1.3. Representative images of A549 cells after 48 h exposure to 125 nM 
concentration of each inhibitor. Peripheral images (top, left to right): control, 125 nM GA, 
125 nM 17-AAG. Central images (bottom, left to right): control, 125 nM GA, 125 nM 17-
AAG. 
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Figure A1.4. Representative images of A549 cells after 45 min exposure to 5 mg/ml citric 
acid coated Fe3O4 nanoparticles with or without 48 h exposure to inhibitors. Peripheral 
images (top, left to right): 5 mg/mL Fe3O4, 125 nM GA + 5 mg/mL Fe3O4, 125 nM 17-
AAG + 5 mg/mL Fe3O4. Central images (bottom, left to right): 5 mg/mL Fe3O4, 125 nM 
GA + 5 mg/mL Fe3O4, 125 nM 17-AAG + 5 mg/mL Fe3O4. 
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Figure A1.5. Percent viability (a) and normalized cell concentration (b) of A549 cells after 
48 h exposure to 125 nM concentrations of GA or 17-AAG with or without a 45 min 
exposure to citric acid coated Fe3O4 nanoparticles. All systems were then exposed to a 30 
min 43°C incubator-mediated hyperthermia treatment.  Results are presented as means ± S 
E of 3 replicates (n=3). 
 
 
a
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Figure A1.6. Representative images of A549 cells exposed to incubator-mediated 
hyperthermia. Peripheral images (top, left to right): control, hyperthermia treatment only, 
5 mg/mL Fe3O4. Central images (bottom, left to right): control, hyperthermia treatment 
only, 5 mg/mL Fe3O4. 
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Figure A1.7. Representative images of A549 cells exposed to incubator-mediated 
hyperthermia. Peripheral images (top, left to right): 125 nM GA, 125 nM GA + 5 mg/mL 
Fe3O4, 125 nM 17-AAG, 125 nM 17-AAG + 5 mg/mL Fe3O4. Central images (bottom, left 
to right): 125 nM GA, 125 nM GA + 5 mg/mL Fe3O4, 125 nM 17-AAG, 125 nM 17-AAG 
+ 5 mg/mL Fe3O4. 
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 Since our working hypothesis was that the local delivery of hyperthermia through 
nanoparticle delivery would be more effective than bulk we went forward with AMF-
mediated studies.  With incubator-mediated hyperthermia, we observed a decrease in cell 
proliferation but no changes in absolute viability.  With AMF exposure, we hoped to 
demonstrate that the local heat delivery would render cells necrotic and quantifiable with 
the live/dead assay.  In the preliminary study (results not shown), the 125 nM GA AMF-
mediated hyperthermia sample overshot the goal temperature of 43 °C and heated to 46 °C.  
The resulting viability was 100% in the peripheral and 60% in the center where the field is 
the strongest.  Similarly, the iron oxide alone AMF-mediated hyperthermia overshot the 
goal temperature but to 45 °C.  The peripheral viability remained at 100% and the center 
decreased slightly to 90%.  Despite exceeding the typical hyperthermia range, this study 
demonstrated the possibility of local heat delivery inducing necrosis in cells sensitized to 
hyperthermia with HSP90 inhibitors. Rethinking our strategy, we increased the 
hyperthermia temperature from 43 to 45 °C.  Since GA was the only sample to show 
differences in proliferation with incubator-mediated hyperthermia, the gamut of studies 
was only repeated at 125 nM GA. 
 Figure A1.8 displays the cell viability and relative cell concentration of all the 
variables tested.  The real time temperature profile of the AMF-mediated hyperthermia 
samples is displayed in Figure A1.9.   The temperature did not exceed 45 °C as the steady 
state averages were 44.72 ± 0.66 °C for iron oxide nanoparticles and 44.56 ± 0.51 °C for 
GA plus iron oxide nanoparticles.  With greater control over the temperature, we did not 
observe any decreases in absolute viability below 90% indicating no cytotoxic effect.  In  
  
141 
 
 
 
Figure A1.8. Percent viability (a) and normalized cell concentration (b) of A549 cells with 
or without 48 h exposure to 125 nM concentrations of GA, with or without 45 min exposure 
to citric acid coated iron oxide nanoparticles (IONP), and with or without 30 minutes of 45 
°C hyperthermia. 
 
 
a
) 
b) 
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Figure A1.9.  Real-time solution temperature obtained using Luxtron FOT.  Field 
parameters were held constant at 17.0 kA/m at 306 kHz. 
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Figure A1.10. Relative mitochondrial activity of PC-9 cells after exposure to GA (a) and 
17-AAG (b) with or without hyperthermia treatments. Results are presented as means ± SE 
(n = 6). 
  
b) 
a
) 
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the case of A549 cells, decreased viability was only observed during the accidental 
overheating of the sample beyond the hyperthermia range. 
 The decrease in cellular proliferation observed with the live/dead assay can be 
explained by the cancer cells entering senescence as a result of the inhibitors.  Recall that 
cancer cells typically overexpress HSP90 to maintain routine cell functions.  By inhibiting 
the function of HSP90, the cells enter a dormant state where they remain in the Gap phase 
since DNA replication is impaired and they cannot go forward with cell division.  Thus, 
the initial cells seeded would appear live using live/dead assay, however proliferation 
would be minimized resulting in decreased overall mitochondrial compared to the control. 
A1.3.3 PC-9 HSP90 Efficacy Screen  
 Around the time the AMF-mediated hyperthermia studies were being concluded, 
Kobayashi et al. published a paper examining the effects of HSP90 inhibitors on non-small-
cell lung cancers [20].  They studied 17-dimethylaminoethylamino-17-
demethoxygeldanamycin, a variant of 17-AAG with better oral availability, and 
determined that A549 cells are resistant to the inhibitor.  PC-9 cells were shown to be 
sensitive and were available for an initial screen displayed in Figure A1.9.  The initial 
screen found the cells to be more sensitive to the inhibitors, with 50% reduction in activity 
in the neighborhood of 75.5 nM.  However, there was no enhancement with 45 °C 
incubator-mediated hyperthermia.  Future work should investigate PC-9 or other EGFR 
mutant cell lines which would be more sensitive to HSP90 inhibitors. 
A1.4. Conclusion  
 The results displayed here represent the exhaustive work performed in conjunction 
with Sarah Seger during her time as an undergrad.  Unfortunately, by the time PC-9 cells 
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became available to us, funds and patience were wearing thin.  A few beneficial take home 
results were determined during the course of this project.  The first is the careful selection 
of a cellular assay.  As demonstrated here, a significant decrease in mitochondrial activity 
does not necessarily mean a decrease in live cells, and multiple assays may be needed to 
understand what is happening at the cellular level.  In the case of A549 cells, they become 
non-proliferative with HSP90 inhibitors and with the application of intense heat (46 °C) 
the cells can become necrotic.  While the goal was to explore hyperthermia, interesting 
future work should investigate temperatures just outside the typically defined range.  
Beyond hyperthermia ranges, HSP90 inhibitors can be used in conjunction with other 
chemotherapeutics, such as erlotnib, to provide multimodal therapies. 
A1.5. References 
References are located at the end of the dissertation subdivided by chapters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Robert John Wydra 2015 
146 
 
Appendix 2: Determining the Effects of Nanoparticle Agglomeration on the 
Generation of Free Radicals in the Presence of an Alternating Magnetic Field 
In chapter 5, we explored the enhanced surface reactivity of iron oxide nanoparticles in the 
presence of an alternating magnetic field (AMF).  We observed that the enhanced 
generation of free radicals through Fenton-like chemistry decreased with concentration and 
exposure time.  This was attributed to possible AMF-induced nanoparticle agglomeration, 
which reduced the amount of surface area available for reaction.  In this study, we 
investigated ways of minimizing agglomeration, namely a cyclical field exposure and 
immobilizing the nanoparticles in a crosslinked network of a poly(ethylene) glycol (PEG)-
based hydrogel.  Part of this work was done in conjunction with Helen Yao as part of her 
NSF-REU research.  
A2.1. Introduction 
 The surfaces of iron oxide nanoparticles are capable of catalytically generating 
reactive oxygen species (ROS) through the Fenton and Haber-Weiss reactions.  Advanced 
oxidation processes (AOP) beneficially use ROS generated through this mechanism to 
degrade contaminants in the environment [1].  In an aqueous environment, the catalytic 
generation would be heterogeneous: surface bound Fe2+ and Fe3+ ions react with H2O2 via 
the Fenton and Haber-Weiss reactions.  This Fenton-like process has been used to break 
down model pollutants, such as methylene blue, a dye utilized by the textile industry [2, 
3].  Previous work with AOP have used free iron ions in the reaction environment and they 
left behind an iron hydroxide sludge waste products [4].  By using heterogeneous catalysts, 
the waste stream could safely be magnetically decanted to remove byproducts. 
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 Iron oxide nanoparticles are an interesting candidate because not only do they have 
high surface area to volume ratio for catalytic purposes, but they remotely heat when 
exposed to an alternating magnetic field (AMF).  The heating mechanism is typically 
attributed to two relaxations: Brownian relaxation and Neel relaxation [5].  There is debate 
in the literature in terms of the potential application of nanoscale heating effects.  The 
theoretical calculations from Rabin suggest the heat generated from a single nanoparticle 
or cluster of nanoparticles would be negligible to a surrounding environment [6].  However, 
Polo-Corrales and Rinaldi provided experimental evidence demonstrating nanoscale 
heating [7].  Specifically, they designed a core-shell nanoparticle with a temperature 
responsive polymer coating.  With AMF exposure, the surface temperature of the 
nanoparticles was shown to instantly increase and to drive a temperature responsive 
polymer beyond its lower critical solution temperature without an immediate increase in 
solution temperature. 
 In previous work, we utilized this nanoscale heating effect to enhance ROS 
generation through the Fenton-like chemistry.  This enhancement was determined by 
measuring methylene blue degradation and comparing it to the Arrhenius prediction at that 
steady state temperature.  However, it was also demonstrated that this enhancement effect 
decreases as AMF exposure time and IONP concentration increases.  We postulated that 
this may have been caused by AMF-induced nanoparticle agglomeration, which reduced 
the amount of surface area available for reaction with H2O2 [8].  In this study, we 
investigated methylene blue degradation while trying to minimize agglomeration influence 
through cyclical field exposure and nanoparticle immobilization in a hydrogel.  By cycling 
the AMF on/off we explore whether the agglomeration is reversible.  As illustrated in 
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Scheme A2.1a, the nanoparticles align in chains along the magnetic field but break up from 
Brownian effects when the magnetic moment is removed.  The second technique utilized 
was immobilizing the nanoparticles in a hydrogel.  A hydrogel is a hydrophilic cross-linked 
polymeric network.  Iron oxide nanoparticles can be entrapped in this network and then 
hydrophilic small molecules, such as methylene blue, can freely diffuse in and out, as 
diagramed in Scheme A2.1b. 
A2.2. Materials and Methods  
A2.2.1 Materials  
 Iron (III) chloride hexahydrate (FeCl3•6H2O); iron (II) chloride tetrahydrate 
(FeCl2•4H2O); hydrogen peroxide (H2O2); poly(ethylene glycol) methyl ether methacrylate 
(PEG1000MA, Mn = 1100.13 g/mol); and methylene blue (MB) were obtained from Sigma 
Aldrich (St Louis, MO).  Ammonium hydroxide (NH4OH) was obtained from EMD 
Chemicals (Gibbstown, NJ) and poly(ethylene glycol) dimethacrylate (PEG400DMA, Mn 
= 454.18 g/mol) was obtained from Polysciences Inc.  All materials were used as received. 
A2.2.2 Iron Oxide Nanoparticle Synthesis 
 A one-pot co-precipitation method was used to prepare the iron oxide nanoparticles 
as similarly reported previously.[9]  Briefly, aqueous solutions of FeCl3•6H2O and 
FeCl2•4H2O were combined in a 2:1 molar ratio in a sealed three-neck flask under vigorous 
stirring and an inert N2 environment.  Once 85 °C was reached, a 1.5 M solution of NH4OH 
was injected into the vessel and the reaction was carried out for 1 hour.  The nanoparticles 
were initially decanted via magnetic decantation to remove majority of the impurities.  
After, they were resuspended in water and transferred to a dialysis bag for 48 hours of 
dialysis.  Following the washing steps, the particles were stored in suspension. 
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Scheme A2.1. Proposed reversible agglomeration of iron oxide nanoparticles aligning in 
chains with the application of a magnetic field (a).  The immobilization of iron oxide 
nanoparticles in a hydrogel and the diffusion of hydrogen peroxide and methylene blue into 
the matrix to interact with the particle surface (b). 
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A2.2.3 Nanocomposite Hydrogel Synthesis  
Nanocomposite hydrogels were synthesized via free radical polymerization using a 
4:1 molar ratio of PEG1000MA to PEG400DMA. Iron oxide nanoparticles (1, 2.5, 5 wt%) 
and  DMSO (50 wt%) were added to the macromers, and the mixture was sonicated to 
disperse the nanoparticles uniformly.  Two different methods were used to initiate the 
hydrogel cross-linking reaction based on iron oxide loading.  Photoinitiation with 1.5 wt% 
2,2-dimethoxy-2-phenylacetophenone (Sigma-Aldrich) was used to synthesize hydrogels 
of low iron oxide concentration (< 5 wt%).  While at the high concentration, 5 wt%, 
chemical initiation with 4 wt% of accelerator N, N, N’, N’-tetramethylethane-1,2-diamine 
(Sigma-Aldrich) and 2 wt% of initiator ammonium persulfate (Sigma-Aldrich) was used.  
After addition of the initiator, the mixture was vortexed for 10 s before transferring to a 
template.  Photoinitiated hydrogels were exposed to an ultraviolet light source (14.0 
mW/cm2) for 5 min, while chemically initiated hydrogels were allowed to react overnight.  
After the reaction was complete, the hydrogels were washed for 48 hours in water.  Upon 
removal from the water bath, the hydrogels were washed for 2 hours in ethanol.  The 
hydrogels were transferred to a freeze-dryer to remove excess solvent.  Freeze-dried 
hydrogels were mechanically ground and sieved to obtain composite microparticles in the 
size range of 150–500 μm and stored under vacuum. 
A2.2.4 Methylene Blue Degradation Assay 
The methylene blue degradation experiments were performed in 2 ml 
microcentrifuge tubes in either temperature controlled water baths at four temperatures (28, 
30, 34, 37°C) or exposed to an AMF.  One ml samples were prepared by diluting stock 
concentrations of methylene blue to 5 µg/ml and iron oxide nanoparticles to 75 µg/ml.  The 
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samples were placed in the water bath for 10 min to equilibrate to the expected temperature.  
The degradation was initiated by spiking the samples with 25 µl of 30% H2O2 to a working 
concentration of 245 mM.  The samples were exposed to a 30 s on/off cyclical field of 
approximately 51.0 kA/m in strength at 292 kHz frequency.  The temperature was 
measured with a Luxtron FOT Lab Kit.  After given time intervals the samples were 
centrifuged for 30 s using a Phenix Quickspin Centrifuge, magnetically decanted, and 
measured using UV-visible spectroscopy (maximum absorbance at 665 nm) with a Varian 
Cary.  To account for nanoparticle scattering from the nanoparticles that remain in 
suspension, samples containing only nanoparticles were measured and subtracted out from 
the sample absorbance.  
Similarly, nanocomposite hydrogel particles of different iron oxide loading 
densities were combined with 1 ml of 5 µg/ml methylene blue.  The samples were placed 
in the water bath for 10 min to equilibrate to the set temperature.  The degradation was 
initiated by spiking the samples with hydrogen peroxide at a working concentration of 1.5 
or 3%.  After given time intervals the samples were centrifuged for 1 min, magnetically 
decanted, and measured using UV-visible spectroscopy.  The controls prepared were 
nanocomposite hydrogel suspended in methylene blue solution, nanocomposite hydrogel 
suspended in water, and pure hydrogel suspended in methylene blue solution.  The working 
concentrations of iron oxide were back calculated from the concentration of nanocomposite 
to 750 and 1067 μg/mL iron oxide. 
 Nanocomposites exposed to the AMF were prepared as described above.  The AMF 
was operated at a field of approximately 30.6 kA/m in strength at 296 kHz frequency.  The 
samples were first pre-heated for 10 min in a water bath to 32°C.  Pre-heated samples were 
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placed inside the magnetic coil for 15 min of pre-exposure to the AMF to allow the sample 
to reach a steady state temperature.  After pre-exposure, 30°C pre-heated hydrogen 
peroxide was added to the suspension, and the reaction was allowed to run for 5, 10, 15, 
20, and 30 min under the AMF.  After the allotted time for AMF exposure, the sample was 
analyzed for degradation using the UV-vis spectrometer. 
 To quantify the enhancement of ROS production, an enhancement factor (EF) 
defined in chapter 5 was utilized.  Recall, the EF is the ratio between experimental 
degradation (exp) and theoretical degradation (theo) from the Arrhenius prediction: 
EF = (1-(At/Ao)exp) / (1-(At/Ao)theo)  Equation A2.1 
Where At is the measured absorbance at a given time normalized to the initial absorbance, 
Ao.  If the sample did not reach steady state at the end of the time interval (as was the case 
for 5 min exposure time), an average temperature over the time period was used instead. 
A2.2.5 Statistical Analysis 
 Statistical analysis of the enhancement factor was determined using a one sample 
t-test where the hypothetical mean was set to 1.  To indicate significant enhancement a 
single, double, or triple asterisk corresponding to p < 0.05, 0.01, and 0.001 respectively 
were included in the figure. 
A2.3. Results and Discussion  
A2.3.1. Cyclical Field Exposure  
 The kinetics of colloidal iron oxide reacting with hydrogen peroxide to degrade 
methylene blue was explored in Chapter 5.  In that chapter, we explored three iron oxide 
concentrations based on their ability to heat a solution with AMF exposure.  In this 
experiment, we focused on the 75 µg/ml iron oxide concentration.  At this concentration, 
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there was minimal (i.e., 1.5 °C) temperature rise with prolonged AMF exposure.  The 
system displayed an initial enhancement at 5 minutes of field exposure but decreased to no 
statistical difference by 15 minutes.  With cyclical field exposure, the temperature profile 
never deviated from room temperature.  30 s intervals were not long enough for the radiant 
heat from the copper coil to heat the solution of methylene blue to 32-32.5 °C.  Initial 
studies were performed with a 34 °C water bath pre-heat, but over the course of reaction 
time the temperature plummeted.  The protocol was revised to keep all reactants at room 
temperature during sample preparation.  The Arrhenius analysis was done using the 
constants from Chapter 5 (A = 1.05e14 s-1, -Ea = 9.91e4 J/mol) at the steady state 
temperature measured during field exposure. 
 The EF results can be found in Figure A2.1 comparing cyclical field exposure to 
the static field exposure data from Chapter 5.  The cyclical field exposure EF remained 
statistically different from the hypothetical mean throughout the three reaction times and 
never statistically deviated from each other.  Note, unlike the static field where reaction 
time corresponds to length of AMF exposure, in this case the field was cycled 30 s on/off 
so total length of AMF exposure would be 50% of the reaction time.  Despite 50% of the 
length of AMF exposure, the cyclical samples displayed a greater EF compared to the static 
field.  Recall the steady state temperature was room temperature so the theoretical 
degradation value, the denominator in the EF equation, would be much lower than the 
theoretical degradation at 34 °C.  Despite no fluctuations in perceived temperature, the 
local temperature surrounding the nanoparticles with field exposure would immediately 
exceed 34 °C driving the reaction kinetics.  If we were to compare net degradation, the 
static field would perform better due to the elevated steady state temperature. 
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Figure A2.1. Enhancement factor comparing extent of methylene blue degradation based 
on experimental and theoretical values at 75 µg/ml of iron oxide nanoparticles in a static 
or cyclical field exposure over varying lengths of reaction time.  The field cycle was 30 s 
on/off. 
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 In chapter 5, we attributed the decrease in EF with time to the agglomeration of 
nanoparticles decreasing the available surface area for reactivity.  In the case of cyclical 
field exposure, there is no decrease in EF with time suggesting that the agglomeration effect 
is not taking place.  The 30 s AMF exposure is either not long enough to induce measurable 
agglomeration or the agglomeration induced is reversible allowing the nanoparticles to 
disperse during the off period.  In both cases, there are minimal fluctuations in available 
surface area allowing the EF to remain constant over the three reaction times measured.   
A2.3.2 Nanocomposite Immobilization  
Initial experiments explored the use of hydrogel nanocomposite discs to degrade 
methylene blue.  The discs proved to have a large diffusional barrier, as the methylene blue 
degradation was very low and did not fit well to any of the three kinetic models (zeroth, 
first, and second order) considered in this experiment.  Additionally, the hydrogel discs 
produced inconsistent methylene blue degradation levels, as it was observed for some of 
the time points the absorbance of the methylene blue was larger at a later time than an 
earlier time.  This would suggest that less methylene blue has degraded over a longer time 
period which is inherently false based on our knowledge of the reaction kinetics.  The study 
was revised to use nanocomposite microparticles to minimize the diffusion length and 
obtain more reproducible results. 
Kinetics data for zeroth, first, and second order models obtained for 5 wt% Fe3O4 
nanocomposite microparticles with a loading density of 750 μg/mL and 1.5 wt% hydrogen 
peroxide are displayed in Figure A2.2 and summarized in Table A2.1.  Based on the fit of 
the data to the zeroth, first, and second order reaction models, it was concluded that the 
reaction most closely followed a second order model as the fit had high R2 coefficients and 
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a y-intercept close to 1.  A general observation was that the zeroth and second order models 
were the best fit to the kinetics data for other loading densities.  However, based on a 
physical model it would be more logical for the degradation to be concentration-dependent; 
i.e. the amount of methylene blue in the solution should affect its degradation rate.  This 
makes the second order reaction model the most feasible.  This matches the kinetic model 
used in Chapter 5 for colloidal iron oxide nanoparticles.  The four temperature trials also 
yielded the relevant Arrhenius constants (derived from Figure A2.3), where the 
exponential prefactor, A, was found to be 2.53e11 and the activation energy, -Ea, was found 
to be 91,800 J/mol. 
This kinetics data was used to determine the EF (Figure A2.4) and it was found 
that the AMF enhanced ROS production and methylene blue degradation at all times tested.  
Similar to Chapter 5, the enhancement factor for methylene blue degradation due to AMF 
exposure decreased as AMF exposure time increased. The decrease in EF from 5 min was 
statistically significant (p < 0.01) starting at 15 min.  Despite the observed decrease, the 
enhancement factor observed at 30 min remained relatively high (1.8 ± 0.3) compared to 
data obtained for free nanoparticles in suspension, where at 15 min and 75 and 150 μg/mL 
loading density the enhancement had dropped to 1 (no enhancement).  The increased 
enhancement factor, relative to that observed in the free nanoparticle system would suggest 
that the hydrogel entrapment of the nanoparticles was able to prevent agglomeration.  
However, there was still a decrease in enhancement factor with AMF exposure time.  
The elevated EF could be in part explained by the inconsistencies in obtaining 
reliable temperature data.  The loading density of the microparticles was 750 μg/ml which 
would lead to local temperatures greater than 37 °C.  The temperature measurement used 
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Figure A2.2. Zero- (a), First- (b), and Second-order (c) kinetic plots of methylene blue 
degradation using 5 wt% nanocomposite microparticles at 750 μg/mL loading density iron 
oxide. 
a) 
b) 
c) 
 
 
Table A2.1. Rate constants for MB Degradation derived from Figure 2. 
Temperature (°C) 
Zero Order First Order Second Order 
k (A min-1) R2 y-intercept k (min-1) R2 y-intercept k (A-1 min-1) R2 y-intercept 
28 0.00125 0.908 0.00208 0.00155 0.911 0.00274 0.00161 0.914 0.997 
30 0.00191 0.926 0.00189 0.00245 0.928 0.00324 0.00262 0.931 0.996 
34 0.00228 0.971 -0.00054 0.00298 0.974 0.00112 0.00324 0.976 0.997 
37 0.00333 0.980 -0.00260 0.00458 0.976 0.00201 0.00529 0.968 0.991 
  
1
5
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Figure A2.3. Arrhenius plots derived from second order kinetic model from methylene 
blue degradation. 
 
 
 
Figure A2.4. Comparison of enhancement factor of methylene blue degradation using 
nanocomposite microparticles based on experimental and theoretical values at different 
durations of AMF exposure.  Samples were compared to 5 minutes to indicate very 
significant (p < 0.01) declines in enhancement with time. 
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to calculate enhancement factor was not the local temperature of the hydrogel particles but 
rather, the average solution temperature with the probe placed in the center of the centrifuge 
tube.  Typically, the microparticles settled to the bottom of the vial and were allowed 15 
minutes of AMF exposure to reach steady state prior to spiking the reaction with hydrogen 
peroxide.  During the reaction, the microparticles would become entrapped in oxygen 
bubbles (byproduct of the Fenton reaction) and circulate in the tube disturbing the flexible 
fiber optic thermoprobe.  Therefore, the calculated enhancement factor is not the true 
enhancement factor reflecting the local reaction kinetics but rather a relative enhancement 
factor to this nanocomposite microparticle system. 
The decrease in EF at 15 min could most likely be explained by the decrease in 
available hydrogen peroxide.  Hydrogen peroxide would be consumed by both the reaction 
and natural degradation into hydrogen and oxygen at elevated temperatures.  The 
observable presence of bubbles in the reaction chamber would indicate a more hydrogen 
peroxide is being consumed compared to the colloidal experiment.  Future research should 
consider a secondary injection of hydrogen peroxide to see if the EF can be sustained for a 
longer period of time.  Another possible reason for the decrease in enhancement factor 
could be a permanent change in the oxidation state of the surface to γ-Fe2O3.  At a higher 
temperature and in the presence of oxygen, this change in oxidation state occurs more 
readily.  This would render the nanoparticles less reactive as Fe3+ would become the 
predominant ion present at the surface. 
Despite the decrease in EF with time, in the section we demonstrated the potential 
to immobilize iron oxide nanoparticles in a polymeric matrix and display enhanced 
reactivity with AMF exposure.  For AOP applications, future work should investigate the 
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use of nanocomposite films or membranes to study the degradation in a flow system.  By 
using an AMF to heat only the local environment there is limited risk of premature 
hydrogen peroxide decomposition compared to bulk heating of the entire fluid. 
A2.4. Conclusion 
 This study investigates means of preventing nanoparticle agglomeration to sustain 
the enhanced reactivity of iron oxide in the presence of AMF.   In the first section, we 
cycled the AMF 30 s on/off to prevent the nanoparticles from agglomerating in chains 
along the magnetic field minimizing the available surface area.  The results displayed 
sustained enhancement demonstrating reversible agglomeration with magnetic field 
exposure.  In the second section, we immobilized iron oxide nanoparticles in 
nanocomposite hydrogel microparticles.  While we observed enhanced reactivity, the 
enhancement was not sustained with time.  Future work is needed to investigate the cause 
of the decrease in enhancement.  However, this demonstration opens up the possibility of 
creating different nanocomposite systems for environmental remediation.  
A2.5. References 
References are located at the end of the dissertation subdivided by chapters. 
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Appendix 3: Composite GMO-GMS Cubosomes Loaded with Iron Oxide 
Nanoparticles for the Controlled Delivery of Therapeutics  
The focus of this work explores the use of thermo-responsive materials for controlled drug 
release applications.  Previous work has demonstrated that oleic acid coated iron oxide 
nanoparticles can be incorporated into a monoglyceride-based thermo-responsive matrix 
and be used as a controllable drug release depot.  Shifting the material from the bulk to 
nanoscale, GMO-GMS cubosomes were prepared through a dispersion method.  
Demonstrating the controlled release of a model protein raises the possibility of designing 
multi-functional nanoparticle systems in the future. 
A3.1. Introduction 
Magnetic nanoparticles are being studied for a wide range of biomedical 
applications such as diagnostic imaging, drug delivery, and thermal therapy of cancer [1-
4].  Recently, we developed a novel monoglyceride-based thermo-responsive matrix for 
the controlled delivery of therapeutics [5].  The monoglycerides, glyceryl monooleate 
(GMO) and glyceryl monostearate (GMS), are amphiphilic molecules that self-assemble 
into a variety of crystalline structures that can be utilized for drug delivery [6, 7].  By 
mixing GMO and GMS in different compositions, the melting and crystallization points 
can be systematically tuned.  Oleic acid coated iron oxide nanoparticles were incorporated 
into the lipid matrix for the magnetic actuated release of the drug.  When exposed to the 
alternating magnetic field (AMF), the iron oxide nanoparticles remotely heat, driving the 
matrix past a melting point triggering the drug release.   
Colloidal lyotropic liquid crystalline nanoparticles represent a growing area of 
advanced nanoparticles for drug delivery [8-11].  Based on the local environment, lyotropic 
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liquid crystals can form a variety of morphologies, of which the non-lameller inverse cubic 
phases, or cubosomes, are of interest.  Mulet et al. identified four advantages of cubosomes 
over liposomes: loading of a range of agents including hydrophobic, hydrophilic, and 
amphiphilic; high loading extant due to increased lipid per particle and surface area; rigid 
internal structure facilitating the loading of imaging agents; and the mesophase has been 
shown to significantly affect release rates [8].  Beyond bioactive agent loading and release, 
researchers are interested in loading nanoparticles into the biocontinuous phase particles.  
With phytantriol-based nanoparticles, Fong et al. was able to successfully load gold 
nanorods into the liquid crystal structure [12].  When excited with NIR light, the 
nanoparticles underwent a reversible switch through different phase transitions.  Acharya 
et al. integrated iron oxide nanoparticles into a phytantriol matrix for use as an enhanced 
MRI contrast agent [13].  To date, no one has studied the triggered release of therapeutic 
with composite cubosomes. 
In this study, we synthesized composite cubosomes based on the aftermentioned 
GMO-GMS matrix blend.  As before, oleic acid coated nanoparticles were synthesized 
with a one-pot co-precipitation method.  Various blends of composite GMO-GMS 
cubosomes (based on the previous work, 75-25 wt% was the preliminary starting point) 
were created by dispersion using ultrasonication and stabilized with Pluronic F-127.  
Lysozyme was used as a model protein and drug release assessed with and without 
alternating magnetic field exposure.  We hypothesized that the protein will preferentially 
partition into the matrix facilitating loading and when exposed to the alternating magnetic 
field, the thermal energy will trigger a phase change altering the release of the drug. 
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A3.2. Materials and Methods 
A3.2.1 Materials  
Iron (III) chloride hexahydrate (FeCl3•6H2O), iron (II) chloride tetrahydrate 
(FeCl2•4H2O), oleic acid (OA), Pluronic F-127, lysozyme, and fluorescein isothiocyanate 
(FITC) were obtained from Sigma Aldrich (St Louis, MO), and used as received.  Glycerol 
monooleate (in the form of Myverol 18-99) and glycerol monostearate (Myverol 18-04) 
were kindly donated by Kerry Scientific (Beloit, WI). 
A3.2.2 Synthesis of Oleic Acid Coated Iron Oxide Nanoparticles  
A one-pot co-precipitation method was used to prepare the oleic acid coated iron 
oxide nanoparticles as previously reported [14].  Briefly, aqueous solutions of FeCl3•6H2O 
and FeCl2•4H2O were combined in a 2:1 molar ratio in a sealed three-neck flask under 
vigorous stirring and an inert N2 environment.  Once 85 °C was reached, 5 mL of NH4OH 
was injected into the vessel followed by 2 ml of oleic acid and the reaction was carried out 
for 1 hour. The particles were washed and retrieved with magnetic decanting.  Following 
the wash the particles were dried and stored under vacuum. 
A3.2.3 Synthesis of GMO-GMS Composite Nanoparticles 
Nanoparticle composite blends of GMO-GMS were prepared as previously 
reported [5].  Briefly, compositions of 75 and 80 w/w% GMO-GMS were prepared by a 
fusion method.  These lipid matrices were prepared with and without 0.5 or 2.0 wt% dried 
oleic acid coated iron oxide nanoparticles.  The mixtures were homogenized by a cycle of 
melting in an oven at 75 °C, vortexing, and chilling in the freezer.  Typical 4-5 cycles were 
required to obtain a homogeneous blend 
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Blends of GMO-GMS at 75:25 and 80:20 and composite blends of oleic acid coated 
iron oxide nanoparticles were used to synthesis cubosomes.  The blends were added to an 
aqueous solution of 0.5 w/v% Pluronic F-127 at a working concentration of 25 mg/ml.  The 
suspension was probe sonicated at 0.5 Hz on/off for 5 minutes resulting in a milky 
dispersion.   
A3.2.4 GMO-GMS Characterization 
Differential scanning calorimitry (DSC).  The thermal behavior and phase diagrams of the 
GMO-GMS blends were investigated with using a differential scanning colorimeter (DSC-
2920, TA Instruments).  DSC thermograms were produced by hermetically sealing samples 
in aluminum pans and heated at 5 °C/min from 5 °C to 90 °C, cooled back to 5 °C, and 
reaheated to 90 °C 
Dynamic Light Scattering (DLS). DLS measurements were obtained using a Malvern 
Zetasizer, Nano ZS90 instrument.  Post synthesis, samples were diluted to 0.5 mg/ml in 
DI-water for DLS measurements. 
Alternating Magnetic Field heating.  The AMF heating profile was observed using a 
custom made Taylor Winfield magnetic induction source and temperature was measured 
with a Luxtron FOT Lab Kit.  Particles were diluted in DI water to a concentration of 2 
mg/mL.  One ml of solution was placed in a 2 ml centrifuge tube and placed in the center 
of the coil.  The solution was heated in a field of approximately 58.1 kA/m in strength at 
292 kHz frequency for 5 minutes.  
A3.2.5 Drug Loading and Release 
Drug release behavior was studied by using lysozyme as a model protein.  
Lysozyme was tagged with FITC following a similar protocol from Takahashi et al. [15].  
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Lysozyme was dispersed into a 0.1 M sodium phosphate buffer solution with 3% DMSO 
co-solvent.  A 100 mM solution of FITC in anhydrous DMSO was made and slowly added 
to the lysozyme such that the final molar ratio was 5:1 FITC-lysozyme.  The workup was 
placed in the refrigerator overnight to facilitate the reaction between the amino N-terminus 
and the isothiocyanate group.  The workup was purified with dialysis for 24 hours and 
lyophilized to remove water. 
 The dried lysozyme was incorporated into the GMO-GMS matrices at 1 wt%.  
Previously prepared GMO-GMS were added to lysozyme in a centrifuge tube and 
underwent similar melt-mixing cycles to incorporate.  Cubosomes from the blends were 
prepared as described above.  Drug loaded cubosomes were diluted to 2 mg/ml in PBS at 
room temperature or pre-heated to 43 °C.  At prescribed periods, 0.4 ml samples were taken 
and placed into Amicon Ultra centrifugal filters (100kDA MWCO) at centrifuged for 10 
minutes at 18000xg.  200 µl sample of filtrate was transferred to a black 96 well plate and 
fluorescent intensity was measured at 495 nm/520 nm. 
A3.2.6 AMF-triggered Release  
 Drug loaded cubosomes were prepared as described above.  The sample was kept 
at room temperature for the first two hours to facilitate initial release.  After this time, the 
sample was transferred to the AMF and exposed at a field of approximately 58.1 kA/m in 
strength at 292 kHz frequency for 30 minutes.  The sample was returned to room 
temperature for one hour followed by another 30 minute field exposure.  As described 
above, 0.4 ml samples were taken per time point and centrifuged. 
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Scheme A3.1. Illustration of the proposed cubosome system with oleic acid coated iron 
oxide and drug molecules loaded into the GMO-GMS matrix.  When the temperature 
exceeds the melting point, either through water bath or AMF activation, the matrix will 
undergo a phase change releasing the drug. 
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A3.3. Results and discussion 
A3.3.1 Nanoparticle Characterization 
 Developing a thermos-responsive matrix combined with the remote heating of iron 
oxide nanoparticle provides the opportunity for controlled release of a therapeutic.  The 
proposed inverse cubic phase is illustrated in Scheme A3.1.  The oleic acid iron oxide 
nanoparticles and drug molecules initially reside within the ordered structure of the GMO-
GMS matrix.  When the system is heated, the matrix will undergo a phase transition 
allowing for the actuated release of the drug molecules.  Different ratios of GMO-GMS 
and iron oxide loading were evaluated to determine key physical properties. 
 The phase behavior of the GMO-GMS blends was determined using differential 
scanning calorimetry.  Figure A3.1 displays the thermograms of two ratios of GMO-GMS, 
75:25 and 80:20, with and without oleic acid coated nanoparticles at 0.5wt% loading.  
Along the initial heating cycle, two endothermic melting, Tm, values were observed.  
Previously, these two Tm were attributed to the GMO-rich and GMS-rich phases in the gel, 
owing to the fact that pure GMO has a Tm of 36.8 °C and pure GMS has a Tm or 82.7 °C 
[5].  The values of Tm are displayed in Table A3.1, and despite slight changes in ratio and 
the presence of nanoparticles there is minimal difference in reported temperatures observed 
on the first pass.  Upon cooling, the crystallization temperature, Tc, of the 72:25 blend was 
36.3 °C compared to 34.5 °C.  For repeated activation cycles such as pulsatile delivery, it 
is important that this value is near physiological so that the delivery system recrystallizes 
constricting drug release.  To simulate multiple cycles, a second heating pass was studied 
and Tm2 is reported in Table A3.1.  During the second heating, the Tm2 better blend into a 
single defined point.  The Tm2 of 75:25 is 41.5 °C which would correspond to a mild  
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Figure A3.1. DSC thermogram of GMO-GMS mixtures with the second heating cycle 
trend in red 
 
 
Table A3.1. Phase behavior of GMO-GMS mixtures 
GMO-GMS Tm GMO rich 
phase 
Tm GMS rich 
phase 
Tc Tm2 
75:25 37.3 53.8 36.3 41.5 
80:20 37.3 51.7 34.5 39.9 
75:25 (0.5wt%) 37.3 51.3 36.1 41.8 
80:20 (0.5wt%) 37.3 51.7 32.4 39.6 
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Table A3.2. Particle size determined by DLS 
 Zavg PDI 
75:25 154.0 0.239 
75:25 0.5wt% 164.5 0.383 
75:25 2wt% 213.5 0.330 
80:20 189.3 0.241 
80:20 0.5wt% 152.1 0.223 
80:20 2wt% 212.6 0.329 
 
 
 
 
 
 
Figure A3.2. Heating profile of composite GMO-GMS samples exposed to the AMF at 
different ratios of GMO:GMS and iron oxide loading percentages.   
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hyperthermia range.  When used as cubosomes, Pluronic F-127 stabilizers are added to the 
GMO-GMS matrix for aqueous stability.  DSC measurements were performed on these 
systems and minimal deviation from the pure system were observed. 
 Prepared cubosomes were analyzed with DLS to determine the hydrodynamic 
particle size reported as Z-average in Table A3.2.   The particle sizes are on the order of 
150-200 nm with an increase in particle size with increase in nanoparticle loading.  The 
iron oxide nanoparticles were exposed to the AMF, as discussed below, and were 
reanalyzed with DLS.  After AMF exposure, there was no change in particle size indicating 
that any local phase change is reversible and does not induce agglomeration.   
 The heating profiles of the cubosomes loaded with iron oxide nanoparticles are 
displayed in Figure A3.2.  The concentration selected (i.e., 2 mg/ml) corresponds to the 
concentrations used in the drug loading and release studies.  At this concentration, there is 
a relatively low level of iron oxide present, and thus, it is not surprising that the heating 
profiles did not deviate from water in the coil.  The measured temperature rise is attributed 
to the radiant heat from the induction source copper coil.  Despite no temperature rise, we 
predict the local nanoscale heating of the nanoparticles are capable of influencing the 
surrounding cubosomes. 
A3.3.2 Drug Loading and Release 
Based on the DSC results, the GMO-GMS 75:25 0.5wt% iron oxide nanoparticle 
was selected for the preliminary drug loading and release study.  The release profile of F-
lysozyme is displayed in Figure A3.3 at temperatures above and below the predicted phase 
transition temperature.  Both samples display a burst type of release over the first hour.  
This could be attributed to unincorporated lysozyme diffusing through bicontinous matrix.   
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Figure A3.3. Release profile of lysozyme from GMO-GMS 0.5wt% iron oxide cubosomes 
over 24 hours at room temperature (RT) or 43 °C water bath.  For the first 6 hours n = 3 
and error is reported as standard deviation.  12 and 24 hour time points are n = 1. 
 
 
 
Figure A3.4. AMF-triggered release profile.  GMO-GMS 75:25 0.5wt% iron oxide was 
held at room temperature for 2 hours before being exposed to two cycles of 30 minutes 
AMF and 60 minutes returned to room temperature. 
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After the first hour, the release profile at room temperature remains relatively constant for 
the next 5 hours before the slow diffusion of the drug becomes measureable over 24 hours.  
At 43 °C, above the phase transition temperature, the release profile continues rapidly until 
6 hours where it plateaus over the next 18 hours.  The maximum lysozyme release 
measured was around 9.5 µg/ml.  Considering the initial loading density was 1wt%, the 
theoretical max would be 20 µg/ml resulting in nearly 50% released over 24 hours. 
To test the ability of iron oxide triggering the drug release, an exploratory sample 
underwent two cycles of 30 minute AMF exposure followed by 1 hour at room temperature.  
The measured release profile is displayed in Figure A3.4 with the room temperature 
release profile included for reference.  With AMF exposure there appears to be a 0.5-0.6 
µg/ml spike in lysozyme release compared to the previous time point.  However, after 1 
hour, the lysozyme release returns to the statistical range of room temperature release.  If 
there had there been an actual spike in release, one would expect to see the prototypical 
stair-step profile of pulsatile release.  Future work is warranted to investigate systems with 
a higher iron oxide nanoparticle loading density. 
A3.4. Conclusion 
 This study presents preliminary work attempted to develop composite GMO-GMS 
cubosomes for the controlled release of therapeutics.  Building off our previous work, we 
looked to translate binary blends of monoglyceride thermo-responsive material from the 
bulk to nanoscale.  Initial characterizations indicated melting and crystallization 
temperatures which should correspond well for biological use.  The release profile of a 
model drug, lysozyme, demonstrated promising results of distinct differences below and 
above the materials melting point.  However, when AMF triggered release was attempted, 
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there was negligible increases in drug release.  While future work should investigate higher 
loading densities, ideally the system would operate in the nanoscale heating regime – where 
the energy output is sufficient to modify the surrounding chemistry but the bulk solution 
temperature remains constant. 
A3.5. References 
References are located at the end of the dissertation subdivided by chapters. 
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